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The porcine reproductive and respiratory syndrome virus (PRRSV) is an 
economically important pathogen of swine and is known to cause abortion and infertility 
in pregnant sows and respiratory distress in piglets. PRRSV contains a major 
glycoprotein (GP5) and three minor glycoproteins (GP2a, GP3, and GP4) on the virion 
envelope, all of which are required for infectious virus production. To study their 
interactions amongst each other and with a cellular receptor for PRRSV, CD163, I cloned 
each of the viral glycoproteins and CD163 in various expression vectors. My studies have 
shown that while the GP2a, GP3, and GP4 are co-translationally glycosylated, the GP5 is 
post-translationally glycosylated. By using co-immunoprecipitation (co-IP) assays, strong 
interaction was demonstrated between GP4 and GP5 proteins, although weak interactions 
among the other envelope glycoproteins were also detected. Further, GP4 was found to 
mediate interactions leading to formation of multiprotein glycoprotein complex. My 
results also show that GP2a and GP4 proteins are the only two GPs that specifically 
interact with the CD163 molecule and that glycosylation of these GPs is required for 
efficient interaction. Based on these studies, I have developed an interactome map of the 
viral GPs and CD163 and have proposed a model of the viral glycoprotein complex and 
its interaction with CD163. Studies reported here also show that glycan addition at 
residue 184 (N184) of GP2a, and residues N42, N50, and N131 of GP3 is essential for 
recovery of infectious virus. Although single site glycosylation mutants of GP4 had no 
effect on infectious virus production, introduction of double mutations was lethal. The 
loss of glycan moieties of GP2a, GP3, and GP4 proteins had no effect on host 
neutralizing antibody production. Overall, I conclude that the PRRSV glycoproteins are 
co-translationally and post-translationally glycosylated, the GP4 protein is central to 
mediating interglycoprotein interactions, and along with GP2a, serves as the viral 
attachment protein that is responsible for interactions with the viral receptor, CD163. 
Further, glycosylation of GP2a, GP3, and GP4 proteins is required for infectious virus 
production, efficient interaction with CD163, but does not play any role in neutralizing 
antibody response in infected animals. 
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Chapter I: INTRODUCTION 
1.1 Economic importance and pathogenesis of PRRSV 
Porcine reproductive and respiratory syndrome virus (PRRSV) is endemic in pork 
producing countries worldwide. Infection of pigs with the virus can result in PRRS 
disease leading to significant economic losses to the swine industry. PRRSV causes 
respiratory disorders leading to pneumonia and is responsible for mortality observed in 
young piglets. The virus also infects pregnant sows causing several reproductive 
disorders resulting in abortion, infertility, mummified fetuses, stillborn piglets etc. 
Initially, this disease was reported in USA and later discovered in Netherlands and other 
parts of the world (Benfield et al., 1999; Paton et al., 1991).  
PRRSV replication occurs in macrophages and the infected pigs show prolonged 
viremia and continue to shed the virus for long period (up to 2-5 months) (Snijder & 
Spaan, 2007). But, the virus does not enter a latent stage (Kimman et al., 2009). In case 
of postnatally infected pigs, the virus persists up to 150 days whereas in congenitally 
infected pigs, it persists up to 210 days (Cho & Dee, 2006). Persistent infection of 
PRRSV is observed in lungs, tonsils, and lymphoid organs of pigs (Lamontagne et al., 
2003).  
1.2 Ultrastructure and morphology of PRRSV 
Mature PRRSV particles are enveloped and pleomorphic. They have spherical to 
oval shape with a diameter of 50-65 nm (Spilman et al., 2009). The cryoelectron 
microscopy tomographic studies have shown a smooth outer surface of the virion with 
few protruding structures. The virion has a double layer hollow core of ~ 40 nm in 
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diameter, which remains separated from the envelope by 2-3 nm gap (Spilman et al., 
2009). 
1.3 Classification of PRRSV 
PRRSV along with equine arteritis virus (EAV), simian hemorrhagic fever virus 
(SHFV) and lactate dehydrogenase-elevating virus (LDV) is grouped under family 
Arteriviridae and the order Nidovirales based on their similar genome organization and 
replication strategy (Snijder & Meulenberg, 1998). PRRSV is classified into two 
genotypes: genotype I (European genotype) and genotype II (North American genotype). 
These two genotypes share approximately 60% of genome sequence homology 
(Forsberg, 2005; Hanada et al., 2005) and are serologically distinct (Kim & Yoon, 2008). 
The European and North American strains of PRRSV can also be differentiated from 
each other based on common and type specific antigenic determinants present on the 
structural proteins (Dea et al., 2000). 
1.4 Genome organization and proteins of PRRSV 
The genome of PRRSV is approximately 15.4 kb in length. The genome contains 
a methylated cap structure at the 5’ end, the 3’ end is polyadenylated, and untranslated 
regions (UTRs) are present at both termini (Meulenberg et al., 1993; Snijder & 
Meulenberg, 1998; Wootton et al., 2000). It has nine open reading frames (ORFs) (Fig. 
1.1A). All the ORFs overlap with each other except between ORF1b and ORF2a. ORF1a 
and ORF1ab, which is accessed by ribosomal frame-shifting during protein synthesis 
(Snijder & Meulenberg, 1998) together span approximately 75% of the genome from the 
5’-end. These ORFs produce polyproteins that are processed by different viral proteases 
encoded in the ORF1a region to generate a total thirteen to fourteen non-structural  
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Figure 1.1 Schematic representation of PRRSV genome organization. (A) Overview 
of the genome organizations. The ORFs are shown as solid rectangles from 5’ to 3’ end 
with the appropriate ORF named on it. The ORF encoding NSPs and structural proteins 
are labeled accordingly. The replicase ORFs (ORF1a and ORF1b) are followed by ORF 
encoding 2b protein and three ORFs encoding three minor envelope glycoproteins (GP2a, 
GP3, and GP4), and ORFs encoding major structural proteins (GP5, M, and N). The 5’ 
cap and 3’ poly (A) tail is shown. The 5’ and 3’ UTRs are shown as dotted lines in each 
end of the genome. (B) Overview of the ORFs encoding NSPs of PRRSV. ORF1a and 
ORF1b are labelled and NSPs encoded by each of the ORFs are shown. The cleavage site 
of NSP1 to NSP1α and NSP1β are indicated by blue downward arrow where as the 
predicted cleavage site of NSP7 to NSP7α and NSP7β are shown as black downward 
arrow. The cleavage site of PLPα, PLPβ, and PLP2 are indicated by black upward arrow.  
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proteins (NSPs), named NSP1α, NSP1β, and NSP 2-6, NSP7α, NSP7β, and NSP8-12 
(Kroese et al., 2008; Meulenberg, 2000; van Aken et al., 2006). The NSPs are involved in 
processing of the viral polyproteins, genome replication, and transcription (Meulenberg, 
2000). The ORFs 2a, 2b, 3-7 encompass approximately 25% of the genome at the 3’-end 
and they produce the viral structural proteins, namely, the glycoprotein (GP) 2a (GP2a), 
non-glycosylated protein 2b (or E), GP3, GP4, GP5, the matrix protein (M), and the 
nucleocapsid protein (N), respectively (Wu et al., 2005). 
 1.5 Non-structural proteins of PRRSV 
The ORF1a and ORF1b are connected with each other by -1 ribosomal frame shift 
site and upon translation it produces a large polyprotein (Fig. 1.1A). Ribosomal frame 
shifting is regulated by specific RNA signals called ‘slippery sequence’ (at the actual 
frame shift site) and a pseudoknot structure downstream of the frame shift site in the 
virion (Godeny et al., 1993; Meulenberg et al., 1993; Snijder & Meulenberg, 1998). It 
results in carboxy terminal extension of a relatively small fraction of ORF1a gene 
product (polyprotein-1a) with ORF1b gene product producing polyprotein-1ab. This 
protein is further cleaved by the four autoproteanases (NSP1α, NSP1β, NSP2, and NSP4) 
to produce 13 to 14 non-structural proteins (Fig 1.1B). The NSP1 cleaves to form NSP1α 
and NSP1β (den Boon et al., 1995; Kroese et al., 2008; Sun et al., 2009). The cleavage of 
NSP7 to NSP7α and NSP7β for PRRSV was predicted based on the similar observation 
in its counterpart of EAV (van Aken et al., 2006). The NSP1α, NSP1β, and NSP2 release 
from polyprotein-1a (or, polyprotein-1ab) first and then NSP4 (3C like protease) cleaves 
each of the rest 7 to 8 NSPs from the polyprotein (Sun et al., 2009; Ziebuhr et al., 2000).  
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The NSP1α and NSP1β cleavage site is important for PRRSV genome 
replication. The NSP1α of PRRSV is important for subgenomic mRNA synthesis 
whereas, NSP1β is mostly required for genome replication (Kroese et al., 2008). Both 
NSP1α and NSP1β have papain like cysteine protease (PCP) domain known as PCPα 
and PCPβ respectively which are required for their autoproteinase activity (Kroese et al., 
2008; Xue et al., 2010). The NSP1α-NSP1β cleavage occurs between Met and Ala amino 
acids of putative cleavage sites Cys-Ala-Met180-Ala-Asp-Val and the carboxy terminal 
PCP domain are required for this cleavage (Kroese et al., 2008; Xue et al., 2010). The 
crystal structure of analysis of NSP1α shows existence of zinc finger domain in its amino 
terminus, PCP domain, and carboxy terminal of extension (CTE). Also, NSP1α was 
shown to exist as a dimer (Sun et al., 2009). The zinc binding domain is present in the 
active site of PCPα (Sun et al., 2009). The crystal structure of NSP1β was recently 
solved (Xue et al., 2010). The amino terminus of NSP1β has divalent cation (Mg2+ and 
Mn2+) dependent nuclease activity (Xue et al., 2010). The NSP1β cleaves between 
NSP1β and NSP2 at Gly and Ala of putative cleavage site Trp-Trp-Gly203-Ala-Gly-Lys 
(Kroese et al., 2008; Xue et al., 2010). 
The NSP2 protein of PRRSV contains an amino terminus cysteine protease 
domain which is required for NSP2 and NSP3 cleavage. Also, NSP2 functions as 
cofactor in the protease activity of NSP4 for cleavage of the polyprotein-1a and 
polyprotein-1b (Snijder et al., 1994; Snijder et al., 1995; Wassenaar et al., 1997). B cell 
epitope mapping studies (de Lima et al., 2006) have shown the existence of more 
immunodominant epitopes in the NSP2 in comparison to other structural proteins of 
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PRRSV. Also, NSP2 region is more tolerant to larger amino acid deletions and insertions 
(Fang et al., 2008; Han et al., 2007; Ran et al., 2008; Shen et al., 2000).  
Out of all 14 NSPs, NSP9 (RNA dependent RNA polymerase, RdRp), NSP10 
(helicase), NSP11 (a Xenopus laevis homolog poly [U] specific endoribinuclease known 
as nidoviral endonucleae specific for U [NendoU]), and NSP12 are encoded by ORF1b of 
PRRSV (Fig.1.1B). The RdRP and helicase are required replication and transcription of 
PRRSV RNA genome (Snijder & Meulenberg, 1998). The NendoU protein possesses 
pyrimidine specific endoribonuclease activity. This protein of PRRSV is required for 
cleavage of U stretches in the RNA substrate in divalent cations (Mn2+) independent 
manner releasing 2’-3’-cyclic phosphodiester products (Nedialkova et al., 2009). 
Besides role of different NSPs of PRRSV in RNA genome transcription and 
replication, recent reports also emphasized their role in suppression of host innate 
immune response. NSP1α, NSP1β, NSP2, NSP4, and NSP11 antagonize IFN response 
and inhibit activation of IFN-β promoter activity (Beura et al., 2010; Chen et al., 2010; 
Kim et al., 2010). NSP1β inhibits double stranded RNA (dsRNA) induced 
phosphorylation and nuclear translocation of IRF3 (Beura et al., 2010). NSP1 also 
degrades CREB binding protein (CBP) and downregulates enhanceosome assembly. This 
in turn inhibits IFN response in PRRSV infected cells (Kim et al., 2010). The cysteine 
protease of NSP2 of PRRSV belongs to ovarian tumor (OTU) protease superfamily 
which is required for inhibition of ubiquitin mediated and ISG15 mediated host innate 
immune response (Frias-Staheli et al., 2007). 
 
 
 7 
1.6 Structural proteins of PRRSV 
PRRSV has seven structural proteins. They are GP2a, 2b (E), GP3, GP4, GP5, M, 
and N protein (Fig. 1.2). GP2a, GP3, GP4, and GP5 are N-glycosylated and are present 
on the viral envelope (Dea et al., 2000) as are the non-glycosylated M protein and 2b 
proteins. GP5, M, and N proteins are known as major structural proteins whereas, GP2a, 
2b (E), GP3, and GP4 proteins are regarded as minor structural proteins. All the major 
and minor envelope proteins are required for generation of infectious PRRSV (Wissink et 
al., 2005). 
1.6.1 Nucleocapsid (N) protein 
In the infected cells, the N protein is the most abundant viral protein (Dea et al., 
2000; Snijder & Meulenberg, 1998). It constitutes 40% of the total mass of the virion. It 
is a basic protein with an isoelectric point of 10.4 (Snijder & Meulenberg, 1998; Wootton 
et al., 2002) and molecular mass of approximately 15kDa. It is encoded by ORF7 and 
exists as a dimer (Dea et al., 2000; Mardassi et al., 1996; Meulenberg et al., 1995). 
Homodimerization of the N protein occurs in the endoplasmic reticulum (ER) and the 
Golgi complex through disulfide linkage via cysteine residue at position 23 in North 
American strain and cysteine-27 in European isolates (Wootton & Yoo, 2003). Cysteine-
23 position is required for infectious virus production and replication of viral genome 
(Lee et al., 2005). PRRSV replicates in the cytoplasm. Besides localization of the N 
protein in the cytoplasm and perinuclear region, nuclear localization of this protein has 
also been observed due to presence of a nuclear localization signal (NLS). Dimerization 
of the N protein does not appear to be required for nuclear translocation 
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Figure 1.2 Schematic representation of PRRSV particle. The location of structural 
proteins GP2a, 2b (E), GP3, GP4, GP5, M, and N are shown. GP5 and M are shown to 
exist as heterodimeric complexes. GP2a, GP3, and GP4 are shown as heterotrimers. The 
PRRSV RNA genome with 5’ cap and 3’ poly (A) tail is shown. The RNA is 
encapsidated by N protein.   
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(Lee et al., 2005). For efficient virus genome replication, nuclear localization of the N 
protein is not required (Lee et al., 2006). Out of two NLS at amino acid positions 10-13 
(NLS-1) and 41-47 (NLS-2) of the N protein, NLS-2 is required for nuclear localization 
(Rowland & Yoo, 2003). The N protein probably localizes to the nucleus because of an 
interaction between NLS and nuclear transporters, importin-α and importin-β (Rowland 
et al., 2003). The N protein has a role in ribosome biogenesis because it binds to the 28S 
and 18S ribosomal RNA (Yoo et al., 2003). The N protein of the North American strain 
of PRRSV has 123 amino acids and the European strain has 128 amino acids (Snijder & 
Meulenberg, 1998; Wootton et al., 2002). The N protein of both North American and 
European strains of PRRSV has a common antigenic region between amino acids 52 and 
69 (Meulenberg et al., 1998; Rodriguez et al., 1997). The N protein is a serine 
phosphoprotein and is highly immunogenic, but it does not produce neutralizing 
antibodies (Kimman et al., 2009; Wootton et al., 2002). Overall, the N protein promotes 
virus assembly in the cytoplasm and its role in the nucleus (and nucleolus) in the infected 
cell is not known (Lee et al., 2006).  
1.6.2 GP5 
  The GP5 is the most abundant glycoprotein found on the surface of the virion. It 
has a predicted signal sequence at its amino terminus. The protein has a ectodomain of 40 
amino acids, cytoplasmic domain of 50-72 amino acid, and  spans the membrane three 
times (Kimman et al., 2009; Mardassi et al., 1996; Meulenberg et al., 1995). The M and 
GP5 proteins form heterodimers within the ER (Mardassi et al., 1996). In EAV, it has 
been shown that heterodimerization of M and GP5 is important for envelope assembly 
and virus infectivity (Snijder et al., 2003) and by analogy, heterodimerization of these 
 10 
proteins in PRRSV is also presumed to play a similar role. GP5 has three N-glycosylation 
sites in North American strains (Fig. 1.3) whereas European strains of PRRSV have two 
N-glycosylation sites (Ansari et al., 2006; Wissink et al., 2004). Previous studies have 
shown that the glycan moities are required for protection against host neutralizing 
antibody response and virus production (Ansari et al., 2006).  
1.6.3 Matrix (M) protein 
M protein is unglycosylated and is the most conserved structural proteins among 
the Arteriviruses (Kimman et al., 2009). It has a molecular weight of 18 to 19 kDa (Dea 
et al., 2000), a short ectodomain of 10-18 amino acids, and amino terminal domains span 
the membrane three times. As described previously, the M protein is involved in 
heterodimer formation with GP5 through disulfide linkage in the amino terminus of both 
the proteins in the ER (Mardassi et al., 1996). Though it is not clear, M protein was 
predicted to play an important role in virus assembly and budding.  
1.6.4 GP2a  
The GP2a protein of PRRSV has two N-glycosylation sites (Fig. 1.3) and has a 
molecular size of 29-30 kDa (Dea et al., 2000).  This protein along with 2b protein are 
synthesized from the same bicistronic mRNA2 (Fig. 1.4) (Lee & Yoo, 2006). Both the 
glycosylation sites of European strains of PRRSV are dispensable or virus production 
(Wissink et al., 2004). However, my recent studies with type II North American isolate of 
PRRSV (reported in this thesis in chapter V) have revealed that the glycan addition at 
amino acid position 184 of GP2a is important for production of infectious virus. In 
addition, this protein also interacts with the PRRSV receptor CD163 (Das et al., 2010).  
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Figure 1.3 schematic representations of GP2a, GP3, GP4, and GP5 proteins. The 
proteins with their size in amino acids shown. Potential N-linked glycosylation sites (with 
residue number on bottom of the rectangular boxes), predicted signal sequences (SS) and 
transmembrane regions (TM) are shown. The amino (N) - and the carboxy (C) - termini 
are identified.  
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1.6.5 E (2b) 
It is a non-glycosylated, hydrophobic protein of 73 amino acids in case of North 
American strain and 70 amino acids in case of European strain. This protein is encoded 
from the internal ORF starting at +6 nucleotide position of the bicistronic mRNA2 
(mRNA for GP2a protein) (Lee & Yoo, 2006). The 2b protein of PRRSV also forms 
homo-oligomers by non-covalent interactions (Lee & Yoo, 2005; 2006). Though this 
protein is dispensable for virus assembly and particle formation, it is required for virus 
infectivity (Lee & Yoo, 2006). The 2b (or E) protein possesses ion-channel like 
properties and may function as a viroporin on the envelope (Lee & Yoo, 2006). After 
entry and transport of virus particle to the endosome, conformational changes occur due 
to the lower pH. This further exposes 2b and let it function as ion channel. The 2b protein 
is required for virus uncoating because it allows ions to enter the virion, triggers internal 
capsid disassembly, and promotes virus release into the cytoplasm (Lee & Yoo, 2006). 
The 2b protein associates with intracellular membranes and localizes around perinuclear 
regions including ER and the Golgi complex (Lee & Yoo, 2006). 
1.6.6 GP3 
It is highly N-glycosylated envelope protein with seven predicted glycosylation 
sites (Fig. 1.3) (Dea et al., 2000), but studies reported in this thesis (chapter V) show that 
only six of these glycosylation sites are used for glycan addition. It has a molecular mass 
of 42-45 kDa (de Lima et al., 2009; Dea et al., 2000). The coding sequence of GP3 is 
highly variable among different strains of PRRSV and most of the variability occurs at 
the amino terminus of the protein (Katz et al., 1995; Mardassi et al., 1995; Murtaugh et 
al., 1995). Although early studies reported that the GP3 protein is not a structural 
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component of the North American (genotype II) PRRS virions (Gonin et al., 1998; 
Mardassi et al., 1998), recent studies from our laboratory have shown that it is present on 
the virion envelope (de Lima et al., 2009), an observation consistent with the European 
(genotype I) PRRS virions (van Nieuwstadt et al., 1996). 
1.6.7 GP4  
It has four N-glycosylation sites (Fig. 1.3) and has a molecular mass of 29-35 kDa 
(Das et al., 2010; Meulenberg et al., 1997). The neutralizing epitopes of GP4 protein in 
North American and European strains are not well conserved (Dea et al., 2000).The most 
variable region for neutralizing epitopes of GP4 for Lelystad virus is between amino 
acids 40 and 79 (Meulenberg et al., 1997). Recent studies from our laboratory (Das et al., 
2010), demonstrated that GP4 interacts with the PRRSV receptor CD163. A detailed 
description of this interaction is described in this thesis (chapter IV).  
1.7 Multimeric complex formation of PRRSV envelope proteins 
Previous studies with both PRRSV and EAV have shown that the minor envelope 
glycoproteins GP2a, GP3 and GP4 and the unglycosylated 2b protein form a 
heterotetrameric complex in infected cells and formation of such a complex is required 
for the transport of these proteins from the endoplasmic reticulum (ER) to the Golgi 
apparatus in infected cells prior to virion assembly (Wieringa et al., 2004; Wissink et al., 
2005). Furthermore, the GP5 and M proteins of EAV and the homologous proteins of 
LDV form a heterodimer through disulfide bonds, which is required for viral infectivity 
(Balasuriya & MacLachlan, 2004; Faaberg et al., 1995; Snijder et al., 2003; Snijder & 
Meulenberg, 1998). This heterodimeric GP5-M protein interaction is required for proper 
post-translational processing of the proteins and the N-linked glycosylation of GP5 is not 
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required for GP5-M heterodimer formation (Mardassi et al., 1996). Although the 
envelope glycoproteins form multimeric complexes, the specific interactions among these 
glycoproteins and how the interactions result in formation of the large multimeric 
complex is currently unknown.   
1.8 Cell tropism and receptors of PRRSV 
PRRSV infects mostly alveolar macrophages of the lung. But, it does not replicate 
in nonactivated monocytes (Thanawongnuwech et al., 2001). The virus also infects other 
cells of monocyte and macrophage lineage including pulmonary intravascular 
macrophages, intravascular macrophages of placenta and umbilical cord, and subsets of 
macrophages in lymph nodes and spleen (Duan et al., 1997; Lawson et al., 1997). 
PRRSV has tropism for porcine alveolar macrophage (PAM) cells and 
sialoadhesin expressed on the surface of these cells is a receptor for PRRSV (Delputte et 
al., 2005; Delputte & Nauwynck, 2004; Delputte et al., 2007). PRRSV has only been 
found to infect and replicate to high levels in MARC-145 cells (Kim et al., 1993), a 
derivative of the African green monkey kidney cell line MA-104. However, MARC-145 
cells do not express sialoadhesin, indicating that molecules other than sialoadhesin 
promote entry of PRRSV in MARC-145 cells. Although several other molecules like 
vimentin, CD151, heparan sulfate have been identified as potential entry molecules for 
PRRSV (Kim et al., 2006; Shanmukhappa et al., 2007), recently porcine CD163 isolated 
from PAM cells was found to confer susceptibility to PRRSV infection to non-permissive 
cells (Calvert et al., 2007). A detailed description of different receptors and cofactors 
identified for PRRSV infection is described below: 
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1.8.1 Heparan sulfate 
 Heparan sulfate was reported as the receptor for PRRSV in MARC-145 cells 
(Jusa et al., 1997) and PAM cells (Delputte et al., 2002; Vanderheijden et al., 2001). 
Either incubation of PRRSV with heparin or treatment of cells with heparinase I (an 
enzyme that cleaves heparin and heparan sulfate) before inoculation with the virus 
decreased virus infectivity (Delputte et al., 2002; Jusa et al., 1997; Vanderheijden et al., 
2001). But, complete block to viral infection was not achieved indicating that this 
receptor is not the only receptor. Heparan sulfate is not macrophage specific and found in 
different animal tissues. It is assumed that the heparan sulfate molecules present on the 
surface of macrophage act as PRRSV attachment factors that helps in concentration of 
virion on the cell surface (Delputte et al., 2005). The M and N proteins of PRRSV can 
interact with heparan sulfate. The M protein binds with heparan sulfate mainly as a 
complex with GP5 whereas the N protein binds with heparan sulfate as a homodimer 
(Delputte et al., 2002). 
1.8.2 Sialoadhesin 
It is a macrophage specific type I transmembrane glycoprotein of 210 kDa in 
molecular mass. It is a prototype member of family of sialic acid binding lectins known 
as siglecs (Munday et al., 1999). Porcine sialoadhesin is considered as the attachment and 
internalization receptor since expression of this protein in non-permissive mammalian 
cells lead to binding and internalization of PRRSV but not productive viral infection 
(Vanderheijden et al., 2003). The sialic acid binding activity of porcine sialoadhesin is 
important for its function as the receptor for PRRSV. The amino terminal 
immunoglobulin like V-set domain of porcine sialoadhesin is important for its binding 
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with PRRSV (Delputte et al., 2007). Mostly α2-3 linked and to a lesser extend α2-6 
linked sialic acids present on the PRRSV envelope are required for binding of the virus 
with sialoadhesin (Delputte et al., 2007). The M and GP5 heterodimeric complex of 
PRRSV interacts with porcine sialoadhesin receptor (Van Breedam et al., 2010). 
1.8.3 Cellular proteases 
Aspartic proteases cathepsin E and unidentified serine proteases are implicated in 
PRRSV infection of macrophages (Misinzo et al., 2008). Their role in the virus life cycle 
is predicted to enhance virus uncoating (Misinzo et al., 2008). PRRSV partially 
colocalizes with cathepsin E and there is existence of positive correlation between 
cathepsin E and PRRSV infection (Misinzo et al., 2008). Expression of cathepsin E is 
restricted to certain cell types and generally it is found in non-lysosomal compartments 
such as endosomes, ER, and Golgi complex (Maric et al., 1994; Rawlings & Barrett, 
1995; Sastradipura et al., 1998). These proteases probably do not act as receptor of 
PRRSV, but their protease activity may be needed to cleave yet unidentified PRRSV GPs 
for uncoating as observed for Ebola virus (Chandran et al., 2005; Kaletsky et al., 2007). 
1.8.4 Simian Vimentin 
Vimentin is associated with cytoskeletal component of cells. Simian vimenin is 
present both in the cytoplasm as well as in the plasma membrane of MARC-145 cells 
(Kim et al., 2006) and appears to be a receptor for PRRSV in these cells. It also interacts 
with the N protein of PRRSV and may regulate virus association with other cytoskeletal 
components and enhance transport in the cytoplasm (Kim et al., 2006). 
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1.8.5 CD151 
CD151 is a member of the tetraspanin superfamily and has important roles in cell 
signalling and platelet aggregation (Fitter et al., 1999; Hasegawa et al., 1998; Roberts et 
al., 1995; Sincock et al., 1999). It interacts with the 3’ UTR of the virus and is an 
important cofactor for PRRSV infection in MARC-145 cells (Shanmukhappa et al., 
2007). 
1.8.6 CD163 
Recently, porcine CD163 isolated from PAM cells was found to confer 
susceptibility for PRRSV infection to non-permissive cells (Calvert et al., 2007; Das et 
al., 2010). Additionally, CD163 is also expressed in MARC-145 cells, suggesting that it 
facilitates entry of PRRSV in these cells. CD163 is a type I transmembrane protein that 
belongs to a scavenger receptor super family. It is mostly expressed in cells of monocyte 
and macrophage lineage. It was earlier reported that porcine sialoadhesin and CD163 act 
co-operatively for productive virus infection (Van Gorp et al., 2008). The major role of 
CD163 was predicted to be in virus uncoating and genome release instead of attachment 
(Van Gorp et al., 2008). Out of nine scavenger receptor cysteine-rich (SRCR) domains of 
porcine CD163, the 5th SRCR domain is the most important for PRRSV infection (Van 
Gorp et al., 2010). The 6th SRCR domain and two proline-serine-threonine (PST) rich 
interdomains of porcine CD163 also positively influence PRRSV infection (Van Gorp et 
al., 2010). Additionally, I have observed that the carboxy terminus 223 amino acids are 
required for PRRSV entry (chapter IV) (Das et al., 2010).The GPs on the virion envelope 
may interact with CD163 to mediate virus entry into these cells. At the present time, it is 
unknown which of the viral envelope glycoproteins directly interact with CD163 to 
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mediate virus entry into susceptible cells. Studies reported in this thesis (chapter IV) 
demonstrated that GP2a and GP4 proteins of PRRSV interact directly with CD163 (Das 
et al., 2010). 
Since GP5 protein is an abundant protein within the PRRSV envelope, it may play 
a role in interacting with the cell surface receptor for PRRSV entry. However, studies in 
which the ectodomains of the GP5 and M proteins of EAV were replaced with the 
ectodomains of the corresponding proteins from PRRSV or LDV in EAV infectious 
clone, the resulting chimeric EAV did not exhibit the altered tissue tropism, indicating 
that the GP5 protein may not be the PRRSV envelope protein that interacts with the 
receptor (Dobbe et al., 2001; Verheije et al., 2002). This finding suggests that other 
PRRSV envelope glycoproteins, especially, the minor envelope glycoproteins of PRRSV, 
also mediate receptor interaction and virus entry.  
1.9 Entry and uncoating of PRRSV 
Upon PRRSV binding with specific receptor(s), the virus internalizes via clathrin 
mediated endocytosis (Nauwynck et al., 1999). Release of the virus genome depends on 
the low pH of the endocytic compartment (Kreutz & Ackermann, 1996). After PRRSV 
entry, it enters early endosomes (pH 6-6.5) and releases its genome (Kreutz & 
Ackermann, 1996; Nauwynck et al., 1999). 
1.10 Replication and Transcription of PRRSV 
PRRSV genome replication occurs in the cytoplasm of the infected cell. A 
schematic of PRRSV genome replication and transcription is shown in Fig. 1.4. This is 
derived from the current knowledge of Nidovirales genome transcription and replication 
(Snijder & Spaan, 2007). The RdRp enzyme complex recognises the RNA signals near 
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the 3’ end of the positive stranded viral genome and initiates replication to generate the 
full-length minus strand anti-genome (Pasternak et al., 2006). The minus-strand again 
acts as template for genomic RNA synthesis. Specific cis-signals present on the 3’ end of 
both the genomic and the anti-genomic RNA are required for replication (Godeny et al., 
1993; Meulenberg et al., 1993; Snijder & Meulenberg, 1998). The newly synthesized 
genomic RNA acts as the template for both synthesis of more anti-genome RNA as well 
as sub-genomic length minus-strands (Snijder & Meulenberg, 1998). PRRSV RNA 
synthesis is asymmetric. During genome replication, more plus stranded RNA is 
synthesized than minus stranded RNA (Sawicki et al., 2001). Sub-genomic messenger 
RNA (sg mRNA) is mostly synthesized from full-length minus-strand anti-genome in 
non-equimolar but constant amounts (Fig. 1.4, step 6). But, there are also reports of sg 
mRNA synthesis from sub-genomic length minus strand templates (Pasternak et al., 
2006; Sawicki et al., 2001; Sawicki & Sawicki, 2005). The ratio of synthesis of genomic 
RNA to sg mRNAs remains constant throughout the replication cycle. The sg mRNAs of 
PRRSV have 3’ co-terminal sequences (nested set of mRNAs) and common 5’ leader 
sequence of 65-100 nucleotides in length (Lai et al., 1983; Lai et al., 1982). All of the sg 
mRNAs of PRRSV except the smallest one (sg mRNA for N protein) are polycistronic. 
But, during translation only the 5’ ORF of the genome gets translated  (Pasternak et al., 
2006).   
For PRRSV sg mRNA synthesis, discontinuous transcription occurs in which case 
the leader sequences of mRNA fuses co-transcriptionally with the body of mRNA 
(Pasternak et al., 2006). Transcription regulating sequences (TRS) play an important role 
for fusion of leader and body sequences of mRNA 
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Figure 1.4 Overview of life cycle of PRRSV. After entry (by receptor mediated 
endocytosis) and uncoating (step 1), the + sense genomic RNA acts as mRNA for 
synthesis of NSP polyprotein complex polyprotein-1a and polyprotein-1b (step 2 and 3), 
which further gets cleaved by viral proteases to produce 13-14 NSPs (step 4). The NSPs 
(especially RdRp) catalyses replication of genomic RNA to produce full-length 
antigenomic RNA (step 5) and transcription to produce 8 sub-genomic mRNAs (sg 
mRNAs) (step 6). The longest sg mRNA (+ sense genome) can be used either as mRNA 
template for NSP polyprotein synthesis (step 7) or as genomic RNA for packaging (step 
8). The different sg mRNAs are translated to produce seven structural proteins – GP2a, 
2b, GP3, GP4, GP5, M, and N. All the structural proteins are required for virus 
packaging. Virus assembly occurs in the ER and Golgi complex (step 9). Budding of 
progeny virus occurs in intra cellular membranes in ER and Golgi complex (step 10) 
followed by release of the virion particle (step 11). 
 21 
(Pasternak et al., 2001; van Marle et al., 1999; Zuniga et al., 2004). TRSs are AU-rich 
sequences of 5 to 8 nucleotides long (Pasternak et al., 2006) which are located at either 
the 3’ end of the leader sequences of sg mRNA, the 5’ end of body segment of sg mRNA, 
or at the leader-body fusion site of sg mRNA (Pasternak et al., 2006; Spaan et al., 1983). 
Two mechanisms proposed for transcription of PRRSV sg mRNA are (a) leader primed 
transcription and (b) discontinuous extension of minus strand RNA synthesis (Pasternak 
et al., 2006; Snijder & Meulenberg, 1998). In the case of “leader primed transcription” 
model (Fig. 1.5A) (Baric et al., 1983; Lai et al., 1984; Spaan et al., 1983), the leader 
primer is initially synthesized by transcription from the 3’ end of the antigenome. The 
leader TRS along with the leader transcript then base pairs with different anti-body TRS 
from the antigenome and continue transcription to produce sg mRNA synthesis.  In the 
case of “discontinuous extension minus strand RNA synthesis” model (Fig. 
1.5B)(Sawicki & Sawicki, 1995; 2005), there is discontinuous synthesis of minus strand 
with attenuation of RNA synthesis occurring at different body TRS. Then the TRS of 
partially synthesized RNA bind with leader TRS to form sub genomic length minus 
strand RNA. This again acts as template for sg mRNA synthesis (Pasternak et al., 2006).  
1.11 Virus assembly and budding 
PRRSV assembly and budding occurs in the ER and Golgi. The four minor 
envelope proteins required to be present together for their transport from the ER to the 
Golgi complex (Wissink et al., 2005). GP5/M heterodimers also assemble in the ER and 
the Golgi complex (Mardassi et al., 1996). Because of virus assembly in the ER and the 
Golgi complex, lower levels of structural proteins accumulate on the plasma membrane 
of the infected cells.  
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Figure 1.5 Models of transcription of PRRSV. (A) Leader primed transcription 
(discontinuous plus-strand RNA synthesis) model. This model proposes that the plus 
strand RNA synthesis is either continuous (producing genomic RNA) or discontinuous 
(producing sg mRNAs). Initially, the leader transcript (+L) is synthesized from the 3’ end 
of the anti-genome. The leader TRS of the leader transcript further base pairs with anti-
body TRS (of anti-genome) at the 5’ end of the genomic RNA and facilitates synthesis of 
sg mRNA. (B) Discontinuous extension of minus strand RNA synthesis model. This 
model proposes that minus strand synthesis from the genomic RNA can be either 
continuous (producing anti-genomic RNA) or discontinuous (producing sg-length minus 
strands). During minus-strand RNA synthesis, the body TRSs (of genome) acts as 
attenuation signal and terminate the minus strand synthesis at different body TRS. The 
nascent minus strand RNAs with the anti-body TRS further transferred to the 5’ end of 
the genomic RNA template, the anti-body TRS base pairs with the leader TRS (of 
genome), and anti-leader (-L) is added to form the sg-length minus strands. Then, the 
differentially terminated sg-length minus strands serves as templates for sg mRNA 
synthesis. 
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1.12 Immune response to PRRSV 
It takes approximately 3 month to develop protective acquired immunity against 
PRRSV during natural infection. Because PRRSV has different strains, immunity 
developed against one strain is not sufficient for protection against another strains 
(Kimman et al., 2009) demonstrating a lack of heterologous protection.  
1.12.1 Innate immunity against PRRSV infection 
 PRRSV infection of pigs fails to elicit any significant cytokine expression 
including type I interferon (IFN), interleukin (IL)-1, and TNF-α in the lungs 
(Thanawongnuwech et al., 2001; Van Reeth et al., 1999). IFN-α inhibits PRRSV 
replication (Albina et al., 1998; Le Bon et al., 2001) and downregulation of IFN-α 
expression is probably one of the key steps in virus pathogenesis. PRRSV infection 
downregulates of IFN-α production in alveolar macrophages by interfering dsRNA 
mediating signalling pathways (Beura et al., 2010).  During PRRSV infection, the weak 
initial innate immune response probably leads to longer survival of the virus in the 
infected animals (Kimman et al., 2009). The virus suppresses immune response by 
altering cytokine production in the macrophages and dendritic cells. It also modifies 
antigen presentation (Kimman et al., 2009). This leads to delayed activation and 
mobilization of natural killer cells, which reduces neutralizing antibody responses, 
lymphoproliferative, and IFN-γ responses against PRRSV (Butler et al., 2008; Chang et 
al., 2008; Flores-Mendoza et al., 2008; Kimman et al., 2009).  Besides weak innate 
immune responses, other factors that lead to viral persistence includes antibody mediated 
enhancement of infectivity and lack of incorporation of viral proteins in the plasma 
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membrane of infected cells (Kimman et al., 2009). The latter is due to the fact that 
PRRSV budding and assembly occurs in the ER and the Golgi complex compartments, 
which leads to accumulation of the nucleocapsid and other viral proteins at the site of 
budding. Hence, PRRSV specific antibodies fail to detect the virus (Costers et al., 2006; 
Kimman et al., 2009). Additionally, IFN-γ response was found to rise in serum 
immediately after PRRSV infection and this serum titer lasts for approximately 3 weeks 
(Wesley et al., 2006). This rise may correlate with an increase in viral load (Loving et al., 
2008) in the infected animals because both IFN-α and IFN-γ inhibit PRRSV replication 
in vitro (Bautista & Molitor, 1999; Gaudreault et al., 2009).  
1.12.2 Cell mediated (T cell) immunity 
PRRSV T cell mediated immune response is characterized by type I cytokine 
expression which includes IFN-γ and IL-2 (Kimman et al., 2009). Although cell mediated 
immunity that includes IFN-γ level is inefficient in downregulating PRRSV infection 
(Batista et al., 2004; Kimman et al., 2009; Lowe et al., 2005; Murtaugh et al., 2002), a 
live attenuated vaccine against PRRSV inducing higher level of IFN-γ secreting cells was 
shown to be protective to pigs against viremia (Meier et al., 2003).  IFN-γ is known to 
reduce PRRSV titers in infected PAM cells in vitro (Gaudreault et al., 2009). T cell 
response in PRRSV infected pigs is directed against GP2a, GP3, GP4, GP5, M, and N 
protein. Of all these proteins, the M protein is the most potent inducer of T cell 
proliferation (Bautista et al., 1999; Jiang et al., 2007a; Jiang et al., 2007b; Kimman et al., 
2009; Wesley et al., 1999). With regard to GP5, amino acid residues 117-131 and 149-
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163 were identified to contain immunodominant T cell epitopes (Vashisht et al., 2008). T 
cell epitopes in other structural proteins have not been characterized yet. 
PRRSV infection causes apoptosis of dendritic cells (Costers et al., 2008; 
Kimman et al., 2009; Lee & Kleiboeker, 2007). It further down regulates inflammatory 
cytokine production and T cell response. Also, virus infections interferes with major 
histocompatibility complex (MHC) I and MHC II antigen presentation leading to down 
regulation of antigen presentation by T cells (Chang et al., 2008; Flores-Mendoza et al., 
2008; Kimman et al., 2009; Loving et al., 2007; Wang et al., 2007). 
1.12.3 Humoral (antibody mediated) immunity 
Both neutralizing and non-neutralizing antibodies are produced during PRRSV 
infection in pigs. Antibodies directed against N protein of PRRSV are most abundant 
during viral infection, but they are non-neutralizing and hence do not confer protection 
against virus infection (Kimman et al., 2009). Non-neutralizing antibodies directed 
against M and N proteins of PRRSV can be detected as early as 5 days post infection. 
Lower titers of neutralizing antibodies appear between 2 and 4 weeks post infection 
(Kimman et al., 2009; Loemba et al., 1996; Plagemann, 2006). It blocks PRRSV by 
reducing the number of virus attachment and internalization (Delputte et al., 2004). The 
epitopes for neutralizing antibody production are present in GP3, GP4, GP5, and M 
protein of PRRSV (Ansari et al., 2006; Cancel-Tirado et al., 2004; Kim & Yoon, 2008; 
Kimman et al., 2009; Plagemann, 2006; van Nieuwstadt et al., 1996; Yang et al., 2000). 
Out of all the above proteins, neutralizing antibodies produced against GP5 is most 
relevant for protection against PRRSV infection (Ansari et al., 2006; Ostrowski et al., 
2002). The major neutralization epitopes of GP5 are located in the middle of the 
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ectodomain of the protein encompassing amino acids 36 to 52 (Ostrowski et al., 2002; 
Plagemann et al., 2002) and this region is flanked by N-glycosylation sites (Ansari et al., 
2006). 
1.13 Immune evasion of PRRSV 
Upon virus infection of a host, neutralizing antibodies are produced against 
specific epitopes of the envelope proteins of the virus. They mostly bind to the epitopes 
to neutralize the virus. On the other hand, viruses evolve various mechanisms to evade 
host immune response. Like other viruses, PRRSV also uses different protective 
strategies for its successful replication inside host cells and evasion against the host 
immune response. Some of the key strategies are outlined below: 
1.13.1 Introduction of random mutations and quasispecies variation 
PRRSV mutates quickly in pigs (Horter et al., 2002; Rowland et al., 1999) and 
several multiple variants co-exist in experimentally infected pigs (Chang et al., 2002). 
Several PRRSV strains exist in the field as quasispecies of each genotypes of PRRSV 
(Goldberg et al., 2003). Heterogeneity of these strains is observed both antigenically and 
clinically but not distinct enough to be regarded as geographical subpopulation (Kapur et 
al., 1996; Meng et al., 1995; Stadejek et al., 2002).  Previous studies for GP5 of PRRSV 
(Rowland et al., 1999) have shown that appearance of quasispecies by variability in the 
single nucleotide level of GP5 leads to positive and negative selection. Existence of 
quasispecies in PRRSV may result in the inability of traditional methods of vaccination 
to control the virus infection in a herd or in a region.  
 The random mutations elicited in the viral genome can be present both in the 
specific epitopes targeted for neutralization as well as other regions of the envelope 
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proteins. Once mutations are present in the neutralizing antibody targeted epitopes, it 
inhibits the binding of the neutralizing antibodies to the epitope (Mascola & Montefiori, 
2003) and the virus escapes neutralization by the antibody. 
1.13.2 Antibody mediated enhancement 
Studies in murine models (Cancel-Tirado et al., 2004; Kimman et al., 2009) for 
PRRSV have shown that virus infection can be enhanced by certain enhancing 
antibodies. In this case, virus specific antibodies either maternal origin or due to previous 
vaccination can facilitate entry of the virus in to target cells. The antibody mediated 
enhancing epitopes were reported to be present N and GP5 proteins of PRRSV (Cancel-
Tirado et al., 2004).  
1.13.3 “Decoy” epitopes 
Presence of immunodominant “decoy” epitopes adjacent to neutralizing epitopes 
in GP5 evokes early and robust of non-protective (non-neutralizing) antibody response 
against PRRSV. This effect further masks the early recognition of crucial neutralizing 
epitopes leading to delay in neutralizing antibody production in the virus infected host 
(Fang et al., 2006; Ostrowski et al., 2002).  
1.13.4 Glycan shielding of neutralizing epitopes 
The viral envelope glycoproteins act as shield or cover for the neutralizing 
epitopes so that the neutralizing antibodies fail to bind to those epitopes. Also, by 
shielding the epitopes it prevents neutralizing antibody production against those epitopes. 
This mechanism was first proposed for Human Immunodeficiency Virus (HIV) and 
Simian Immunodeficiency Virus (SIV) (Reitter et al., 1998; Scanlan et al., 2007; Wei et 
al., 2003) and latter discovered in many other viruses including PRRSV. The glycan 
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moities present on the GP5 of PRRSV are required for protection against neutralizing 
antibody response (Ansari et al., 2006). It is unknown whether glycan moities present in 
three other minor envelope glycoproteins (GP2a, GP3, and GP4) of PRRSV are also 
required for glycan shielding. I have examined the role of N-glycosylation of these three 
proteins of PRRSV in glycan shielding mechanism in this dissertation (chapter V). 
1.14 N-glycosylation as a post-translational modification of the protein 
N-glycosylation is one of the post-translational modifications of the proteins. The 
motif of N-glycosylation is N-X-S/T where X can be any amino acid other than proline. 
Oligosaccharyl transferase (OST) enzyme is required for glycosylation and is composed 
of seven to eight subunits (Kelleher & Gilmore, 2006). STT3 subunit of yeast has 
homolog (STT3A and STT3B) in mammals. STT3A and STT3B subunits of OST are 
essential for co-translational and post-translational glycosylation of a glycoprotein. Most 
of the glycoproteins are co-translationally glycosylated during their synthesis in the ER. 
But, recent studies have shown that some of the host glycoproteins are also post-
translationally glycosylated (Bolt et al., 2005; Ruiz-Canada et al., 2009). Besides host 
proteins, the large envelope protein of hepatitis B virus is also post-translationally 
glycosylated (Lambert & Prange, 2007). Whether post-translational glycosylation occurs 
in PRRSV is not known and studies reported in this dissertation address this aspect. 
1.15 Role of N-glycosylation of viral proteins 
 Viruses take advantage of N-glycosylation for their propagation in the host. 
There are several reports regarding the different roles played by N-glycosylation of viral 
proteins of Hantaan virus, hepatitis C virus, influenza virus, Dengue virus, West Nile 
virus, Bunyamwera virus, and prototype foamy virus for tissue tropism, receptor 
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interactions, viral entry, protein folding, targeting, secretion, assembly, exit, immune 
evasion, and morphogenesis etc (Beasley et al., 2005; Daniels et al., 2003; Fournillier et 
al., 2001; Hanna et al., 2005; Luftenegger et al., 2005; Mondotte et al., 2007; Shi et al., 
2005; Shi & Elliott, 2004; Vigerust & Shepherd, 2007). N-glycosylation of SIV, HIV and 
Bunyamwera virus, HCV, and Ebola virus not only promotes viral replication and 
infectivity, but also provides a glycan shield against host neutralizing antibodies and 
thereby facilitates virus spread (Lin et al., 2003; Reitter et al., 1998; Scanlan et al., 2007; 
Shi et al., 2005; Vigerust & Shepherd, 2007; Wei et al., 2003). 
1.16 Experimental plan 
1.16.1 Overall objective 
PRRSV has four N-glycosylated envelope proteins present on its surface. 
Although the OST enzyme is required for glycosylation, it is unknown whether the four 
glycoproteins of PRRSV are co-translationally and/or post-translationally glycosylated. 
There is not much information available regarding the intermolecular interactions of the 
four glycoproteins among themselves and with the receptor CD163 for PRRSV. Previous 
studies from our laboratory examined the role of glycosylation of GP5 in virus infectivity 
and neutralizing antibody response (Ansari et al., 2006). However, little is known about 
the role of glycosylation of the other minor envelope glycoproteins (GP2a, GP3, and 
GP4) on production of infectious PRRSV and neutralizing antibody response. The studies 
reported in this thesis were undertaken to decipher the molecular interactions of GP2a, 
GP3, GP4, and GP5 among themselves and with the receptor CD163. Additionally, the 
role of N-glycosylation of GP2a, GP3, and GP4 in virus infectivity, neutralizing antibody 
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response, and receptor interactions was examined. The following hypotheses were 
developed and experiments were conducted to examine each of these hypotheses. 
1.16.2 Hypothesis I, objective, and experimental approach 
I hypothesized that GP2a, GP3, GP4, and GP5 of PRRSV are co-translationally 
and/or post-translationally glycosylated. My objective was to determine which of the 
viral glycoproteins are co-translationally and/or post-translationally glycosylated. 
The experimental approach for this objective was to clone the individual viral 
glycoproteins in various expression vectors and examine expression of the individual 
glycoproteins in transfected cells and compare to those synthesized in PRRSV-infected 
cells. Subsequently, the proteins were metabolically labelled in transfected cells by short 
pulse-labelling to allow synthesis of the proteins, chased for various lengths of time and 
examine how the synthesized proteins are glycosylated. These pulse-chase studies 
allowed me to determine if the glycoproteins are co-translationally and/or post-
translationally glycosylated. 
1.16.3 Hypothesis II, objective, and experimental approach 
All four envelope glycoproteins are required for infectious PRRSV production. 
The proteins must be transported from the ER to the Golgi complex during virus 
assembly. I hypothesized that these proteins interact with each other for virus assembly 
and to facilitate entry by binding to cell receptors. The objective of this study was to 
determine the intermolecular interactions of these glycoproteins and identify which of the 
glycoproteins specifically interact with CD163. 
 In order to study the interactions among the glycoproteins of PRRSV, the 
glycoproteins were co-expressed in various combinations in BHK-21 cells and co-
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immunoprecipitation (co-IP) assays performed. Similarly, the porcine CD163 molecule 
was cloned from porcine alveolar macrophage (PAM) cells and its specific interaction 
with the envelope glycoproteins examined. These studies allowed me to develop an 
interactome map of PRRSV GPs and CD163. 
1.16.4 Hypothesis III, objective, and experimental approach 
The N-glycosylation of GP5 of PRRSV was shown to be important for infectious 
virus production and protection against host neutralizing antibody response. 
Hypoglycosylation of GP5 was also shown to be important for induction of higher 
neutralizing antibody titers in infected animals. I hypothesized that glycosylation of 
GP2a, GP3, and GP4 may be required for infectious virus production, protection against 
host neutralizing antibody response in infected animals, and interaction with receptor 
CD163. Hypoglycosylation of these minor glycoproteins may also induce higher 
neutralizing antibody response. The objective of this study was to determine if 
glycosylation at certain sites in the glycoproteins was important for infectious virus 
production and whether deglycosylation affects neutralizing antibody response. 
To study the importance of N-glycosylation in virus production, the asparagine 
(N) residues of each predicted glycosylation site were mutated to alanine (A) in the 
coding sequences of the glycoproteins. Expression and glycosylation of these proteins 
were compared to that seen in wild type proteins. Further, the mutant coding sequences 
were cloned in the FL12 infectious clone and the effect of glycosylation mutation on 
infectious virus production examined. Subsequently, neutralizing antibody response in 
mutant virus-infected pigs was examined.  
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Chapter II: MATERIALS AND METHODS 
2.1 Cell culture and maintenance of cells 
The Baby hamster kidney-21 (BHK-21) cells were maintained in minimal 
essential media (MEM) containing 5% FBS and 100 units of Penicillin, 20 units of 
Kanamycin and 20 units of Streptomycin (1X PKS) antibiotics per one milliliter of 
media. MARC-145 cells were maintained in low bicarbonate-low glucose Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% FBS and 1X PKS (Ansari et al., 2006; 
Truong et al., 2004). HeLa cells were maintained in high glucose containing DMEM with 
10% FBS and 1X PKS. 
2.2 Preparation of recombinant vaccinia virus (vTF7-3) stocks 
The vTF7-3 virus (Fuerst et al., 1986), a recombinant vaccinia virus that 
expresses the bacteriophage T7 RNA polymerase in the cytoplasm of infected cells, was 
grown and titrated in BHK-21 cells as described before (Ansari et al., 2006) and stored at 
-800C in small aliquots.  
The frozen vTF7-3 virus was thawed and reconstituted in PBS containing 0.01% 
CaCl2 and 0.01% MgCl2. BHK-21 cells plated in 100 mm tissue culture dish were 
infected with 0.1 multiplicity of infection (MOI) of vTF7-3 virus and incubated in 37oC 
with 5% CO2 concentration for 45 min with intermittent rocking in each 10 min interval. 
Following incubation, the residual virus was aspirated and the cells were washed with 
DMEM twice. The BHK-21 cells were further incubated in 37oC with 5% CO2 
concentration containing 8 ml of DMEM with 2% FBS and 1X PKS antibiotics per one 
milliliter of media. The cells were incubated for 42–48 h until the 90–95% of cells show 
extensive cytopathic effect (CPE). The supernatant was aspirated and the cells were 
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collected in 2ml of 10mM Tris-HCl pH 9.0 by scrapping with rubber polishman. The 
collected cells were centrifuged at 500 X g for 5 min and the supernatant was discarded. 
The cell pellet was frozen in -80oC overnight. Then, the cell pellet was thawed and 
resuspended in 10mM Tris-HCl pH 9.0 and sonicated for 2 min. The freeze-thawing 
procedure was repeated twice and the collected supernatant from each step was pooled 
together and aliquoted in 40µl volume and stored in -80oC. The titer of the prepared 
vTF7-3 virus stock was determined by plaque assay in BHK-21 cells.  
2.3 Preparation of PRRSV stocks 
The infectious clone derived FL12 virus was grown in MARC-145 cells as 
described before (Ansari et al., 2006; Truong et al., 2004). The MARC-145 cells were 
plated in 100 mm tissue culture dish. Two days after cell splitting, the cell monolayers 
with 90% confluency were washed with 1X phosphate buffered saline (PBS) twice. 
Previously stored FL12 or mutant FL12 virus was used to infect fresh MARC-145 cells 
with 0.1 MOI. The virus was diluted in low bicarbonate-low glucose DMEM with 10% 
FBS and 1X PKS media. The cell monolayer in 100 mm tissue culture dish was treated 
with 1ml of the diluted virus and incubated at 37oC for 45 min with intermittent rocking 
at 10 min intervals. After virus adsorption, the residual virus was aspirated and 8ml of 
media containing low bicarbonate-low glucose DMEM with 10% FBS and 1X PKS was 
added to the culture dish. The culture dish was incubated at 37oC and 5% CO2 
concentration for 4–5 days or until 95% of the cells in the monolayer exhibited 
significant CPE. The media containing virus and cell debris were collected in a tube and 
kept in -80oC. After overnight storage, the supernatant was freeze-thawed 2-3 times and 
centrifuged at 500 X g for 5 min to pellet the cell debris. The supernatant containing the 
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virus was aliquoted in 500 µl volume and stored in -80oC. The viral titer in plaque 
forming unit (PFU)/ml was determined by plaque assay in MARC-145 cells.  
2.4 Virus concentration by ultracentrifugation 
The thawed FL12 virus stock was centrifuged at 3000 X g for 30 min (or 6000 x g 
for 10 min) to clarify the supernatant. 5ml of 10% (w/v) sucrose solution in NTE (50mM 
NaCl, 10mM Tris-HCl pH 7.5, and 1mM EDTA) was loaded in polyallomer 
ultracentrifuge tube (Beckman, Palo Alto, CA) and the clarified virus stock was slowly 
added on top of this sucrose cushion. One ml of low bicarbonate-low glucose DMEM 
was added slowly on top of the loaded virus stock. The virus was pelleted by 
centrifugation at 100,000 X g for 3 h at 4oC in SW41 rotor (Beckman, Palo Alto, CA). 
Following centrifugation, the supernatant was aspirated and the virus pellet was 
resuspended in 100 µl of PBS. The titer of the concentrated virus stock was measured by 
plaque assay and the virus was stored in -80oC.  
2.5 RNA electroporation and virus recovery 
RNA electroporation was performed as described before (Ansari et al., 2006; 
Truong et al., 2004). MARC-145 cells were plated in 100 mm dish two days before 
electroporation. The cells were trypsinized, washed with 1X PBS and resuspended in E 
buffer (DMEM containing 1.25% dimethyl sulfoxide [DMSO]) with a final concentration 
of 5 x 106 cells per milliliter. Approximately 2µg each of MARC-145 cell RNA and 
FL12 (wild type or its mutant form) RNA was mixed in a microfuge tube and further 
transferred to a 4mm cuvette (BioRad laboratories, CA) containing 2 X 106 MARC-145 
cells per 400µl of E buffer. The RNA-MARC-145 cell suspension was subjected to 
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electroporation using Gene Pulser Xcell electroporator (BioRad, CA) at 225 volts and 
925 µF capacitance. The electroporated cells were transferred to a 35mm dish containing 
2 ml of recovery media (media for MARC-145 cells as described earlier). Roughly 10% 
of the electroporated cells were separately plated in a 24 well plate for indirect 
immunofluorescence to check for the biological activity of the transfected RNA as 
described latter. The media from the plates were replaced with fresh media 12 h after 
electroporation and incubated for desired length of time. 
2.6 Multi step growth kinetics assay 
Multi step growth kinetics was performed by infecting MARC-145 cells seeded in 
a six well plate with 0.1 MOI of FL12 and N-glycosylation defective mutant viruses. Due 
to significantly lower titer of some of the recovered GP3 N-glycosylation defective 
mutant viruses, 0.001 MOI was used for performing multi step growth kinetics. The 
appropriately diluted virus with the low bicarbonate-low glucose DMEM was added on 
top of the 90% confluent MARC-145 cells and incubated at 37oC and 5% CO2 
concentration for 45 min with intermittent rocking. After adsorption, the residual virus 
was aspirated; the cell monolayer was washed with 1X PBS, and 2ml of low bicarbonate-
low glucose DMEM containing 10% FBS and 1X PKS was added on the cell monolayer. 
The cells were further incubated at 37oC for up to 5 days. The supernatant was collected 
at 12 h intervals up to 120 h post infection. Approximately 300µl of supernatant was 
collected at each time point and equal volume of fresh media was added after each 
collection.  
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2.7 Plaque assay 
Previously collected virus supernatant was used for plaque assay. Each virus was 
diluted with 10-fold dilution. After 45 min post infection of MARC-145 cells with either 
FL12 or mutant viruses, the cells were washed with cold PBS twice followed by an 
overlay of 4 ml of DMEM containing 1.2% low melting point (LMP) agar, 2% FBS, and 
IX PKS as described before (Ansari et al., 2006). After polymerization of agar, the cells 
were incubated at 37oC for 4-5 days as per the requirement (till the plaques appear). 
Following incubation, the cell monolayer was fixed by addition of 2% glutaraldehyde for 
2 h. The agar plugs were removed and the cells stained with 0.01% crystal violet and 
30% methanol solution for 30 min followed by washing off the excess stain by water. 
The plaques were counted manually. 
2.8 Antibodies 
The porcine anti-CD163 monoclonal antibody was purchased from AbD Serotec 
USA (Raleigh, NC). The monoclonal antibody (SDOW17) against the PRRSV N protein 
(Nelson et al., 1993) was purchased from National Veterinary Services Laboratories 
(Ames, Iowa). The anti-HA polyclonal antibody was purchased from Santa Cruz 
biotechnology, Inc (Santa Cruz, CA). The anti-FLAG monoclonal antibody, anti-FLAG 
polyclonal antibody, and anti-cMyc monoclonal antibody were purchased from Sigma 
Aldrich (St. Louis, MO). The anti-GP5 rabbit polyclonal antibody was kindly provided 
by Dr. Carl Gagnon (University of Quebec, Montreal, Canada). Alexa Fluor-488 and 594 
goat anti-rabbit and anti-mouse IgG antibodies were purchased from Molecular Probes 
and used as secondary antibody for fluorescence microscopy.  Monospecific antibodies 
against GP2a, GP3, and GP4 were generated by co-immunization of rabbits with two 
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highly immunogenic peptides for each protein as described (de Lima et al., 2009). The 
details of production and characterization of the GP3 monospecific antibody were 
reported earlier (de Lima et al., 2009). The selection of peptides, their synthesis, and 
production of anti-GP2a and anti-GP4 monospecific polyclonal antibodies were followed 
similarly as reported previously (de Lima et al., 2009; de Lima et al., 2006). The amino 
acid residues of the selected peptides for GP2a are CEMVSRRMYRTMEKA and 
CKAGQAAWKQVVSEAT. The amino acid residues of the selected peptides for GP4 
are CLFYASEMSEKGFK and CFTSYVQHVKEFTQR. The peptides were synthesized 
and conjugated to a carrier protein (keyhole limpet hemocyanin [KLH]) either by adding 
a cysteine residue at the amino terminus (underlined) or via activated 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) chemistry to its N-terminal 
region. The antibodies were produced by Sigma and were characterized in our laboratory. 
Sera collected at day 77 post-immunization were used in all experiments. 
2.9 Preparation of chemically competent bacterial cells 
For preparation of the competent cells, DH5α cells were used. Two buffers were 
prepared prior to the preparation of competent cells: (1) 0.5 M PIPES (piperazine-1,2-
bis[2-ethanesulfonic acid]) and (2) Inoue transformation buffer – The buffer contains 55 
mM  MnCl2 (H2O)4, 15 mM CaCl2(H2O)2, 250 mM KCl, and 10 mM PIPES (pH 6.7). 
Both the solutions were filter sterilized and stored at -20oC.   
The Escherichia coli (E.coli) strain DH5α cells were streaked on LB agar plate 
(without any antibiotics) and incubated at 37oC incubator for overnight. Starter culture 
was prepared by inoculating a single bacterial colony in 25 ml of LB media and 
incubating at 37oC incubator with a shaking speed of 300 rpm for 6-8 h. Approximately 8 
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ml of starter culture was further inoculated in to 250 ml of LB media and incubated in an 
incubator with constant shaking speed of 250 rpm at 18-20oC. The bacterial growth was 
checked periodically with a spectrophotometer and once the OD600 reading of 0.5 was 
achieved, the culture was removed from the incubator and kept on ice cold water bath for 
10 min. The bacteria were pelleted by centrifuging at 2500 X g for 10 min at 4oC. After 
aspiration of the supernatant, the bacterial pellet was resuspended in 80 ml of ice cold 
Inoue transformation buffer by gentle swirling. The resuspended bacterial pellet was 
again centrifuged as described above and the bacterial pellet was finally resuspended in 
20 ml of Inoue transformation buffer containing 1.5 ml of DMSO. The cell suspension 
was mixed gently by swirling and kept on ice cold water bath for 10 min. The competent 
bacterial cells were then aliquoted as 100µl volume in 0.5 ml tubes and snap-frozen in 
liquid nitrogen. The competent cells were further stored in -80oC for future use.  
2.10 DNA Ligation 
The restriction endonuclease enzymes were purchased from New England Biolabs 
(Ipswich, MA). Restriction digestion of the plasmid and PCR product was performed by 
restriction endonuclease enzyme as per manufacturer’s instruction. The enzymes and 
buffers were stored in -20oC. The digested plasmid (or PCR product) was resolved in 
0.8% LMP agarose gel and purified by either phenol-chloroform extraction method or 
glass silica extraction method. The DNA was resuspended in water.  The concentration of 
the insert and vector was checked by examining small aliquots of DNA in agarose gel. T4 
DNA ligase (Invitrogen) was used for DNA ligation reaction as per manufacturer’s 
instructions. Generally, for ligation reaction, the vector-insert ratio was kept as 1:3. The 
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ligation reaction was either incubated at room temperature for 2-3 h or at 16oC for 
overnight.  
2.11 Bacterial transformation 
Transformation of bacteria was performed as described in ‘Molecular Cloning: A 
laboratory Manual’ (Russell, 2001) with modifications. About 5µl of the ligation mixture 
was incubated with 50µl of competent DH5α bacterial cells for 30 min on ice. Following 
incubation, the bacterial cells were heat shocked at 42oC for 90 seconds. After the heat 
shock, the cells were incubated on ice for 5 min, 950µl of LB was added and the cells 
were incubated at 37oC for 1 h with gentle shaking (160 rpm). Cells were concentrated 
and reconstituted in 100µl of LB and plated in dry and warm LB agar plates containing 
100 µg/ml of ampicillin (Shelton Scientific, Shelton, CT) as 10µl and 90µl fraction 
volumes. The plates were incubated at 37oC in inverted posture for overnight for the 
growth of bacterial colonies.  
2.12 Plasmid preparation 
Miniprep and midiprep was performed for small scale and large scale plasmid 
preparation, respectively. For miniprep plasmid preparation method, individual bacterial 
colonies were inoculated in 1.5 ml of LB containing 100µg/ml of ampicillin in either 5 
ml or 14 ml tubes and incubated at 37oC overnight with a rotor speed of 280-300 rpm. 
The grown bacterial culture was transferred to microfuge tube. The cells were pelleted by 
centrifugation at 10,000 X g and the supernatant was aspirated leaving 40-50 µl of media 
on top of the pellet. The bacterial pellet was resuspended by vortexing and the cells lysed 
by adding 300 µl of TENS buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M NaOH, 
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0.5% SDS).The suspension was neutralized by addition of 150 µl of 3M sodium acetate, 
pH 5.2. Cellular debris was pelleted by centrifugation at 16,000 X g for 5 min. The 
supernatant was transferred to fresh microfuge tubes and the plasmid DNA was recovered 
by addition of 900µl of ice cold absolute ethanol followed by centrifugation at 16,000 X 
g for 5 min. The precipitated plasmid DNA was washed with ice cold 70% ethanol and 
dried. The dried plasmid DNA was resuspended in 40 µl of tris-
ethylenediaminetetraacetic acid [EDTA] (TE) buffer containing 100 µg/ml of RNaseA. 
The size of the plasmid was analyzed by agarose gel electrophoresis.  
For large scale plasmid preparation, midiprep was performed. About 100µl of 
previously grown bacterial culture was transferred to 100 ml of LB containing 100µg/ml 
of ampicillin and incubated at 37oC shaker overnight. The plasmid DNA was prepared by 
gravity flow column purification method using Qiagen’s midiprep method (Qiagen tip-
100) as per manufacturer’s instructions. The buffers used for midiprep are: (1) Buffer P1 
resuspension buffer) - It contains 50 mM Tris-Cl (pH 8.0), 10 mM EDTA, and 100 µg/ml 
RNase A; (2) Buffer P2 (lysis buffer) - It contains 200 mM NaOH and 1% sodium 
dodecyl sulfate (SDS) (w/v); (3) Buffer P3 (neutralization buffer) - It contains 3.0 M 
potassium acetate (pH 5.5); (4) Buffer QBT (equilibration buffer) - It contains 750 mM 
NaCl, 50 mM MOPS (pH 7.0), 15% isopropanol (v/v), and 0.15% Triton X-100 (v/v); (5) 
Buffer QC (wash buffer) - it contains 1.0 M NaCl, 50 mM MOPS (pH 7.0), and 15% 
isopropanol (v/v); and (6) Buffer QF (elution buffer) - It contains 1.25 M NaCl, 50 mM 
Tris-Cl (pH 8.5), and 15% isopropanol (w/v). The plasmid DNA concentration and purity 
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was determined using Eppendorf’s biophotometer (Hauppauge, NY) and also quantitated 
by agarose gel electrophoresis using known amounts of DNA.  
2.13 Plasmid construction 
The coding regions of the minor GPs were cloned from the infectious clone FL12 
of PRRSV (Truong et al., 2004). The genes for the individual minor GPs were amplified 
by PCR using gene-specific primers (Table 2.1) and cloned in pGEM3 vector (Promega 
Biotech, Madison, WI) under the control of T7 RNA polymerase promoter or in 
pcDNA3.1 (+) vector (Invitrogen) under the control of CMV promoter and T7 RNA 
polymerase promoter. 
2.13.1 Subcloning of genes of structural proteins of PRRSV 
The FL12 genome of PRRSV was previously cloned in pBR322 vector (Truong et 
al., 2004). The FL12 clone was digested with EcoRV and BstZ17I restriction enzymes to 
release ~ 4.9 kilo base pair (kbp) fragment containing majority of ORF2 and rest of the 
ORFs for structural proteins of PRRSV. The 4.9 kbp fragment was cloned in pBR322 
vector (Ansari et al., 2006). This intermediate vector (EP vector) was used for subcloning 
of mutants of GP2a, GP3, GP4, and GP5 ORFs in to FL12 infectious clone. 
2.13.2 Construction of GP2a, GP3, GP4, and GP5 plasmids 
The coding regions of individual structural proteins were amplified by polymerase 
chain reaction (PCR) and cloned in pGEM3 vector (Promega Biotech, Madison, WI) 
under the control of T7 RNA polymerase promoter. The FLAG-tag (DYKDDDDK) was 
fused at the carboxy-terminus of GP2a by PCR using primers GP2a-FLAG-EcoRI-Rev 
and GP2a-NheI-For (Table 2.1) and cloned in pGEM3 vector that was modified to 
contain CMV promoter in addition to the T7 RNA polymerase promoter. The ORF for  
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Table 2.1 Primers used for cloning of ORF of GP2a, GP3, GP4, GP5, and CD163 
proteins 
 
Primer name Primer nucleotide sequence 
GP2a-EcoRI-For ATATATGAATTCGCCACCATGAAATGGGGTCCATGC 
GP2a-SphI-Rev ATATATGCATGCTCACCGTGAGTTCGAAGG 
GP2a-NheI-For ATATGCTAGCGCCGCCACCATGAAATGGGGTCCATGC 
GP2a-FLAG-EcoRI-Rev ATATGAATTCTCACTCGAGCTTGTCATCGTCGTCCTTGT
AGTCCATCCGTGAGTTCGAAGGAAAAATTGC 
GP2a-N178A For CATGACAGGGTCAGCTGTAACCATAG 
GP2a-N184A For GTAACCATAGTGTATGCTAGTACTTTG 
GP2a-N178/184A For CATGACAGGGTCAGCTGTAACCATAGTGTATGCTAGT
ACTTTGAATC 
GP3-EcoRI-For ATATAGAATTCGCCACCATGGCTAATAGCTGTGC 
GP3-BamHI-Rev TATATGGATCCCTATCGCCGCGCGGC 
GP3-N29A-Rev CAGTACGTAGTAGCGGAATCCGC 
GP3-N42A-Rev GAGTTCGAAGGAAAAAGCGCCCCTAAC 
GP3-N50A-For TCCTTCGAACTCACGGTGGCTTACACGGTG 
GP3-N131A-For GGGATAGGGGCTGTGAGTCAAG 
GP3-N152A-For CGACGGGGAGGCCGCCACCTTGCC 
GP3-N160A-For CGTCATGACGCTATTTCAGCCG 
GP3-N195A-For GTTGGTTTTAGCTGTTTCTTGG 
GP4-EcoRI-For ATATAGAATTCGCCACCATGGCTGCGCCCCTTC 
GP4-BamHI-Rev TATATGGATCCTCAAATTGCCAGTAAGATG 
GP4-FLAG-BamHI-Rev TATATGGATCCTCACTTGTCATCGTCGTCCTTGTAGTCA
ATTGCCAGTAAGATGGCAAAAAAACAGGC 
GP4-N37A-Rev CGGTAGTGGCGGTTTTGATGTC 
GP4-N84A-For CCCGTGTACATCACTGTCACAGCCGCTGTCACAGATG 
GP4-N120A-Rev GATGCCTGACACAGCGCCAAATATC 
GP4-N130A-Rev CGTAGCTGGTAAAGGCGACACAC 
GP5-EcoRI-For GCCGGAATTCGGAGCCGCCGCCACCATGTTGGGGAGA
TGCTTGAC 
GP5-HindIII-XhoI-Rev ATCACTCGAGAAGCTTCTAAAGACGACCCCATTGTTC 
GP5-Myc-XhoI-Rev ATATATCTCGAGTTACAGATCTTCTTCAGAAATAAGTT
TTTGTTCAAGACGACCCCATTGTTC 
pBR131-For CTGGATGCTGTAGGCATAGGCTTG 
FL12-12816-For GGGGCAATTTTTCCTTCGAACTCA CGG  
FL12-13177-For CTACCAACATCAGGTCGATGGCGG 
FL12-13465-Rev CTGTGATGGTGATATACACGGGTG 
FL12-14473-Rev GTCGGCCGCGACTTACCTTTAGAG 
CD163-HindIII-For ATATAAGCTTATGGACAAACTCAGAATGGTGCTAC 
CD163-XhoI-Rev ATATCTCGAGTCATTGTACTTCAGAGTGGTCTCCTG 
Primer sequences are in the 5’ to 3’ direction. Restriction enzymes are underlined. The 
nucleotides for N to A mutation are shown in bold. 
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GP3 and GP4 was PCR amplified and cloned in pGEM3 vector by EcoRI and BamHI 
restriction sites. A FLAG tag was fused at the carboxy-terminus of GP4 by PCR using 
GP4-EcoRI-For and GP4-FLAG-BamHI-Rev primers (Table 2.1) and cloned in the 
pGEM3 vector. Additionally, an HA tag (YPYDVPDYAL) was fused at carboxy-
terminus of GP4 by PCR using the primers GP4-HA-XhoI-Rev and GP4-EcoRI-For 
(Table 2.1) and cloned in pcDNA3.1(+) vector at EcoRI and XhoI restriction sites. The 
GP5 ORF was cloned in pGEM3 by EcoRI and HindIII restriction sites. A c-Myc tag 
(EQKLISEEDL) was fused at the carboxy terminus of GP5 by PCR using primers GP5-
EcoRI-For and GP5-myc-XhoI-Rev (Table 2.1) and cloned in pcDNA3.1 (+) vector by 
EcoRI and XhoI restriction sites. Nucleotide sequence of the plasmids encoding various 
GPs was determined to ensure that correct clones were used in the studies.   
2.13.3 Construction of plasmids encoding N-glycosylation mutants of GP2a, GP3, 
and GP4 
EP-GP2a-N178A construct was generated by megarprimer based PCR (Sarkar & 
Sommer, 1990) by use of GP2a-N178A-For, GP2a-SphI-Rev and pBR131-For primers 
and cloned in EP vector by BstBI and EcoRV restriction digestion. EP-GP2a-N184A and 
EP-GP2a-N178/184A constructs were generated similarly as described for EP-GP2a-
N178A construct but by use of GP2a-N184A-For and GP2a-N178/184A-For primers 
respectively. The coding region of GP2a harbouring appropriate mutation was further 
transferred from EP vector to FL12 viral genome by EcoRV and PacI restriction enzyme 
digestion (FL-GP2a-N178A, FL-GP2a-N184A, and FL-GP2a-N178/184A). The cloning 
of the carboxy terminal FLAG tagged GP2a protein was described earlier. The ORF of 
GP2a-FLAG containing N to A mutation was further PCR amplified by GP2a-NheI-For 
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and GP2a-FLAG-NheI-Rev primers and  cloned in pGEM3 vector which in addition to 
T7 RNA polymerase promoter also contain cytomegalovirus (CMV) promoter from 
pCDNA3.1(+) to produce GP2a-FLAG-N178A, GP2a-FLAG-N184A, and GP2a-FLAG 
N178/184 mutant constructs. 
The FL-GP3-N29A plasmid was generated by PCR using GP3-N29A-Rev and 
pBR131-For primers and cloned in FL12 viral genome by SnaBI and EcoRV restriction 
enzyme digestion. The FL-GP3-N42A plasmid was generated by PCR using GP3-N42A-
Rev and pBR131-For primers and cloned in FL12 genome by BstBI and EcoRV 
restriction enzyme digestion. EP-GP3-N50A was generated by PCR using GP3-N50A-
For and GP4-N120A-Rev primers (Table 2.1) and cloned in EP vector by BstBI and 
BsrGI restriction enzyme digestion. EP-GP3-N131A, EP-GP3-N152A, EP-GP3-N160A, 
and EP-GP3-195A plasmids were generated megaprimer PCR using respective forward 
primers, GP4-N120A-Rev, and FL12-12816-For primers (Table 2.1) and cloned in EP 
vector by BstBI and BsrGI restriction enzyme digestion. The FL-GP3-N50A, FL-GP3-
N131A, FL-GP3-152A, and FL-GP3-N160A plasmids were generated by transferring the 
coding sequences from respective EP vectors to FL12 genome by EcoRV and PacI 
restriction enzyme digestion. The FL-GP3-N29/152A, FL-GP3-N29/160A plasmids were 
generated by fragment exchange between FL-GP3-N29A, FL-GP3-N152A, and FL-GP3-
N160A respectively. EP-GP3-N152/160A plasmid was generated by megaprimer PCR 
using EP-GP3-N160A as template plasmid, GP4-N120A-Rev, GP3-N152A-For, and 
FL12-12816-For primers (Table 2.1) and cloned in EP vector by BstBI and BsrGI 
restriction enzyme digestion. The FL-GP3-N152/160A plasmids were generated by 
transferring appropriate coding sequences from EP-GP3-N152/160A to FL12 genome by 
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EcoRV and PacI restriction enzyme digestion. The FL-GP3-N29/152/160A plasmid was 
generated by fragment exchange between FL-GP3-N152/160A and FL-GP3-N29/152A 
plasmids by BstBI and PacI restriction enzyme digestion. The ORF of GP3 containing 
specific N to A mutation was amplified by GP3-ECoRI-For and GP3-BamHI-Rev and 
cloned in pGEM3 vector under T7 RNA polymerase promoter. 
Megaprimer PCR was performed by using GP4-N37A-Rev, FL12-1286-For and 
FL12-14473-Rev primers (Table 2.1) and the PCR product was cloned in EP vector by 
BstBI and BstEII restriction enzyme digestion to generate EP-GP4-N37A plasmid. EP-
GP4-N84A plasmid was generated by PCR mutagenesis using GP4-N84A-For and FL12-
14473-Rev primers (Table 2.1) and cloned in EP vector by BsrGI and BstEII restriction 
enzyme digestion. EP-GP4-N120A construct was generated by megaprimer PCR using 
FL12-13177-For, GP4-N120-Rev, and FL12-14473-Rev primers (Table 2.1) and cloned 
in EP vector by BsrGI and BstEII restriction enzyme digestion. EP-GP4-N130A construct 
was generated similarly as described for EP-GP4-N120A but using GP4-N130A-Rev 
primer instead of GP4-N120A-Rev primer (Table 2.1). The FL-GP4-N37A, FL-GP4-
N84A, FL-GP4-N120A, and FL-GP4-N130A plasmids were generated by transferring 
specific coding sequences from EP vector to FL12 genome by EcoRV and PacI 
restriction enzyme digestion. The EP-GP4-N37/84A, EP-GP4-N37/120A, and EP-GP4-
N37/130A plasmids were generated by restriction digestion and fragment exchange 
between EP-GP4-N37A, EP-GP4-N84A, and EP-GP4-N130A plasmids with BstBI and 
BsrGI enzymes. The EP-GP4-N84/120A plasmid was generated by megaprimer PCR 
using EP-GP4-N84A template plasmid, GP4-N120A-Rev, FL12-13177-For, and FL12-
14473 Rev primers (Table 2.1) and cloned in EP vector by BsrGI and BstEII restriction 
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enzyme digestion. The EP-GP4-N84/130A plasmid was generated by megaprimer PCR 
using EP-GP3-N84A template plasmid, GP4-N130A-Rev, FL12-13177-For, and FL12-
14473-Rev primers (Table 2.1) and cloned in EP vector by BsrGI and BstEII restriction 
enzyme digestion. The EP-GP4-N120/130A plasmid was generated by megaprimer PCR 
using EP-GP4-N130A template, GP4-N120A-Rev, FL12-13177-For, and FL12-14473-
Rev primers (Table 2.1) and cloned in EP vector by BsrGI and BstEII restriction enzyme 
digestion. The FL-GP4-N37/84A, FL-GP4-N37/120A, FL-GP4-N37/130A, FL-GP4-
N84/120A, FL-GP4-N84/130A, and FL-GP4-N120/130A constructs were generated by 
transferring coding sequences from their respective EP vectors to FL12 genomes by 
EcoRV and PacI restriction enzyme digestion. The ORF of GP4 containing N to A 
mutation was amplified by GP4-EcoRI-For and GP4-BamHI-Rev primers (Table 2.1) and 
cloned in pGEM3 vector under T7 RNA polymerase promoter.  
2.13.4 Construction of GP5 N-glycosylation defective plasmids 
Previously GP5-IE-M construct was generated by cloning GP5, internal ribosome 
entry sites (IRES) element of encephalo myocarditis virus (EMCV), and M in pGEM3 
vector (Ansari et al., 2006). Also GP5-N34A, GP5-N44A, GP5-N51A, GP5-N34/44A, 
GP5-N44/51A, GP5-N34/51A, and GP5-N34/44/51A constructs were generated 
introducing corresponding mutations in the GP5 protein in GP5-IE-M plasmid (Ansari et 
al., 2006). I further released GP5 containing the above mentioned mutations from GP5-
IE-M plasmid by restriction digestion with EcoRI restriction enzyme and cloned the 
fragments in pGME3 vector. The GP5 mutant clones obtained are pGEME3-GP5-N34A, 
pGEME3-GP5-N44A, pGEME3-GP5-N51A, pGEME3-GP5-N34/44A, pGEME3-GP5-
N44/51A, pGEME3-GP5-N34/51A, and pGEME3-GP5-N34/44/51A. The correct 
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orientation of the clones was checked by SacI and SacII restriction enzyme digestion. The 
presence of appropriate mutations was confirmed by nucleotide sequencing.  
2.13.5 Construction of GP2a and GP4 deletion mutant plasmids 
Seven deletion constructs were generated for GP2a protein by sequentially 
deleting 35-40 amino acids from amino terminus to carboxy terminus of the protein by 
PCR based mutagenesis. The FLAG tag was fused at the carboxy terminus of the GP2a 
(described earlier). The PCR product was purified and cloned in pGEME3 vector by 
ECoRI and BamHI restriction enzyme digestion. GP2a-FLAG ∆2-38 construct was 
generated by PCR using GP2a ∆2-38 EcoRI-For and GP2a-FLAG-SphI-Rev primers 
(Table 2.2). GP2a-FLAG ∆39-75 construct was generated by megaprimer based PCR 
using GP2a-EcoRI-For, GP2a ∆39-75-Rev, GP2a ∆39-75-For and GP2a-FLAG-SphI-
Rev primers (Table 2.2). GP2a-FLAG ∆ 76-112, GP2a-FLAG ∆113-149, GP2a-FLAG 
∆150-181, GP2a-FLAG ∆182-218, and GP2a-FLAG ∆219-256 constructs were generated 
using appropriate primer pairs (Table 2.2).   
Five deletion constructs were generated for GP4 by sequentially deleting ~ 35 
amino acids from amino terminus to carboxy terminus of the protein. A FLAG tag fused 
at the carboxy terminus of GP4 (GP4-FLAG) and its deletion constructs by PCR 
mutagenesis. The PCR product was digested with EcoRI and BamHI restriction enzyme 
and cloned in pGEM3 expression vector. GP4-FLAG ∆2-35 construct was generated by 
PCR using GP4 ∆2-35-EcoRI-for and GP4-FLAG-BamHI-Rev primers (Table 2.2). 
Other GP4 deletion mutant constructs were generated similarly using appropriate primer 
pairs (Table 2.2).  
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Table 2.2 Primers used for GP2a and GP4 deletion mutant construction 
Primer name Primer nucleotide sequence Constructs generated 
GP2a-FLAG-SphI Rev TATATGCATGC  TCACTTGTCATCG
TCGTCCTTGTAGTCCCGTGAGTTC
GAAGGAAAAATTGCCCC 
GP2a ∆2-38 EcoRI For ATATATGAATTC GP2a-FLAG ∆2-38 GCCACCATGTTGGCTTTACCATCGCTG 
GP2a ∆39-75 For CATATTTTTGGCCATTTTGTGAGGC
CTTTCTTTCTCAG GP2a-FLAG ∆39-75 GP2a ∆39-75 Rev CTGAGAAAGAAAGGCCTCACAAA
ATGGCCAAAAATATG 
GP2a ∆76-112 For GCAATTACAGAAGATCCTATCGTC
GGATGTACCGCACC GP2a-FLAG ∆76-
112 GP2a ∆76-112 Rev GGTGCGGTACATCCGACGATAGG
ATCTTCTGTAATTGC 
GP2a ∆113-149 For GATTGATGAAATGGTGTCGCATCT
TGCCGCCATTGAAG GP2a-FLAG ∆113-
149 GP2a ∆113-149 Rev CTTCAATGGCGGCAAGATGCGACA
CCATTTCATCAATC 
GP2a ∆150-181 For GATGTGGTGGCTCATTTTCAGGTG
TATAATAGTACTTTGAATCAGG GP2a-FLAG ∆150-
181 GP2a ∆150-181 Rev CCTGATTCAAAGTACTATTATACA
CCTGAAAATGAGCCACCACATC 
GP2a ∆182-218 For GGGTCAAATGTAACCATATCCTCC
GTTGCGGCTTCTTG GP2a-FLAG ∆182-
218 GP2a ∆182-218 Rev CAAGAAGCCGCAACGGAGGATAT
GGTTACATTTGACCC 
GP2a-FLAG ∆219-256 -
SphI-Rev 
TATATGCATGC GP2a-FLAG ∆219-
256 
TCACTTGTCATCG
TCGTCCTTGTAGTCAAATATGGAG
GAGTGCACAGCTATTAG 
GP4 ∆2-35 EcoRI For ATATAGAATTCGCCACCATGACCA
ACACTACCGCAGCATC 
GP4-FLAG ∆2-35 
GP4 ∆36-70 For 
 
CAAGTCTTTCGGACATCAAAGCGG
CGATAGGGACGCCC GP4-FLAG ∆36-70 GP4 ∆36-70 Rev GGGCGTCCCTATCGCCGCTTTGAT
GTCCGAAAGACTTG 
GP4 ∆71-105 For CAAAAGCTCTCAGTGCCGCGCTTC
TGAGATGAGTGAAAAG GP4-FLAG ∆71-105 GP4 ∆71-105 Rev CTTTTCACTCATCTCAGAAGCGCG
GCACTGAGAGCTTTTG 
GP4 ∆106-140-For CTTTCTTCTTGCCTTTTCTATTTTAC
CCAACGCTCCTTG GP4-FLAG ∆106-
140 GP4 ∆106-140-Rev CAAGGAGCGTTGGGTAAAATAGA
AAAGGCAAGAAGAAAG 
GP4-FLAG ∆141-178-
BamHI-Rev 
TATATGGATCCTCACTTGTCATCG
TCGTCCTTGTAGTCCTCCTTGACAT
GTTGGACGTAG 
GP4-FLAG ∆141-
178 
Primer sequences are in the 5’ to 3’ direction. Restriction enzyme sites are underlined. 
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2.13.6 Subcloning of receptor porcine-CD163 
The ORF of porcine CD163 receptor was amplified from the total RNA isolated 
from PAM cells by reverse transcription and PCR using specific primers, CD163-
HindIII-For and CD163-XhoI-Rev  (Table 2.1) and cloned in pGEM-T vector (Promega 
Corporation). Four clones of the CD163 receptor with correct size inserts were further 
transferred from the pGEM-T vector by restriction enzyme digestion with HindIII and 
XhoI and cloned by blunt-end ligation in pcDNA3.1 (+) vector. 
2.14 RNA extraction and reverse transcription PCR (RT-PCR) 
The RNA from the MARC-145 cells was obtained by Trizol LS reagent 
(Invitrogen) treatment as per the manufacturer’s instruction. The RNA was dissolved in 
20µl of nuclease free water and quantitated. Approximately 2µg of RNA was denatured 
by heating at 95oC for 5 min followed by cooling on ice. RT-PCR reaction was set using 
superscript III kit (Invitrogen) as per the manufacturer’s instructions. To the chilled RNA 
solution, 5X first strand buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl2), 0.1 
M DTT, 5 mM dNTPs, 40 units RNasin (RNase inhibitor), and 200 units Superscript III 
enzyme, and appropriate reverse primer were added to make the final reaction volume of 
10 µl. The reaction mixture was incubated at 55oC for 1 h to synthesize cDNA. Following 
cDNA synthesis, the target DNA was PCR amplified using either Taq polymerase or PFU 
turbo polymerase as per the manufacturer’s protocol.   
2.15 Generation of in vitro transcript  
The capped in vitro transcripts for either FL12 virus or mutant FL12 virus was 
generated by using mMEESAGE mMACHINE T7 Ultra (Ambion, Austin, TX) as per the 
manufacturer’s instructions. The pBR322-FL12 (or mutant FL12) plasmids were digested 
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with AclI restriction enzyme and treated with mungbean nuclease (or DNase I) enzyme 
(NEB) to digest the DNA template and remove single stranded DNA overhangs 
respectively. The restriction enzyme digested DNA was purified by phenol-chloroform 
extraction and the DNA was resuspended in 3-4 µl of nuclease free water. The 
concentration of the DNA was checked by agarose gel electrophoresis. For in vitro 
transcription reaction, 1 µg of linearized template DNA was incubated with 1 X T7 NTP / 
anti-reverse cap analog (ARCA) (7.5 mM ATP, 7.5 mM CTP, 7.5 mM UTP, 1.5 mM 
GTP, 6 mM ARCA), 4.5 mM GTP, 1X T7 reaction buffer, and T7 RNA polymerase in a 
final reaction volume of 10 µl at 37oC for 2 h. Then, 1µl (2 units) of DNase I was added 
to the reaction mixture to remove the template DNA and further incubated at 37oC for 15 
min. The in vitro transcription reaction was stopped by addition of 40µl of ammonium 
acetate stop solution (5M ammonium acetate and 100mM EDTA) and 1µl of glycogen 
was added to serve as a carrier during RNA extraction and precipitation.  The in vitro 
transcript was recovered by phenol chloroform extraction and precipitation by addition of 
equal volume of isopropanol and centrifugation at 16,000 X g for 30 min. The RNA 
pellet was washed with 75% cold ethanol. The dried RNA pellet was resuspended in 20µl 
of nuclease free water. The purity, concentration, and size of the in vitro transcript were 
checked by spectrophotometer and glyoxal-agarose gel electrophoresis.  
2.16 Plasmid transfection 
Plasmids were transfected into cells using Lipofectamine2000 (Invitrogen) as 
described earlier (Ansari et al., 2006). Briefly, BHK-21 cells were plated in 6-well 
culture plates 24 h before transfection. The cells were first infected with vTF7-3 (Fuerst 
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et al., 1986) at a MOI of 5. The DNA-Lipofectamine2000 complexes prepared according 
to the manufacturer’s recommendations were added to the infected and washed BHK-21 
cells and incubated at 37oC for 4 h. Following incubation, the cells were washed and 
incubated in media containing Dulbecco’s modified Eagle’s media (DMEM) containing 
2% FBS and antibiotics as described before (Ansari et al., 2006).  The transfected cells 
were processed for radiolabeling or immunofluorescent staining as described below.  
2.17 Metabolic labeling of proteins 
The plasmid transfected cells at 16-18 h post-transfection were washed twice in 
PBS and incubated with cysteine-methionine-free DMEM for 1 h prior to radiolabeling 
with 33 μCi of Expre35S35S protein labeling mix (Perkin Elmer) per ml of methionine-
cysteine free DMEM without serum for 4 h.  
2.18 Immunoprecipitation, co-immunoprecipitation, and analysis of proteins 
Following radiolabeling, the cells were washed with cold PBS and the cell lysate 
was prepared in radioimmunoprecipitation (RIPA) buffer as described before (Ansari et 
al., 2006) or co-IP  buffer ( 1% NP40, 0.5% Triton X-100, 50mM Tris-HCl pH 7.6 , 500 
mM NaCl, 2mM EDTA and 1X protease inhibitor cocktail) as described before (Das & 
Pattnaik, 2005). The cell lysate was clarified by centrifugation at 16,000 X g for 5 min. 
The supernatant was used for immunoprecipitation with appropriate antibody at 40C for 
8-10 h. A slurry of approximately 3.0 mg of protein A sepharose (GE Health care 
Bioscience AB) washed and resuspended in 100 ml RIPA or co-IP buffer was added and 
incubated further for 2 h at 40C. The protein A sepharose beads with bound immune 
complexes were washed in RIPA or co-IP buffer three times, resuspended in sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (50 mM 
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Tris-HCl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, and 10% 
glycerol) and boiled for 5 min. After centrifugation at 16,000xg for 1 min, the proteins in 
the clarified supernatant were resolved by SDS-10% or 12% polyacrylamide gel 
electrophoresis (PAGE). Following electrophoresis, the gels were processed for 
fluorography as described previously (Ansari et al., 2006).  
2.19 Endo H and PNGase F treatment of glycoproteins 
The endoglycosidase H (endo H) and the peptide N-glycosidase F (PNGase F) 
was purchased from New England Biolabs. For Endo H treatment, RIPA buffer was 
removed from the immunoprecipitated complexes and 50 μl of 1X denaturing buffer 
(0.5% SDS, 1.0% β-mercaptoethanol) was added to it. The resuspended 
immunoprecipitated complex was boiled for 10 min. The supernatant was collected and 
split in to two tubes. The reaction mixture was then adjusted to 1X G5 buffer (0.05 M 
sodium citrate, pH 5.5) and 100 units of Endo H was added to one of the two tubes while 
an equal volume of 1X G5 buffer was added to the other tube. Both the samples were 
incubated at 370C for 16 h (Ansari et al., 2006; Truong et al., 2004). Following endo H 
digestion, the sample was mixed with an equal volume of 2X SDS-PAGE sample buffer, 
boiled for 5 min and resolved by SDS-10% PAGE under denaturing conditions along 
with protein marker (Bio-Rad, Hercules, CA).  
For PNGase F digestion, the reactions were carried out as described for endo H 
digestion, except that 1X G7 buffer (0.05 M sodium phosphate, pH 7.5), 1.0% NP-40, 
and 2 units of PNGase F was added. Following PNGase F digestion, the sample was 
mixed with an equal volume of 2X SDS-PAGE sample buffer, boiled for 5 min and 
resolved by SDS-10% PAGE under denaturing conditions. 
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2.20 Tunicamycin treatment  
Tunicamycin was purchased from Sigma Aldrich. After 16 h of transfection, the 
cells were washed and treated with 2.0 µg of tunicamycin per ml of cysteine-methionine-
free DMEM for 1 h prior to radiolabeling with by 33 μCi of Expre35S35S protein labeling 
mix (Perkin Elmer) per ml of methionine-cysteine free DMEM without serum. The 
radiolabeling was performed in the presence of the tunicamycin for 4 h (Ansari et al., 
2006). 
2.21 Pulse-chase assay  
We performed pulse-chase assay to study co-translational and post-translational 
glycosylation of envelope glycoproteins of PRRSV. The individual envelope proteins 
were expressed in BHK-21 cells by plasmid transfection in 35mm cell culture dish. The 
transfected cells were washed with PBS after 16 h of transfection and incubated with 
cysteine-methionine-free DMEM for 1 h prior to radiolabeling with by 55 μCi of 
Expre35S35S protein labeling mix per 100μl of methionine-cysteine free DMEM without 
serum for 1 min at 37oC. After incubation, the radiolabeling mix was promptly removed 
from the cell culture dish and the cells were washed with DMEM containing 2% FBS and 
1X PKS twice. DMEM containing 2% FBS, 1X PKS, and 100μl of cycloheximide per ml 
was added on the cells and the cells were further incubated in 37oC. The chase times were 
0 min, 10 min, 30 min, and 60 min post radiolabeling. The cells were processed for 
immunoprecipitation as described earlier. 
2.22 Fluorescence microscopy 
The transfected cells were either fixed with 4% paraformaldehyde for 30 min at 
room temperature (for surface staining) or with methanol-acetone solution (1:1) for 30 
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min at -200C (for cytoplasmic staining). The cells were blocked with 5% BSA in PBS 
containing 0.05% Tween20 for 30 min at room temperature. Immunofluorescence 
staining was performed (Das et al., 2006) with appropriate primary and secondary 
antibodies and visualized under Olympus FV500/IX81 inverted laser scanning confocal 
microscope (Center for Biotechnology, University of Nebraska-Lincoln). The images 
were captured with a charge-coupled-device camera. 
2.23 Animal experiment 
Recently weaned 21 days mixed breed piglets were purchased from a PRRSV free 
farm (University of Nebraska-Lincoln swine unit, NE). The pigs were free from any 
clinical signs of disease and were serologically negative for any detectable antibodies 
against PRRSV. Four animals were grouped in one room. The animals were bled at time 
0 (pre-inoculation time) to obtain a sample of pre-inoculum serum. Subsequently, the 
animals were inoculated on the same day with PRRSV (wild type and mutant viruses). 
Viral supernatants collected on 2nd passage post electroporation were used for inoculation 
of the animals. The animals were maintained in biosafety level 2 (BSL-2) with strict 
biosecurity to prevent cross contamination between strains. The biosecurity measures 
included changing lab coats, boots, mask, and gloves in each room per strain. One empty 
room was maintained between two groups of animals to further prevent cross 
contamination. One group was used as negative control, in which all the pigs were 
injected intramuscularly with 2ml of low bicarbonate-low glucose DMEM with 10% FBS 
and 1X PKS. The other group was kept as positive control, in which case the pigs were 
intramuscularly injected with FL12 virus with a viral load of 5 x 104 PFU/animal (105 
TCID50/animal). The mutant strains of PRRSV used for animal studies are FL-GP2a-
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N178A, FL-GP3-N29/152A, FL-GP3-N29/152/160A, FL-GP4-N37A, FL-GP4-N84A, 
FL-GP4-N120A, and FL-GP4-N130A. The serum was collected on 0, 7, 14, 21, 35, and 
46 days post inoculation. The animals were killed and incinerated at the animal research 
facility in the university. Serum samples of 7, 14, and 21 days were used to test 
infectivity on MARC-145 cells. RT-PCR was performed from 21st day collected serum to 
check the stability of the mutation and to test glycosylation phenotype of the virus 
recovered from the cell culture.  All the serum samples collected on different time points 
were used to check neutralizing antibody titer by serum neutralization assay. 
2.24 Serum neutralization assay 
This assay was performed in 96 well cell culture plates. Serum from each animal 
was diluted by two-fold serial dilution. First, 50µl of medium (low bicarbonate-low 
glucose DMEM with 10% FBS and 1X PKS) was mixed with 50µl of serum from each 
specific animal from each group. Subsequent two-fold dilution of sera was prepared 
similarly. To the serum-media mixture, equal volume (100µl) of virus stock with a titer 
of 100 TCID50 was added (final reaction volume- 200µl) and incubated at 37oC for 1hr. 
After incubation, 100µl of serum-virus mix was transferred to the MARC-145 cells 
plated in 96 well cell culture plates two days earlier. The cells were further incubated for 
36 h at 37oC in cell culture incubator. The infected cells were fixed with 50% methanol-
50% acetone solution and stained for N protein of PRRSV by SDOW-17 primary 
antibody (Nelson et al., 1993). Alexa Fluor-488 goat anti-mouse IgG antibody was used 
as secondary antibody. For positive control for serum neutralization assay, MARC-145 
cells (in one well of the same 96 well plate) were infected with 100 TCID50 titer of FL12 
 56 
virus. For homologous serum neutralization assay, serum and virus was from the same 
mutant strain. For heterologous serum neutralization assay, serum from mutant virus 
infected pigs was titrated against wild type (FL12) PRRSV. 
 The above protocol for animal studies was approved by institutional animal care 
and use committee (IACUC) at University of Nebraska-Lincoln.  
2.25 Bioinformatics analysis 
The putative N-glycosylation sites of envelope glycoproteins of PRRSV were 
determined by use of NetNGly 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc/). 
Multiple nucleotide sequence alignment was performed using Clustal W server 
(http://www.ebi.ac.uk/Tools/clustalw/). NEB cutter V 2.0 server 
(http://tools.neb.com/NEBcutter2/) and reverse complement server 
(http://www.bioinformatics.org/sms/rev_comp.html) was used during primer design. 
NCBI server (http://www.ncbi.nlm.nih.gov/) and ExPASy server (http://ca.expasy.org/) 
was used for general nucleotide and protein sequence analysis.   
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CHAPTER III 
 
 
 
 
 
EXPRESSION OF ENVELOPE GLYCOPROTEINS OF PRRSV AND 
EXAMINATION OF CO-TRANSLATIONAL AND POST-TRANSLATIONAL 
GLYCOSYLATION 
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The envelope glycoproteins GP2a, GP3, GP4, and GP5 of PRRSV are 256 amino 
acids (aa), 254 aa, 178 aa, and 200 aa long, respectively. The unglycosylated forms of 
these proteins have the predicted sizes of approximately 29 kDa, 29 kDa, 20 kDa, 18 kDa 
respectively, whereas that of the unglycosylated FLAG-tagged GP2a used in latter studies 
is approximately 30 kDa. Each of these proteins also has several predicted N-linked 
glycosylation sites as well as amino-terminal signal sequences (Fig. 1.3). 
3.1 Expression of PRRSV glycoproteins in BHK-21 and HeLa cells 
 We had previously shown that the major glycoprotein GP5, when expressed 
ectopically in transfected cells remained in the endoplasmic reticulum or in the cis-Golgi 
region (Ansari et al., 2006). To examine expression of the minor glycoproteins in 
transfected cells, plasmids encoding these glycoproteins under the control of T7 RNA 
polymerase promoter were transfected into BHK-21 cells that had been infected with 
vTF7-3 that expresses the T7 RNA polymerase. Expression of these proteins could be 
readily detected (Fig. 3.1) by radiolabeling and immunoprecipitation with monospecific 
polyclonal antibodies prepared against peptides containing immunodominant epitopes (de 
Lima et al., 2006) from each of these glycoproteins. The molecular masses of the fully 
mature glycoproteins (identified by white dots on the left side of the lanes in the panels) 
were estimated to be approximately 32 kDa, 42 kDa, and 29 kDa, respectively, for GP2a, 
GP3, and GP4 proteins. Although the major species of GP3 and GP4 corresponded to the 
fully glycosylated and mature forms of the proteins (white dots in lanes 4 and 6), the fully 
glycosylated GP2a (white dot in lane 2) represented only a small fraction, while a smaller 
GP2a was detected as the major protein species (top black dot in lane 2). The 
electrophoretic mobility of this protein appeared to be consistent with GP2a lacking 
 59 
                                   
Figure 3.1 Expression of the GPs in BHK-21 cells. The BHK-21 cells were infected 
with vTF7-3 and subsequently mock-transfected (mock) or transfected with plasmids 
encoding individual envelope glycoproteins as shown on top of the lanes. The cells were 
radiolabeled with 35S protein labeling mix as described in the materials and methods, cell 
extracts were prepared and immunoprecipitated with monospecific polyclonal antibodies 
as shown on the bottom of the lanes and the proteins were detected by SDS-10%PAGE 
and fluorography. The fully-glycosylated proteins are identified by white dots whereas 
the partially glycosylated forms of the proteins are identified by black dots on the left 
side of the lanes. Relative mobilities of molecular mass markers in kDa are shown on the 
right.  
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glycans at one of the sites and may represent a partially glycosylated form of the protein. 
In addition, it should be noted that these proteins contain signal sequences at the amino 
terminus, which appear to be cleaved off to generate the mature proteins and therefore 
may be smaller than the expected length non-glycosylated proteins. Furthermore, based 
on the predicted size, it appears that these proteins possess anomalous mobilities in the 
gels.  
I also transiently expressed four envelope glycoproteins of PRRSV in HeLa cells 
(Fig. 3.2). Like BHK-21 cells, HeLa cells can also express these four proteins and apart 
from the fully glycosylated version of each protein, I can detect partially glycosylated 
forms of the proteins in my system (Fig. 3.2, white dots in lanes 2, 4, 6, and 8).  
3.2 Expression of glycoproteins in MARC-145 cells 
Since the predominant protein species in cells transfected with GP2a expression 
plasmid was smaller than the fully-glycosylated mature GP2a protein, I examined if 
incompletely glycosylated forms of GP2a and possibly other minor glycoproteins were 
also synthesized in MARC-145 cells that are normally used for propagation of PRRSV. 
Additionally, since the major species of GP2a possessed electrophoretic mobility similar 
to GP4 (Fig. 3.3, lanes 2 and 6), I also examined the expression of a carboxy-terminal 
FLAG-tagged GP2a protein (GP2a-FLAG) for use in latter studies as GP2a-FLAG fusion 
protein is expected to have a different electrophoretic mobility compared to GP4. My 
results revealed that the predominant protein in MARC-145 cells transfected with GP2a-
Fl encoding plasmid also corresponded to the partially glycosylated form of the protein 
(Fig. 3.3) as observed earlier in BHK-21 and HeLa cells. Furthermore, the GP2a-FLAG- 
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Figure 3.2 Expression of the GPs in HeLa cells. HeLa cells were infected with vTF7-3 
virus and transfected with specific plasmids encoding for GP2a, GP3, GP4, and GP5 
proteins as described in materials and methods. The transfected cells were radiolabeled 
with 35 S and immunoprecipitated with specific antibodies as denoted in the bottom of the 
representative fluorogram. The proteins were resolved in SDS-10% PAGE. The mature 
glycoproteins (fully glycosylated) are denoted as white dots and labeled on the right side 
of the fluorogram. The partially glycosylated proteins are denoted as black dots. The 
relative mobilities of the molecular mass markers in kDa are shown on the left. 
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Figure 3.3 Expression of the GPs in MARC-145 cells. The MARC-145 cells were 
infected with vTF7-3 and subsequently mock-transfected or transfected with plasmids 
encoding individual envelope glycoproteins as shown on top of the lanes. The cells were 
radiolabeled with 35S protein labeling mix as described in the materials and methods, cell 
extracts were prepared and immunoprecipitated with monospecific polyclonal antibodies 
as shown on the bottom of the lanes and the proteins were detected by SDS-10%PAGE 
and fluorography. The plasmid encoding GP2a with FLAG-tag was used in place of 
GP2a and the fusion protein was detected with anti-FLAG antibody. The full-length 
mature GPs are identified with white dots in lanes 2, 4, and 6 whereas the partially 
glycosylated forms of the proteins are identified by black dots in the lanes. Relative 
mobilities of molecular mass markers in kDa are shown on the right.  
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tagged protein could be readily distinguished from the GP4 protein based on the mobility 
in the gel, a property that I have used in my protein-interaction studies reported later. 
Interestingly, in MARC-145 cells, these three proteins produced ladder-like pattern (Fig. 
3.3, lanes 2, 4, and 6), indicating that the proteins were also incompletely glycosylated in 
these cells. However, the fully mature glycoproteins (identified by white dots in Fig. 3.3, 
lanes 2, 4, and 6) with mobilities similar to that observed in BHK-21 cells were readily 
detected in each case. Ladder-like pattern of the glycoproteins were also seen in MARC-
145 cells infected with PRRSV FL-12 (data not shown). It is possible that the ladder-like 
pattern of the viral glycoproteins may represent various degraded forms of the proteins. 
However, my observation that single and multiple N-linked glycosylation mutant proteins 
co-migrate with the protein bands seen in the ladder-like pattern (data to be reported 
elsewhere) and the fact that endo-H digestion (Fig. 3.4) has resulted in detection of single 
species of these proteins (except for GP2a for which the signal-cleaved form of the 
protein is also detected), argue against the possibility that the ladder-like pattern represent 
degraded proteins.       
3.3 Intracellular localization of glcoproteins of PRRSV         
 The intracellular localization of the minor glycoproteins in BHK-21 cells was 
further studied by examining their sensitivity to Endo H digestion and also by confocal 
microscopy. All of the fully and partially glycosylated proteins in BHK-21 cells were 
found to contain only high-mannose type glycans as they were sensitive to digestion by 
Endo H, yielding species that corresponded to the protein backbones only (Fig. 3.4). It 
should be noted that a smaller protein species (identified by asterisk on the right of lane 
3) was also detected. This protein is most likely the signal-cleaved GP2a without glycans. 
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Figure 3.4 Endo H sensitivity of the GPs. The proteins expressed in BHK-21 cells and 
radiolabeled as described above were recovered by immunoprecipitation, treated without 
(-) or with (+) Endo H and detected by electrophoresis as above. Mock-transfected cells 
immunoprecipitated with the antibodies and treated without Endo H are shown in lanes 1, 
4, and 7. White dots show the fully glycosylated proteins, black dots show the protein 
species generated by the enzyme treatment. The protein band identified by asterisk (*) is 
most likely the signal-cleaved deglycosylated form of GP2a. Relative mobilities of 
molecular mass markers in kDa are shown on the right. 
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Sensitivity of the glycoprotein to digestion by endo H suggests that these glycoproteins 
are localized in the ER. Immunofluorescent staining of cells expressing the individual 
glycoproteins with monospecific antibodies showed that most of the minor glycoproteins 
were localized in the cytoplasm in association with the ER (Fig. 3.5).  Similar results 
were also obtained in MARC-145 cells. Overall, my results show that the minor 
glycoproteins (GP2a, GP3, and GP4) synthesized in transfected cells are localized in the 
ER, similar to that previously described for the major envelope protein GP5 (Ansari et 
al., 2006; Wissink et al., 2005). 
3.4 Comparison of envelope glycoprotein expression pattern of FL12 PRRSV 
infected cells and transiently transfected cells 
 I compared the protein expression pattern of GP2a, GP3, GP4, and GP5 in 
MARC-145 cells infected with FL12 virus and BHK-21 cells transiently expressing 
individual envelope glycoproteins (Fig. 3.6A to D). In FL12 virus infected MARC-145 
cells, one of the two N-glycosylation sites of GP2a protein is favourably glycosylated in 
comparison to other sites (Fig 3.6A, lanes 2 and 4). I did not observe any significant 
difference between protein expression pattern of GP3 (Fig 3.6B), GP4 (Fig 3.6C), and 
GP5 (Fig 3.6D) proteins in FL12 infected cells and in transiently expressed BHK-21 
cells. The slight difference of mobilities of transiently expressed proteins in contrast to 
virus-infected cells may be attributed to interactions of these proteins among themselves 
as has been described later.  
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Figure 3.5 Intracellular localization of PRRSV GPs. The BHK-21 cells were infected 
with vTF7-3 and subsequently transfected with empty vector control (EV), plasmids for 
GP2a, GP3, GP4, and GP5-myc. The cells were fixed with 50% methanol-acetone 
solution after 16 h posttransfection. The cytoplasmic staining was performed using 
specific GP specific antibodies (as mentioned on the left side of each panel) and Alexa-
594 conjugated secondary antibody. 
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Figure 3.6 Comparison of protein expression in FL12 infected MARC-145 cells and 
transiently expressed BHK-21 cells.  MARC-145 cells were infected with FL12 virus 
and BHK-21 cells were transfected with individual plasmids encoding specific envelope 
glycoproteins as described in materials and methods. The infected (lanes 1 and 2) and 
transfected (lanes 3 and 4) cells were radiolabeled with 35S, lysed and incubated with 
specific antibodies. The immunoprecipitated proteins were resolved in SDS-10%PAGE 
and representative fluorograph are shown. The antibodies against specific proteins are 
shown at the bottom of each fluorograph. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. 
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3.5 Co-translational and post-translational glycosylation of PRRSV glycoproteins 
The glycoproteins after their synthesis in the ER are post-translationally 
glycosylated. Based on the position of N resides in the newly synthesized protein, the 
various putative glycosylation sites in the protein can be either co-translationally or post-
translationally glycosylated (Ruiz-Canada et al., 2009).  The predicted glycosylation sites 
for envelope glycoproteins of PRRSV are shown in Fig.  1.3. To study the glycosylation 
pattern of envelope proteins of PRRSV, I transiently expressed individual glycoproteins 
in HeLa cells and studied their glycosylation kinetics by pulse-chase assay (Fig. 3.7, 3.8, 
3.9, and 3.10). Previously it was reported that the rate of amino acid synthesis in the ER 
is 6 residues/second. I pulsed the individual envelope proteins for 1 min which would 
allow synthesis of full-length proteins and then followed by chase for up to 1 h in 
presence of cycloheximide. The samples were collected at 0, 10, 30, and 60 min post-
pulse period. A previous report has shown that treatment of HeLa cells with 10 µg/ml of 
cycloheximide can prevent 98% protein synthesis (Loh et al., 1970). To prevent complete 
protein synthesis during chase period, I used a ten times higher concentration than that 
reported before. Following chase, cell extracts were prepared and the proteins were 
immunoprecipitated with antibodies against the specific proteins. My results show that 
both the predicted glycosylation sites of GP2a are co-translationally glycosylated to 
different extents. But, latter in the chase period one site is preferentially glycosylated 
(Fig. 3.7, lanes 3 and 6). In contrast, the glycosylation sites in GP3 were all used for 
glycosylation in a co-translational mechanism (Fig. 3.8), immediately after the pulse, 
indicating that glycan addition is very efficient. Glycan addition at various sites in GP4 
also followed the co-translational mechanism but with slower kinetics (Fig. 3.9). Overall,  
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Figure 3.7 Examination of co- or post-translational glycosylation of GP2a protein. 
Plasmids encoding GP2a protein was transfected in vTF7-3 infected HeLa cells as 
described in materials and methods. The cells were pulsed with 35S for 1 minute followed 
by chase 0, 10, 30, and 60 min as indicated (lanes 3 to 6). The empty vector transfected 
cells are indicated above (lane 1). The GP2a protein immunoprecipitated from cells 
radiolabeled with 35S are indicated as ‘mature’ (lane 2). The specific antibody for 
immunoprecipitation is shown at the bottom. The proteins were resolved by SDS-
10%PAGE and detected by fluorography. The bands corresponding to number of 
glycosylation sites are shown at the right. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. 
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Figure 3.8 Examination of co- and post-translational glycosylation of GP3 protein. 
Plasmids encoding GP3 protein was transfected in vTF7-3 infected HeLa cells as 
described in materials and methods. The cells were pulsed with 35S for 1 minute followed 
by chase 0, 10, 30, and 60 min as indicated (lanes 3 to 6). The empty vector transfected 
cells are indicated above (lane 1). The GP3 protein immunoprecipitated from cells 
radiolabeled with 35S are indicated as ‘mature’ (lane 2). The specific antibody for 
immunoprecipitation is shown at the bottom. The proteins were resolved by SDS-
10%PAGE and detected by fluorography. The bands corresponding to number of 
glycosylation sites are shown at the right. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. 
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Figure 3.9 Examination of co- and post-translational glycosylation of GP4 protein. 
Plasmids encoding GP4 protein was transfected in vTF7-3 infected HeLa cells as 
described in materials and methods. The cells were pulsed with 35S for 1 minute followed 
by chase 0, 10, 30, and 60 min as indicated (lanes 3 to 6). The empty vector transfected 
cells are indicated above (lane 1). The GP4 protein immunoprecipitated from cells 
radiolabeled with 35S are indicated as ‘mature’ (lane 2). The specific antibody for 
immunoprecipitation is shown at the bottom. The proteins were resolved by SDS-
10%PAGE and detected by fluorography. The bands corresponding to number of 
glycosylation sites are shown at the right. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. 
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these studies suggest that GP2a, GP3, and GP4 proteins are glycosylated co-
translationally. However, immediately after pulse, GP5 is only synthesized as a full-
length, unglycosylated protein (Fig. 3.10, lane 3). At this time, fully or partially 
glycosylated forms of the protein were not detectable. Following various times of chase, 
the fully glycosylated mature form of the protein could be detected (Fig. 3.10, lanes 4-6), 
indicating that the glycosylated GP5 was generated after synthesis of the unglycosylated 
GP5. These results suggest that GP5 is post-translationally glycosylated. 
3.6 Discussion 
The four glycoproteins of PRRSV GP2a, GP3, GP4, and GP5 are present on the 
envelope and are highly glycosylated. My studies have revealed that (i) recombinant 
vaccinia virus based transient expression of envelope proteins of PRRSV mimic the 
protein expression pattern in virus infected cells; (ii) GP2a, GP3, and GP4 are co-
translationally glycosylated; and (iii) GP5 is post-translationally glycosylated. 
Expression of the individual minor glycoproteins in transfected cells resulted in 
detection of these proteins by the corresponding monospecific antibodies. Several 
partially glycosylated forms of the proteins could be readily detected by the antibodies. 
Particularly striking was the detection of ladder-like pattern of GP3 in MARC-145 cells 
(Fig. 3.3), which most likely correspond to the partially glycosylated forms of the protein. 
Partially glycosylated forms were also observed for GP2a and GP4 proteins in BHK-21, 
HeLa and MARC-145 cells. For GP2a, the size of the major species of the protein 
corresponds to the one lacking one glycan moiety. GP2a contains two N-glycosylation 
sites at residues 178 and 184 (Fig. 1.3). The reason(s) for the synthesis of predominantly 
a GP2a molecule with one glycan moiety is not clear at this time. But, it is possible that 
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Figure 3.10 Examination of co- and post-translational glycosylation of GP5-myc 
protein. Plasmids encoding GP5-myc protein was transfected in vTF7-3 infected HeLa 
cells as described in materials and methods. The cells were pulsed with 35S for 1 minute 
followed by chase 0, 10, 30, and 60 min as indicated (lanes 3 to 6). The empty vector 
transfected cells are indicated above (lane 1). The GP5-myc protein immunoprecipitated 
from cells radiolabeled with 35S are indicated as ‘mature’ (lane 2). The specific antibody 
for immunoprecipitation is shown at the bottom. The proteins were resolved by SDS-
10%PAGE and detected by fluorography. The bands corresponding to number of 
glycosylation sites are shown at the right. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. 
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one of the N-glycosylation sites is glycosylated inefficiently or with reduced frequency 
resulting in a predominantly monoglycosylated GP2a. It has been suggested that N-
glycosylation sites are less likely to be used if they have not passed through the OST 
active site prior to translation termination (Gavel & von Heijne, 1990). The estimated 
distance between the peptidyl transferase site of a ribosome attached to the translocation 
pore on the ER membrane and the active site of OST complex roughly corresponds to 75 
amino acid residues (Ben-Dor et al., 2004; Gavel & von Heijne, 1990; Glabe et al., 1980; 
Whitley et al., 1996). Since co-translational and post-translational glycosylation on a 
single protein has been demonstrated (Bolt et al., 2005) and that such modifications occur 
by distinct mammalian OST isoforms (Ruiz-Canada et al., 2009), I speculate that the 
glycosylation site at residue 184 in GP2a is most likely modified inefficiently and/or 
modified by post-translational glycosylation. It is possible that glycan addition at the sites 
in GP3 and GP4 proteins is also inefficient and may be occurring through co- and post-
translational mechanisms resulting in ladder-like patterns of these proteins as seen in 
Fig.3.1, 3.2, and 3.3.  
Comparison of protein expression pattern of envelope glycoproteins in FL12 
infected cells and plasmid transfected cells lead us to conclude that there is no significant 
difference observed between these two systems of protein expression used in my study. 
GP2a expression pattern observed in virus infected cells and plasmid transfected cells 
indicate that one of the two N-glycosylation sites is preferentially glycosylated in the 
virion. But, when I mutated each of the two glycosylation sites and expressed the two 
mutant proteins in BHK-21 cells, I did not observe any difference in protein expression 
pattern of the two mutant proteins (described in chapter V). As observed for N-glycans of 
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rabies virus G protein (Wojczyk et al., 2005), it is plausible that glycosylation at one 
sequon of GP2a of PRRSV probably regulates glycosylation of the second sequon in the 
protein. It is also possible that because both of these sequons of GP2a are present in the 
carboxy terminus of the protein, one of the two sites passes out from the translocon 
complex (sec 61) without being actually glycosylated as the difference between the last 
sequon of the protein and termination codon of the protein is less than 75 resides in 
length (Fig. 1.3) (Ruiz-Canada et al., 2009). Further studies would be needed to confirm 
this conclusion. 
Though N-glycosylation of a protein is mostly co-translational, post-translational 
modification of some of the host protein including human coagulation factor VII (Bolt et 
al., 2005) is observed.  It is not known whether the phenomenon that dictates co- and 
post-translational glycosylation of a host protein (Ruiz-Canada et al., 2009) also regulate 
viral protein glycosylation. Not much information is available regarding glycosylation 
pattern of different envelope viruses. As per my knowledge, one report suggests existence 
of post-translational glycosylation in case of hepatitis B virus large (L) protein (Lambert 
& Prange, 2007). My study shows for the first time the existence of post-translational 
glycosylation for PRRSV GP5 protein. Even if all the three minor envelope proteins of 
PRRSV are co-translationally glycosylated, one of the two sequons of GP2a is also post-
translationally glycosylated. As STT3A and STT3B subunits of OST complex regulate 
co- and post-translational glycosylation of the proteins (Ruiz-Canada et al., 2009), further 
study is required to find which of these two subunits of OST preferentially controls the 
glycosylation pattern of the four PRRSV envelope proteins. I performed co- and post-
translational glycosylation studies in HeLa cells transiently expressing the individual 
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glycoproteins. Considering the fact that I did not observe any significant difference in 
protein expression pattern in FL12 infected cells and BHK-21 cells expressing the 
individual proteins, I speculate co- and post-translational glycosylation pattern as 
observed in HeLa cells expressing individual proteins may also reflect the actual pattern 
in the virus infected cells. But, I also do not rule out the possibility of effect of 
glycosylation of one of the four envelope protein on the other proteins in virus infected 
cell. Further studies are warranted to clarify this issue in future.  
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INTERACTION OF ENVELOPE GLYCOPROTEINS OF PRRSV AMONG 
THEMSELVES AND WITH THE PRRSV RECEPTOR, CD163 
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4.1 Interaction of envelope glycoproteins of PRRSV amongst each other 
4.1.1 Interaction of GP2a with other glycoproteins of PRRSV 
 To examine if the envelope glycoproteins interact with each other, I co-
transfected BHK-21 cells with plasmids encoding GP2a-FLAG along with GP3, GP4, or 
GP5 encoding plasmids. Approximately 16 h after transfection, the cells were 
radiolabeled with 35S methionine and the cell extracts were examined for protein 
interactions by co-IP assays using monospecific antibody against one of the proteins. 
Results (Fig. 4.1) show that the GP2a polyclonal antibody was able to co-
immunoprecipitate GP3 (lane 6) or GP4 (lane 7) protein when expressed together. Since 
the GP2a antibody did not immunoprecipitate GP3 (lane 3), GP4 (lane 4), or GP5 (lane 5) 
proteins when these proteins were expressed alone in transfected cells, co-IP of GP3 or 
GP4 by GP2a antibody in co-transfected cells indicates that GP2a interacts with both of 
these proteins. On the other hand, GP5 protein could not be immunoprecipitated from co-
transfected cells by GP2a antibody indicating that no detectable level of interaction was 
observed between GP2a and GP5 (lane 8). 
4.1.2 Interaction of GP3 with other glycoproteins of PRRSV 
BHK-21 cells were co-transfected with the plasmid encoding GP3 along with 
plasmids encoding GP2a-FLAG, GP4, or GP5. Approximately 16 h after transfection, 
cells were radiolabeled and the cell extracts were examined for protein interactions by co-
IP assays. By the use of anti-GP3 polyclonal antibody, GP2a (Fig. 4.2, lane 9) and GP4 
(lane 10) proteins could be co-immunoprecipitated with GP3 in co-transfected cells, 
suggesting that GP3 interacts with GP2a and GP4. Interaction between GP3 and GP5 was 
not observed (lane 11) under these conditions.  
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Figure 4.1 Examination of GP interactions using GP2a antibody. BHK-21 cells were 
infected with vTF7-3 virus and mock-transfected (lane 1) or transfected with plasmids 
encoding the GPs as shown in the bottom of the panel. – and + indicate without or with 
the plasmid shown on the left. At 16 h post-transfection, the cells were radiolabeled with 
35S protein labeling mix as described in the materials and methods, cell extracts were 
prepared and immunoprecipitated with monospecific polyclonal antibodies as shown on 
the bottom of the lanes and the proteins were detected by SDS-12%PAGE and 
fluorography. The full-length mature GPs are identified with white dots whereas the 
partially glycosylated forms of the proteins are identified by black dots on the left side of 
the lanes. Relative mobilities of molecular mass markers in kDa are shown on the right.  
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Figure 4.2 Examination of GP interactions using anti-GP3 antibody. BHK-21 cells 
were infected with vTF7-3 virus and mock-transfected (lane 1) or transfected with 
plasmids encoding the GPs as shown in the bottom of the panel. – and + indicate without 
or with the plasmid shown on the left. At 16 h post-transfection, the cells were 
radiolabeled with 35S protein labeling mix as described in the materials and methods, cell 
extracts were prepared and immunoprecipitated with monospecific polyclonal antibodies 
as shown on the bottom of the lanes and the proteins were detected by SDS-12%PAGE 
and fluorography. The full-length mature GPs are identified with white dots whereas the 
partially glycosylated forms of the proteins are identified by black dots on the left side of 
the lanes. Relative mobilities of molecular mass markers in kDa are shown on the right. 
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4.1.3 Interaction of GP4 with other glycoproteins of PRRSV 
BHK-21 cells were co-transfected with the plasmids encoding GP4 along with 
GP2a-FLAG, GP3, or GP5. Approximately 16 h after transfection, the cells were 
radiolabeled and the cell extracts were examined for GP4 protein interactions with other 
glycoproteins by co-IP assays using monospecific antibody against GP4 protein. The 
anti-GP4 polyclonal antibody immunoprecipitated GP2a, GP3, and GP5 proteins 
indicating interaction of GP4 with the other three glycoproteins (Fig. 4.3, lanes 9, 10, and 
11, respectively). 
4.1.4 Interaction of GP5 with other glycoproteins 
Similarly, BHK-21 cells were co-transfected with plasmids encoding GP5 along 
with GP2a-FLAG, GP3, or GP4. Approximately 16 h after transfection, the cells were 
radiolabeled and the cell extracts were examined for GP5 protein interactions with other 
glycoproteins by co-IP assays. By the use of monospecific anti-GP5 antibody, GP4 
protein could be efficiently immunoprecipitated from cells co-transfected with plasmids 
encoding the GP4 and GP5 proteins (Fig. 4.4, lane 11), indicating strong interaction 
between these two proteins. GP2a protein could be consistently detected at low levels 
when co-expressed with GP5 and immunoprecipitated with anti-GP5 antibody (lane 9).  
However, undetectable to very low levels of GP3 protein could be seen in some but not 
all experiments when GP3 is co-expressed with GP5 and immunoprecipitated with anti-
GP5 antibody (lane 10).  
To further confirm GP4-GP5 interaction, I used confocal immunofluorescent 
microscopy. GP4-HA and GP5-myc tagged proteins were co-expressed in cells co- 
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Figure 4.3 Examination of GP interactions using anti-FLAG antibody. BHK-21 cells 
were infected with vTF7-3 virus and mock-transfected (lane 1) or transfected with 
plasmids encoding the GPs as shown in the bottom of the panel. – and + indicate without 
or with the plasmid shown on the left. At 16 h post-transfection, the cells were 
radiolabeled with 35S protein labeling mix as described in the materials and methods, cell 
extracts were prepared and immunoprecipitated with monospecific antibodies as shown 
on the bottom of the lanes and the proteins were detected by SDS-12%PAGE and 
fluorography. The full-length mature GPs are identified with white dots whereas the 
partially glycosylated forms of the proteins are identified by black dots on the left side of 
the lanes. Relative mobilities of molecular mass markers in kDa are shown on the right.  
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Figure 4.4 Examination of GP interactions using anti-GP5 antibody. BHK-21 cells 
were infected with vTF7-3 virus and mock-transfected (lane 1) or transfected with 
plasmids encoding the GPs as shown in the bottom of the panel. – and + indicate without 
or with the plasmid shown on the left. At 16 h post-transfection, the cells were 
radiolabeled with 35S protein labeling mix as described in the materials and methods, cell 
extracts were prepared and immunoprecipitated with monospecific polyclonal antibodies 
as shown on the bottom of the lanes and the proteins were detected by SDS-12%PAGE 
and fluorography. The full-length mature GPs are identified with white dots whereas the 
partially glycosylated forms of the proteins are identified by black dots on the left side of 
the lanes. Relative mobilities of molecular mass markers in kDa are shown on the right.  
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transfected with the two plasmids and after 16 h of transfection, the cells were subjected 
to immunofluorescent microscopy using the primary antibodies against the two tags 
followed by the use of two secondary antibodies conjugated to two different 
fluorophores. The GP4-HA and GP5-myc proteins were found to be co-localized in co-
expressed cells (Fig. 4.5) as judged by the overlapping of the two fluorescent signals. 
From this result and those from the co-IP studies, I conclude that GP5 protein interacts 
strongly with GP4 protein and that both the proteins are co-localized in the cytoplasm of 
the cell.  
Overall, the results from these co-IP studies suggest that GP2a protein interacts 
with GP3, GP4 and GP5 proteins, GP3 interacts with GP2a and GP4 but not with GP5, 
GP4 also interacts with all the three glycoproteins, whereas GP5 interacts with GP4 and 
GP2a proteins (Table 4.1). Although the extent of interaction between the GPs is difficult 
to estimate from the co-IP studies, it is clear that the interaction of GP4 with GP5 appears 
to be much stronger than the interactions between the other GPs.  
4.2 GP4 mediates interactions resulting in detection of multiprotein complex 
 To further examine if multiprotein glycoprotein complexes can be detected by co-
IP assay, I transiently expressed multiple glycoproteins of PRRSV in BHK-21 cells and 
attempted to pull down all the interacting glycoproteins using one monospecific antibody 
by co-IP. I chose to use GP3 antibody in this study, as the use of this antibody in BHK-21 
cell extracts resulted in less background bands (Fig. 4.2). I observed that the GP3 
antibody was not able to pull down GP5 protein when both of these proteins were co-
expressed (Fig. 4.6, lane 6), confirming the results obtained previously. Furthermore, this 
antibody was able to pull down small amounts of GP2a protein, but not GP5 protein 
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Figure 4.5 Co-localization of GP4 protein and GP5 protein in transfected cells. 
BHK-21 cells plated on glass coverslips were infected with vTF7-3 and transfected with 
plasmids encoding HA-tagged GP4 (GP4-HA) and myc-tagged GP5 (GP5-myc) proteins. 
At 16 h after transfection, the cells were fixed, permeabilized, and processed for 
immunofluorescent microscopy as described in the materials and methods. The GP4 
protein was detected using rabbit anti-HA polyclonal antibody and Alexa-488 conjugated 
goat anti-rabbit IgG as secondary antibody whereas the GP5 protein was detected with 
and anti-myc monoclonal antibody and Alexa-594 conjugated anti-mouse IgG as 
secondary antibody. Images were captured using 100X aperture. Intracellular expression 
of GP4 (A) GP5 (B) in the same cell is shown. (C) Merged image showing co-
localization of the two proteins. (D) DIC image of the cell. N, nucleus. 
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Table 4.1 Complete map of interaction pattern of envelope glycoproteins. 
  
 GP2a GP3 GP4 GP5 
GP2a  ++++ ++++ -/+ 
GP3 +++  +++ -/+ 
GP4 +++ +++  ++++ 
GP5 -/+ -/+ ++++  
 
The strength of interaction between two glycoproteins is denoted by different numbers of 
plus or minus signs. A non-significant to weaker interaction between two glycoproteins is 
denoted as -/+ sign whereas, the strongest interaction between two glycoproteins is 
denoted as ++++ sign. The interaction pattern between homologous proteins was not 
studied and hence the space is left as blank. 
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Figure 4.6 Interaction of GP5 with GP4 is necessary for multiprotein complex 
formation. BHK-21 cells were infected with vTF7-3 and subsequently mock-transfected 
(lane 1) or transfected with individual or combinations of plasmids encoding various GPs 
as shown in the bottom of each lane. Cells were radiolabeled as described in the materials 
and methods and immunoprecipitated with antibodies shown below the lanes. The 
proteins were detected by SDS-12%PAGE and fluorography. Various GPs are identified 
on the right. The fully glycosylated GPs are identified with white dots on the left side of 
the lanes. GP2a (1N), the monoglycosylated form of GP2a, is identified with a black dot 
on the left side of the lanes. Relative mobilities of molecular mass markers in kDa are 
shown on the left.  
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when these three proteins were co-expressed (lane 7), indicating that GP3 interaction 
with GP2a is not sufficient to pull down GP5 protein in co-IP assay. However, when 
GP3, GP4, and GP5 proteins were co-expressed, all three proteins could be specifically 
immunoprecipitated with anti-GP3 antibody (lane 8), indicating that GP4 protein was 
important for generation of this tripartite glycoprotein complex. Additionally, when all 
the four glycoproteins were co-expressed and immunoprecipitation was carried out with 
GP3 antibody, all the four proteins could be detected (lane 9). The results suggest that the 
GP4 most likely mediates the interactions among PRRSV glycoproteins to generate the 
multiprotein glycoprotein complex. 
4.3 Role of N-glycosylation of GP5 on its interaction with GP4 protein 
 GP5 of North American strain of PRRSV has three N-glycosylation sites with N 
at positions 34, 44, and 51. Previously the role of these three glycosylation sites in 
infectious virus production and evasion of neutralizing antibody response was reported 
(Ansari et al., 2006). I further studied the role of glycosylation of GP5 in its interaction 
with GP4 proteins. Seven mutant constructs were generated having N to A mutation in 
different combination. Three single N mutant clones were GP5-N34A, GP5-N44A, and 
GP5-N51A. Three double mutant constructs generated were GP5-N34/44A, GP5-
N34/51A, and GP5-N44/51A. The triple glycosylation mutant construct GP5-
N34/44/51A construct was generated by mutating all the three glycosylation sites of GP5. 
Stable protein expression for all the seven GP5 constructs were observed by expression 
of these proteins in BHK-21 cells. The anti-GP5 polyclonal antibody was able to 
immunoprecipitate both completely glycosylated as well as partially glycosylated form of 
GP5 (Fig. 4.7). Faster electrophoretic mobility of GP5 N-glycosylation defective proteins 
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Figure 4.7 Expression of GP5 N-glycosylation defective mutants. BHK-21 cells were 
infected with vTF7-3 and transfected with pGEM3 (E. Vector, lane 1) or GP5 and its N-
glycosylation defective mutant clones. Cells were radiolabeled for 4 h at 16 h post-
transfection, and the radiolabeled proteins were analyzed by immunoprecipitation with 
anti-GP5 polyclonal antibody, resolved in SDS-15%PAGE and detected by fluorography. 
The fully glycosylated proteins are identified by white dots, whereas the partially 
glycosylated forms of the proteins are identified by black dots, on the left side of the 
lanes. Mobilities of completely glycosylated GP5 and partially glycosylated form GP5 
are shown on the right.  
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was observed that correlated with the loss of glycosylation sites by mutation of N to A 
residues. Overall, these results showed that various N-glycosylation mutant GP5 proteins 
are stable and can be readily detected in transfected cells. 
To further study the role of N-glycosylation of GP5 in its interaction with GP4 
protein, I co-expressed GP4 with various GP5 constructs in BHK-21 cells. After 16 h of 
transfection, the cells were radiolabeled with 35S and co-IP assay was performed. The 
proteins complexes were immunoprecipitated by anti-GP5 polyclonal antibody. Results 
show that single N-glycosylation sites mutants of GP5 interact with GP4 since GP4 
protein could be readily immunoprecipitated with GP5 antibody (Fig. 4.8, lanes 7 to 9). 
Further, the double and triple glycosylation mutant GP5 proteins also have been shown to 
interact with GP4 (Fig. 4.8, lanes 10 to 13). These results indicate that N-glycosylation of 
GP5 is dispensable for its interaction with GP4.  
4.4 Cloning, expression, and functionality of porcine CD163, the cellular receptor 
for PRRSV 
4.4.1 Cloning of porcine CD163 
 It was previously reported that the expression of porcine CD163 in non-
permissive cells confers susceptibility to the PRRSV infection (Calvert et al., 2007). A 
recent study (Van Gorp et al., 2008) suggested that CD163 acts internally to uncoat the 
virus genome and that expression of both CD163 and sialoadhesin are simultaneously 
required for efficient infection by PRRSV. However, in the same study (Van Gorp et al., 
2008), it was also shown that expression of CD163 alone in BHK-21 cells that are 
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Figure 4.8 Examination of GP4 interaction with GP5 N-glycosylation defective 
mutants using anti-GP5 antibody. BHK-21 cells were infected with vTF7-3 virus and 
mock-transfected (lane 1) or transfected with plasmids encoding the GPs as shown in the 
bottom of the panel. – and + indicate without or with the plasmid shown on the left. At 16 
h post-transfection, the cells were radiolabeled with 35S protein labeling mix as described 
in the materials and methods, cell extracts were prepared and immunoprecipitated with 
monospecific polyclonal antibodies as shown on the bottom of the lanes and the proteins 
were detected by SDS-12%PAGE and fluorography. 
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otherwise non-permissive to PRRSV infection, led to productive infection, indicating that 
CD163 alone is sufficient to establish a productive replicative cycle of the virus. 
Therefore, PRRSV must bind to cells expressing CD163 to initiate the viral replication 
process. To determine which of the PRRSV envelope glycoproteins interact with CD163, 
I first cloned in pcDNA3.1 (+) vector, the full-length cDNA of CD163 from porcine 
alveolar macrophage (PAM) cells by RT-PCR amplification of total RNA from the cells 
using CD163 specific primers (Table 2.1).  
4.4.2 Expression of receptor CD163 
Four clones were used to examine the expression of the encoded protein by 
transfection, radiolabeling, and immunoprecipitation with porcine anti-CD163 antibody. I 
observed that three of the clones expressed proteins (Fig. 4.9B, lanes 3-5) that could be 
specifically immunoprecipitated with anti-CD163 antibody and possessed electrophoretic 
mobility (~130 kDa) corresponding to the full-length CD163 (Calvert et al., 2007). A 
smaller protein product of ~100 kDa encoded in another the clone was also detected by 
the CD163 antibody (Fig. 4.9B, lane 2). Sequence analysis of the clones showed that 
CD163 in the clone that produced the smaller protein contained a premature termination 
codon at aa position 893, resulting in a truncated protein of 892 aa corresponding to the 
observed molecular mass. This truncated protein lacks the carboxy-terminal cytoplasmic 
domain, the transmembrane (TM) domain as well as the ninth repeat unit of the 
scavenger receptor cysteine-rich (SRCR) protein domain (Fig. 4.9A) (Madsen et al., 
2004). I have termed this truncated protein as CD163∆TM. The CD163 cDNAs in the 
other clones contained full-length sequences of 1115 amino acids with greater than 99%  
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Figure 4.9 Porcine CD163. (A) The structure of porcine CD163, the cellular receptor for 
PRRSV. The extracellular amino terminus (NH2), transmembrane (TM) and cytoplasmic 
(COOH) domains at the carboxy-terminus of the molecule are shown. The main 
backbone of the protein contains nine scavenger receptor cysteine-rich (SRCR) domains. 
Two proline-serine-threonine (PST) rich interdomains (PST1 and PST2) are shown. 
(B) Expression of CD163 in transfected cells.  BHK-21 cells were infected with vTF7-3 
and transfected with pcDNA3.1 (E. Vector, lane 1) or CD163 cDNA containing clones (# 
1, 2, 3, and 4, lanes 2-5, respectively). Cells were radiolabeled for 4 h at 16 h 
posttransfection, the radiolabeled proteins were analyzed by immunoprecipitation with 
porcine anti-CD163 monoclonal antibody, resolved in SDS-10%PAGE and detected by 
fluorography. Mobilities of full-length (CD163) and the truncated form (CD163∆TM) of 
CD163 are shown on the right. Relative mobilities of molecular mass markers in kDa are 
shown on the left.  
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sequence identity with the reported sequence of the porcine CD163 (Calvert et al., 2007; 
Sanchez-Torres et al., 2003). 
4.4.3 Functionality of receptor CD163 
 To determine if the cloned CD163 confers susceptibility to PRRSV infection, I 
transfected the plasmids into BHK-21 cells that are non-permissive to PRRSV infection.  
Subsequently, the cells at about 48 h post-transfection were infected with PRRSV. 
Synthesis of N protein, indicative of PRRSV entry, transcription, and replication was 
examined in these cells by immunofluorescent staining of the cells at 48 h post-infection 
with anti-N monoclonal antibody, SDOW17 (Nelson et al., 1993). Synthesis of the N 
protein was readily detected in the cells transfected with clones encoding the full-length 
CD163 (Fig. 4.10), indicating that the CD163 encoded in these clones conferred 
susceptibility to PRRSV infection. The N protein was not detected in cells transfected 
with the clone encoding CD163∆TM, suggesting that this truncated protein is non-
functional in conferring PRRSV susceptibility to the cells. The inability of CD163∆TM 
to confer PRRSV susceptibility to the cells is not due to low levels of expression of the 
protein since under similar transfection conditions, CD163∆TM is detected at least at 
levels similar to or greater than that of the full-length protein (Fig. 4.9B). The results 
indicate that the carboxy-terminal 223 amino acids of CD163 are required for the 
function of the protein in conferring PRRSV susceptibility. It is possible that the 
CD163∆TM may have defective cellular localization or improper folding leading to loss 
of its function. 
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Figure 4.10 Susceptibility of BHK-21 cells expressing CD163 encoded in the clones 
to PRRSV infection. Cells were transfected with the plasmid clones as shown (EV, 
empty vector control) and expression of CD163 was driven by CMV promoter in 
pcDNA3.1 vector. Forty-eight hours after transfection, cells were infected with PRRSV 
and expression of N protein was examined using the monoclonal antibody SDOW17 and 
secondary antibody conjugated to Alexa-488.  
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Immunofluorescence microscopic examination of cells transfected with one of the 
full-length CD163 clone showed that CD163 protein was seen localized on the plasma  
membrane (Fig. 4.11, panel c) as well as in the cytoplasm (Fig. 4.11, panel d). Cells 
transfected with the clone encoding CD163∆TM showed no surface expression of the 
protein (Fig. 4.11, panel e), although the protein was expressed in the cytoplasm (Fig. 
4.11, panel f), indicating that CD163∆TM is defective in plasma membrane localization.  
Empty vector transfected cells did not exhibit any immunofluorescent staining on the 
plasma membrane or in the cytoplasm (Fig. 4.11, panels a and b).   
4.5 Interaction of receptor CD163 with the envelope proteins of PRRSV 
 I next wanted to examine which of the PRRSV envelope glycoprotein(s) interact 
with the receptor CD163. To perform the studies, the CD163 along with each of the four 
envelope glycoproteins were co-expressed in transfected cells and interactions were 
examined by co-IP with porcine CD163 monoclonal antibody. This antibody did not 
immunoprecipitate the individual glycoproteins when these glycoproteins were expressed 
alone (Fig. 4.12, lanes 7-10), demonstrating that the antibody does not immunoprecipitate 
the proteins non-specifically. However, when the individual glycoproteins were co-
expressed with CD163, GP2a and GP4 proteins could be specifically immunoprecipitated 
with anti-CD163 antibody (lanes 11 and 13) in multiple repeat experiments. Interestingly, 
both the mature GP2a and partially glycosylated GP2a proteins (identified by white and 
black dots, respectively, in lane 11) could be immunoprecipitated with the CD163 
antibody (lane 11), indicating that both forms of GP2a interact with CD163. The use of 
GP-specific antibodies also showed that CD163 protein could be immunoprecipitated 
with anti-GP2a or anti-GP4 antibodies (data not shown). The GP3 and GP5 proteins 
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Figure 4.11 Intracellular distribution of CD163. Immunofluorescent staining of BHK-
21 cell transfected with empty vector (panels a and b), full-length CD163 receptor 
encoding clone # 2 (panels c and d), or CD163∆TM encoding clone (panels e and f). Cell 
surface or cytoplasmic staining was performed with CD163 monoclonal antibody and 
Alexa-488 conjugated secondary antibody.  
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Figure 4.12 Interaction of CD163 with PRRSV GPs.  BHK-21 cells were infected with 
vTF7-3 and transfected with various GPs alone or in combination with CD163 (clone #2). 
The cells were radiolabeled and the proteins were immunoprecipitated with antibodies as 
shown below the lanes. Immunoprecipitated proteins were detected by SDS-10%PAGE 
and fluorography. Mobilities of molecular mass marker proteins in kDa are shown on the 
right. CD163 and the fully glycosylated viral GPs are identified on the left. Fully 
glycosylated GPs are identified with white dots in the fluorograms on the left side of each 
lane. The monoglycosylated GP2a is identified with black dots on the left side in lanes 3 
and 11.  
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could not be detected by immunoprecipitation with anti-CD163 antibody (lanes 12 and 
14) from co-transfected cells. These results suggest the GP3 and GP5 proteins do not 
interact with the CD163 or that their interactions can not be detected under conditions in 
which interactions with GP2a and GP4 could be readily detected. 
 To further address whether CD163 co-localizes with either with GP2a or GP4, I 
co-expressed CD163 with GP2a, GP3, and GP4 proteins (Fig. 4.13). By confocal 
microscopic studies, I found that strong co-localization of CD163 with both GP2a and 
GP4 (Fig. 4.13, panels C and I) observed whereas GP3 did not co-localize with CD163 
(Fig. 4.13, panel F). This result confirmed the previous observation from co-IP studies 
that CD163 specifically interacts with both GP2a and GP4 proteins.  
4.6 Interaction of CD163∆TM with envelope proteins of PRRSV 
Further, I performed a co-IP assay in which the CD163∆TM was co-expressed 
with the viral GPs (Fig. 4.14). By using the CD163 monoclonal antibody, I was able to 
pull down GP2a or GP4 protein, indicating that the 223 amino acids from the carboxy 
terminus of CD163 that are missing in CD163∆TM, are not required for its interaction 
with GP2a or GP4 proteins. 
4.7 Mapping of the domains of GP2a that interact with CD163 
 To map the amino acid residues of GP2a that are required for its interaction with 
receptor CD163, I generated a series of deletion mutant proteins of GP2a by sequentially 
deleting ~ 35-40 amino acids from amino-terminus to carboxy-terminus of the protein 
and cloned them in pGEM3 expression vector. To avoid the problem of losing possible 
anti-GP2a antibody binding epitope by deletion of amino acids, a FLAG tag was fused in 
frame at the carboxy-terminus of the GP2a (GP2a-FLAG) and its deletion  
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Figure 4.13 Co-localization of CD163 with GP2a and GP4. BHK-21 cells plated on 
glass coverslips were infected with vTF7-3 and transfected with plasmids encoding 
CD163 and FLAG tagged GP2a (GP2a-FLAG), GP3 and HA tagged GP4 (GP4-HA) 
proteins. At 16 h post transfection, the cells were fixed, permeabilized, and processed for 
immunofluorescent microscopy as described in the materials and methods. The CD163 
protein (green) was detected using mouse anti CD163 monoclonal antibody and Alexa-
488 conjugated goat anti-mouse IgG as secondary antibody whereas the GP2 protein 
(red) was detected with and anti-FLAG polyclonal antibody and Alexa-594 conjugated 
anti-mouse IgG as secondary antibody. The GP3 (red) was detected with anti-GP3 
polyclonal antibody and Alexa-594 conjugated anti-rabbit IgG as secondary antibody. 
The GP4-HA (red) protein was detected with anti-HA polyclonal antibody and Alexa-594 
conjugated anti-rabbit IgG as secondary antibody. Images were captured using 100X 
aperture. Intracellular expression of CD163 (A, D, and G), GP2 (B), GP3 (E), and GP4 
(H) in the same cell is shown. (C, F, and I) Merged image showing co-localization of the 
two proteins.  
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Figure 4.14 Interactions of GP2a and GP4 with CD163∆TM. BHK-21 cells were 
infected with vTF7-3 and transfected with various GPs alone or in combination with 
CD163∆TM protein. The cells were radiolabeled and the proteins were 
immunoprecipitated with antibodies as shown below the lanes. Immunoprecipitated 
proteins were detected by SDS-10%PAGE and fluorography. CD163∆TM and the fully 
glycosylated viral GPs are identified on the left. Fully glycosylated GPs are identified 
with white dots in the fluorograms on the left side of each lane. The monoglycosylated 
GP2a is identified with black dots on the left side in lanes 3 and 11. Mobilities of 
molecular mass marker proteins in kDa are shown on the right. 
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 mutant constructs. In this process, seven GP2a deletion mutant protein were constructed 
as schematically shown in Fig. 4.15A and named as GP2a-FLAG ∆2-38, GP2a-FLAG 
∆39-75, GP2a-FLAG ∆76-112, GP2a-FLAG ∆113-149, GP2a-FLAG ∆150-181, GP2a-
FLAG ∆182-218, and GP2a-FLAG ∆219-256. The GP2a and its deletion constructs were 
expressed in BHK-21 cells and all these constructs showed stable protein expression (Fig. 
4.16A). The GP2a-FLAG protein possesses an electrophoretic mobility of 33 kDa (Fig. 
4.16A, lane 2) whereas the GP2a-FLAG ∆2-38 protein has a molecular mass of ~ 20kDa 
(Fig. 4.16A, lane 3). This construct lacks the signal cleavage sequence (cleavage between 
amino acids 40 and 41 of GP2a) and probably does not get glycosylated. The molecular 
mass of fully mature form of GP2a-FLAG ∆39-75, GP2a-FLAG ∆76-112, GP2a-FLAG 
∆113-149, GP2a-FLAG ∆150-181, GP2a-FLAG ∆182-218, and GP2a-FLAG ∆219-256 
were estimated to be approximately 29 kDa, 26 kDa, 29 kDa, 26 kDa, 22 kDa, and 32 
kDa, respectively (Fig. 4.16A, lanes 4-9). The anti-FLAG polyclonal antibody was also 
able to immunoprecipitate partially glycosylated form the GP2a-FLAG and its deletion 
constructs. 
The deletion constructs of GP2a was co-expressed with CD163 molecule and co-
IP study was performed by use of anti-CD163 monoclonal antibody. The results show 
that CD163 antibody immunoprecipitated all the deletion mutants of GP2a proteins 
except GP2a-FLAG ∆2-38 and GP2a-FLAG ∆76-112 proteins (Fig. 4.16B, lanes 4 and 6, 
respectively). The signal cleavage sequence of GP2a is present between amino acids 40 
and 41. Even if, I observed loss of interaction of GP2a with CD163 by deletion of 2-38 
amino acid sequences, this region may not be actually responsible for the interaction.  
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Figure 4.15 Schematics of GP2a (A) and GP4 (B) deletion mutants constructed. The 
name of each of the mutant construct is shown on the left. The predicted N-glycosylation 
sites in amino acids numbers for GP2 and GP4 are shown. The signal cleavage sites (SS), 
transmembrane (TM) domains, and FLAG tag positions are indicated. The deleted amino 
acids are shown as dotted lines.  
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Figure 4.16 Mapping of the amino acids of GP2a required for its interaction with 
CD163. (A) Expression of GP2a deletion constructs. BHK-21 cells were infected with 
vTF7-3 virus and transfected with pGEM3 (E. vector, lane 1), or GP2a-FLAG (lane 2) 
and its deletion mutant clones (lane 3-9). Cells were radiolabeled with 35S for 4h at 16h 
post-transfection, and radiolabeled proteins were analyzed by immunoprecipitation with 
anti-FLAG polyclonal antibody, resolved in SDS-10% PAGE, and detected by 
fluorography. The fully mature from of GP2a and its deletion constructs are identified 
with white dots in the fluorogram on the left side of each lane where as the partially 
glycosylated form of GP2a are shown as black dots. (B) Interaction of GP2a deletion 
constructs with CD163. BHK-21 cells were infected with vTF7-3 and transfected with 
pGEM3 vector alone (E. vector, lane 1), CD163 along with pGEM3 (lane2) or GP2a-
FLAG (lane 3) and its deletion constructs (lane 4-10) as indicated at the top of panel. 
Cells were radiolabeled for 4h at 16h post-transfection, the proteins were 
immunoprecipitated with anti-CD163 monoclonal antibody, resolved in SDS-10% 
PAGE, and detected by fluorography. Mobility of CD163, fully mature form of GP2a 
deletion proteins are shown as white dots and immature forms are shown as black dots  in 
the left side of each lane. The CD63 is identified. Relative mobilities of molecular mass 
markers in kDa are shown on the right. 
 105 
Overall, these results indicate that amino acids 76-112 of GP2a are required for its 
interaction with CD163.   
4.8 Mapping of the domains of GP4 that interact with CD163 
 To map the amino acid regions of GP4 that are required for its interaction with 
CD163, I generated deletion mutants of GP4 by sequentially deleting ~ 35 amino acid 
residues of GP4 from its amino-terminus to carboxy-terminus. To avoid the problem of 
potentially losing the GP4 antibody binding epitopes by deletion, I fused FLAG tag on 
the carboxy-terminus of GP4 to generate GP4-FLAG construct and cloned it in pGEM3 
vector. Similarly all the five GP4 deletion constructs were generated with the FLAG tag 
fused in their carboxy terminus and cloned in pGEM3 vector. The GP4 deletion 
constructs are GP4-FLAG ∆2-35, GP4-FLAG ∆36-70, GP4-FLAG ∆71-105, GP4-FLAG 
∆106-140, and GP4-FLAG ∆141-177 (Fig. 4.15B). All the deletion constructs of GP4 
were found to be stable when expressed in BHK-21 cells (Fig. 4.17A). The GP4-FLAG 
migrated with an electrophoretic mobility of 30 kDa (Fig. 4.17A, lane 2). The GP4-
FLAG ∆2-35 construct lacks the signal cleavage sequence (between amino acids 22 and 
23) of GP4 and migrated with an electrophoretic mobility of 25 kDa (Fig. 4.17A, lane 3). 
The GP4-FLAG ∆36-70, GP4-FLAG ∆71-105, GP4-FLAG ∆106-140, and GP4-FLAG 
∆141-177 protein has molecular mass of 21 kDa, 21 kDa, 18 kDa, and 23 kDa, 
respectively (Fig. 4.17A, lanes 4-7).  
 Either GP4-FLAG or its deletion constructs were co-expressed in BHK-21 cells 
and  co-IP study was performed to check the effect of deletion of amino acids of GP4 
with its interaction with receptor CD163 molecule by anti-CD163 monoclonal antibody  
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Figure 4.17 Mapping of the amino acids of GP4 required for its interaction with 
CD163. (A) Expression of GP4 deletion constructs. BHK-21 cells were infected with 
vTF7-3 virus and transfected with pGEM3 (E. vector, lane 1), or GP4-FLAG (lane 2) and 
its deletion mutant clones (lane 3-7). Cells were radiolabeled for 4h at 16h post-
transfection, and the proteins were analyzed by immunoprecipitation with anti-FLAG 
polyclonal antibody, resolved in SDS-10% PAGE, and detected by fluorography. The 
fully mature from of GP4 and its deletion constructs are identified with white dots in the 
fluorogram on the left side of each lane where as the partially glycosylated form of GP4 
are shown as black dots. (B) Interaction of GP4 deletion constructs with CD163. BHK-21 
cells were infected with vTF7-3 and transfected with pGEM3 vector alone (E. vector, 
lane 1), CD163 along with pGEM3 (lane2) or GP4-FLAG (lane 3) and its deletion 
constructs (lane 4-8) as indicated at the top of panel. Cells were radiolabeled for 4h at 
16h post-transfection, the proteins were immunoprecipitated with anti-CD163 
monoclonal antibody, resolved in SDS-10% PAGE, and detected by fluorography. 
Mobility of CD163 is shown on the left whereas the mobilities of GP4 deletion proteins 
are shown as white dots in the left side of each lane.  Relative mobilities of molecular 
mass markers in kDa are shown on the right.  
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(Fig. 4.17B).  The results show that the CD163 antibody immunoprecipitated all the 
deletion mutants of GP4 protein except GP4-FLAG ∆141-178 protein (Fig. 4.17B, lane 
8), indicating that the amino acids 141-178 of GP4 are required for its interaction with 
CD163. 
4.9 Discussion 
PRRSV contains one major glycoprotein (GP5) and three minor glycoproteins 
(GP2a, GP3, and GP4) on the virion envelope. All of these glycoproteins are required for 
generation of infectious virions, indicating that they play critical roles in virion assembly 
and/or interactions with the cell surface receptor for virus entry and/or uncoating. 
Previous studies have reported that GP2a, GP3, GP4, and the unglycosylated envelope 
protein 2b form a multiprotein complex in cells expressing these proteins (Wissink et al., 
2005). In this report, I have examined the interactions of the envelope glycoproteins 
among themselves as well as the interactions of these proteins with the cell surface 
receptor, CD163. Overall, my studies lead me to conclude that (i) the GP4 and GP2a 
proteins interact with the other GPs; (ii) GP4 mediates the formation of the multiprotein 
complex between the minor GPs and the major envelope GP, the GP5; and (iii) the GP4 
along with GP2a interact with CD163. These studies for the first time show that the GP4 
protein is the key glycoprotein of PRRSV that is responsible for formation of the 
multiprotein complex and along with GP2a, may serve as the viral attachment protein, 
allowing virus binding to the cell surface receptor during infection.  
It has been previously reported for the genotype II Lelystad virus that the minor 
envelope glycoproteins and 2b (or E) protein together form a heterotetrameric complex 
and that this complex formation is crucial for intracellular targeting of these proteins 
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from the ER through the Golgi complex to the plasma membrane (Wissink et al., 2005). 
My studies not only confirm these observations but also show that the major envelope 
glycoprotein GP5 interacts with GP4 strongly (Table 4.1). Although direct interaction 
between GP3 and GP5 could not be demonstrated, a multiprotein complex comprising of 
all the four envelope glycoproteins could be readily detected by immunoprecipitation 
with anti-GP3 antibody (Fig. 4.6). The studies reported here suggest that the GP4 
mediates the formation of the large multiprotein complex between the minor and the 
major envelope proteins of PRRSV. In cells expressing the GP5 alone or in the presence 
of M protein, GP5 does not acquire endo-H resistance even after 4 h of synthesis (Ansari 
et al., 2006), but in virus-infected cells or in the extracellular virions, the GP5 becomes 
Endo H resistant  (Ansari et al., 2006). These results indicate that the multiprotein 
complex generated by the interactions of the envelope proteins may be critical for the 
transport of these proteins from the ER to the Golgi complex and finally to the plasma 
membrane for incorporation into virus particles, consistent with previous findings that the 
minor envelope glycoproteins of Lelystad virus form a multimeric complex for their 
transport to the plasma membrane (Wissink et al., 2005).  
Although multiprotein complexes can be detected in transfected cells, the molar 
ratio of the proteins in such complexes is unknown. Since GP5 and M proteins are the 
major envelope proteins, they are likely distributed uniformly throughout the virion 
envelope. Recent cryoelectron tomographic studies (Spilman et al., 2009) reveal that 
PRRSV particles mostly display smooth envelope outlines, for which the authors suggest 
that the small ectodomains of GP5 and M proteins are possibly not large enough to be 
detected as visible spikes on the virion envelope. On the other hand, the authors also 
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detected few features protruding from the virion envelope, which most likely correspond 
to the large multimeric complexes made from the bulkier but less abundant minor 
envelope glycoproteins such as GP2a (Spilman et al., 2009). I reason that the protruding 
features seen on PRRSV virion envelope (Spilman et al., 2009) represent the multimeric 
complexes of the minor envelope glycoproteins with or without the GP5 and M proteins 
and these are likely to be directly involved in interactions with the cell surface receptor 
during PRRSV infection.  
The data presented here support the contention that the multimeric complexes of 
the minor glycoproteins with or without the M and GP5 proteins are involved in direct 
interaction with the cell surface receptor. Since GP5 and M proteins are present in 
abundant amounts on the virion envelope, these two proteins were considered to play a 
major role in receptor interaction. However, this contention was challenged by the results 
from the studies using chimeric viruses (Dobbe et al., 2001; Verheije et al., 2002), which 
suggested that the GP5 and M proteins do not play a role in receptor interaction. My 
studies show that only the GP2a and GP4 proteins interact with CD163. It appears that 
the GP4 is a critical viral envelope protein that not only mediates interactions with other 
GPs on the virion envelope, but also along with GP2a, mediates interactions with the 
CD163 for virus entry. Since the minor envelope proteins are not required for particle 
formation (Wissink et al., 2005) and there are only few large multimeric glycoprotein 
complexes present on the virion envelope (Spilman et al., 2009), I suggest that the major 
function of the minor glycoprotein complex on the virion envelope is to interact 
specifically with the cell surface receptor for virus entry. On the other hand, the GP5 and 
M heterodimeric complexes, which are present in large amount and are uniformly 
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distributed throughout the virion envelope (Spilman et al., 2009), play major roles in 
virion assembly. The GP5-M complexes on the virion envelope may also play additional 
roles in nonspecific interactions with heparin-like receptors on PAM cells since M 
protein has been shown to bind to such molecules (Delputte et al., 2002). The nonspecific 
interaction would allow initial virus binding to the cell surface followed by specific 
interaction with the receptor through GP2a and GP4 proteins for receptor-mediated entry 
of the virion.  
It is possible then that GP2a and GP4, by containing viral receptor-interacting 
domains, would potentially be involved in the establishment of protective immunity 
against PRRSV infection. Viral receptor-interacting proteins and domains are known to 
induce highly neutralizing antibodies and contribute important targets for vaccine and 
therapeutic development (Delrue et al., 2009). While a single report so far suggests that 
GP4 contains at least one neutralizing epitope (Meulenberg et al., 1997), the full potential 
of GP4 and GP2a to induce PRRSV-neutralizing antibodies and T-cell immunity should 
be further investigated. This becomes  particularly important in  the light of recent studies 
indicating that viral receptor-interacting domains may be directly involved in the 
induction of broadly reacting neutralizing antibodies, as shown for hepatitis C virus (Tarr 
et al., 2006), SARS coronavirus (Du et al., 2009), influenza virus (Lim et al., 2008), 
paramyxovirus (Hashiguchi et al., 2007) etc. These broadly reactive, cross-neutralizing 
and possibly cross-protective antibodies may be of central importance for protection 
against highly variable viruses such as PRRSV (Lopez & Osorio, 2004). 
Based on the results presented in this chapter, I propose a tentative model for the 
multiprotein complex on PRRSV envelope and its interaction with the cell surface 
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receptor CD163 (Fig. 4.18). Although the involvement of proteins 2b and M in the 
formation of this complex or interaction with CD163 has not been examined in the 
current study, several of these interactions have already been confirmed. Further studies 
are being conducted to test this preliminary model of GP-CD163 interaction.  Although 
preliminary data on mapping of the regions of GP2a and GP4 that interact with CD163 
have been generated, addition mutational and biochemical studies would be required to 
confirm the preliminary findings.    
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Figure 4.18 A preliminary model of PRRSV envelope protein complex and its 
interaction with CD163 on the host cell plasma membrane. For the sake of simplicity 
and convenience, the GPs are depicted as globular structures with lines spanning the viral 
envelope. CD163 is shown as a structure with extracellular region having repeating units 
(corresponding to the nine SRCR domains) projecting from the plasma membrane of a 
host cell. The carboxy-terminal cytoplasmic domain and the transmembrane domains are 
also shown. The dotted lines in the schematic represent the regions of the proteins that are 
masked by GP2a.      
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INFECTIOUS VIRUS PRODUCTION, NEUTRALIZING ANTIBODY 
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Previous studies from our laboratory had shown that N-glycosylation of GP5 
protein of PRRSV was required for protection against host neutralizing antibody response 
by glycan shielding mechanism (Ansari et al., 2006). Out of three predicted N-
glycosylation sites in GP5 of North American strain of PRRSV, glycan addition on N44 
was shown to be absolutely required for viral particle formation and infectious virus 
production. Whereas, glycosylation at N34 and N51 residues were important for the virus 
to escape from neutralization by the antibody (Ansari et al., 2006).  Similar to North 
American strain, N46 of Lelystad virus was shown to be important for infectious virus 
production (Wissink et al., 2004).  The same study also showed that both the N-
glycosylation sites of GP2a protein of Lelystad virus were dispensable for infectious 
virus production (Wissink et al., 2004). But, these studies did not address the role of 
glycosylation of the viral GPs on virus neutralization or induction of neutralizing 
antibody response.  
5.1 Role of N-glycosylation of GP2a and GP4 of PRRSV on infectious virus 
production 
5.1.1 N184 of GP2a protein is important for virus recovery 
The N-glycosylation of GP2a was shown to be dispensable for infectious virus 
production for Lelystad virus (Wissink et al., 2004). The GP2a of North American strain 
(FL12 virus) has two predicted glycosylation sites at positions 178 and 184 (Fig. 5.1). 
The N at these positions was mutated to A which abolished the ability of glycan moieties 
to be added at these positions. I used GP2a-FLAG encoding construct to generate 
glycosylation site mutants. Three mutant clones were generated for GP2a protein by 
mutating glycosylation sites for this protein. N178A and N184A denotes the mutation of 
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Figure 5.1 Schematic representation of GP2a protein showing positions of the two 
glycosylation sites. The signal sequence (SS) present of the amino-terminus and 
transmembrane (TM) domain at the carboxy terminus is denoted. The size of the protein 
in amino acids is shown on the left. The name of each of the mutant construct is shown 
on the left. Potential N-glycosylation sites with residue number on bottom of the 
rectangular boxes are shown. The N to A mutation sites are left blank without any glycan 
moiety. 
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individual glycosylation sites where as N178/184A denotes mutation of both the 
glycosylation sites of GP2a protein. The proteins were expressed in vitro by transfection 
of plasmid constructs into BHK-21 cells (Fig. 5.2). Both the wild type and mutant 
proteins were expressed at similar levels. The GP2a-FLAG protein has a molecular 
weight of 33 kDa. While the N178A-FLAG and N184A-FLAG proteins migrated with a 
molecular weight of 30.5 kDa (Fig. 5.2, lanes 3 and 4), the N178/184A-FLAG protein 
migrated with a molecular mass of 28 kDa (Fig. 5.2, lane 5). These results showed that 
mutation of glycosylation sites resulted in synthesis of the proteins with faster 
electrophoretic mobility that correlated with loss of glycan addition. 
The N to A mutations was further introduced in the GP2a of FL12 genome and a 
virus recovery experiment was performed by electroporation of in vitro transcribed RNA 
in case of MARC-145 cells. The N protein expression was observed after 48 h post 
electroporation (Fig. 5.3). It indicated that the electroporated RNA was able to replicate 
inside the cells and produce N protein. Five days after electroporation, CPE was observed 
for FL-GP2a-N178A whereas, no CPE was observed for either FL-GP2a-N184A or FL-
GP2a-N178/184A mutant clones. The presence of the correct mutation in FL-N178A 
recovered virus was confirmed by sequencing. In cells infected with the mutant virus, the 
GP2a-N178A protein migrated with a mobility that correlated with loss of one 
glycosylation site (Fig. 5.4A, lane 2). Further, the introduced mutation was found to be 
stable upon passage of the virus in cell culture as the cells infected with the passage 10 
mutant virus still synthesized GP2a-N178A protein (Fig. 5.4A, lane 3) that co-migrated 
with GP2a-N178A protein synthesized in passage 1 mutant virus-infected cells. The 
GP2a proteins synthesized in these mutant virus-infected cells clearly migrated 
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Figure 5.2 Protein expression of GP2a and its N-glycosylation mutant proteins. 
BHK-21 cells were infected with vTF7-3 and transfected with pGEM3 (Empty vector, 
lane 1) or GP2a and its N-glycosylation defective mutants (lanes 2-5). Cells were 
radiolabeled for 4 h at 16 h post-transfection, and the radiolabeled proteins were analyzed 
by immunoprecipitation with anti-GP2a antibody, resolved in SDS-12%PAGE and 
detected by fluorography. The completely glycosylated protein is indicated as white dot 
whereas, the partially glycosylated or unglycosylated forms are indicated as black dots. 
The protein band identified by an asterisk is most likely the signal-cleaved 
deglycosylated form of GP2a. The different glycosylated forms of GP2a proteins are 
shown on the right side of the fluorogram. Relative mobilities of molecular mass markers 
in kDa are shown on the left. 
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Figure 5.3 Expression of N proteins in GP2a N-glycosylation defective mutant 
viruses. MARC-145 cells were electroporated with in vitro transcripts derived from 
pFL12-Pol- (mock), pFL12, pFL-GP2a-N178A, pFL-GP2a-N184A, and pFL-GP2a-
N178/184A. At 48h after electroporation, cells were permeabilized and expression of N 
protein was examined using the monoclonal antibody SDOW17 and Alexa-488 
conjugated anti-mouse IgG as secondary antibody. 
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Figure 5.4 Protein expression of FL-GP2a-N178A virus. (A) MARC-145 cells were 
either left uninfected (lane 1) or infected with FL-GP2a-N178A virus of passage-1 (lane 
2), FL-GP2a-N178A virus of passage-10 (lane 3), and FL12 virus (lane 4). Cells were 
radiolabeled for 4 h at 48 h post-infection, and the radiolabeled proteins were analyzed by 
immunoprecipitation with anti-GP2a antibody, resolved in SDS-12%PAGE and detected 
by fluorography. The extent of glycosylated forms of GP2a protein are identified on the 
right. Relative mobilities of molecular mass markers in kDa are shown on the left. (B) 
Fluorograph of immunoprecipitated GP2a-wild type and GP2a N-glycosylation mutant 
proteins synthesized in infected cells with virus recovered after 21 days post inoculation 
in piglets. The experiment was performed similarly as described in panel A except that  
sera collected from sham infected animal (lane 1), FL-GP2a-N178A virus infected animal 
(lane 2), and FL12 virus infected animal (lane 3) were used for infection of naïve MARC-
145 cells. The relative mobilities of the molecular mass markers in kDa are shown on the 
left. 
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faster than the GP2a protein synthesized in FL12 virus-infected cells (Fig. 5.4A, lane 4), 
demonstrating the stability of the mutant virus under in vitro growth and passage 
conditions.  Similarly, the cells infected with sera collected on 21 days post inoculation 
from FL-GP2a-N178A infected piglets also synthesize GP2a-N178A protein which 
migrated with a mobility that correlated with a loss of one glycan site (Fig. 5.4B, lane 2) 
in comparison to GP2a from FL12 virus inoculated piglets (Fig. 5.4B, lane 3). This 
indicated that the specific mutation in GP2a-N178A protein was stable in virus infected 
animals. To compare the growth characteristics of recovered FL-GP2a-N178A virus with 
the FL12 virus, multi step growth kinetics study was performed by infecting MARC-145 
cells with 0.1 MOI of both wild type and mutant viruses as described in materials and 
methods. Subsequently, plaque assays were performed to measure the virus titers at 
different times post-infection. The growth characteristics of both FL-GP2a-N178A and 
FL12 virus were similar to that observed by multi step growth curve analysis (Fig. 5.5). 
My results show that glycan addition at amino acid position 184 of GP2a protein was 
important for infectious virus production in North American strain of PRRSV (FL12). 
5.1.2 Role of individual N-glycosylation sites of GP4 on infectious virus production 
GP4 protein of FL12 genome of PRRSV has four predicted sites at positions 37, 
84, 120 and 130 (Fig. 5.6). To study the effect of N-glycosylation of GP4 protein on 
infectious virus production, I individually mutated N to A amino acid in all these four 
positions (N37A, N84A, N120A and N130A). All the mutant proteins were expressed at 
comparable levels to that of GP4 wild type protein (Fig. 5.7). The GP4-wild type protein 
migrated with a molecular weight of 29 kDa (Fig. 5.7, lane 2). All four N-glycosylation  
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Figure 5.5 Multistep growth kinetics of FL12 and FL-GP2a-N178A recovered virus. 
MARC-145 cells were infected with FL12 and FL-GP2a-N178A viruses with 0.1 MOI 
and supernatant was collected in every 12 h interval up to 120 h. Plaque assay was 
performed as described in materials and methods. The viral titer was measured and 
expressed in log10 scale. The data points represent mean values from two independent 
experiments, and the error bars denote standard deviation. 
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Figure 5.6 Schematic of GP4 single N-glycosylation defective mutants constructed. 
The size of the GP4 protein in amino acids is mentioned on the left. The amino acid 
position four predicted N-glycosylation sites were mentioned below each site. The signal 
cleavage site (SS) and transmembrane (TM) domain is indicated. The name of each of the 
mutant construct is shown on the left. The N to A mutation sites are left blank without 
any attached glycan moiety. 
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Figure 5.7 Protein expressions of GP4 single N-glycosylation mutant proteins. BHK-
21 cells were infected with vTF7-3 and transfected with pGEM3 (Empty vector, lane 1) 
or GP4 (lane 2) and its N-glycosylation defective clones (lanes 3-6). Cells were 
radiolabeled for 4 h at 16 h post-transfection, and the radiolabeled proteins were analyzed 
by immunoprecipitation with anti-GP4 antibody, resolved in SDS-12%PAGE and 
detected by fluorography. The relative mobilities of the molecular mass markers in kDa 
are shown on the left. 
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mutant proteins migrated with a molecular weight of 26.5 kDa (Fig. 5.7, lanes 3-6). I 
observed a slight difference in electrophoretic mobility of the four GP4 mutant proteins. 
This may be due to the fact that mutations of N residues lead to further modification of 
GP4 protein folding. I introduced the N to A mutation of GP4 protein in full length 
genome of FL12 (FL-GP4-N37A, FL-GP4-N84A, FL-GP4-N120A, and FL-GP4-
N130A). Forty-eight hours post electroporation, the N protein expression was observed in 
cells transfected with RNA derived from each of the GP4 mutant clones (data not 
shown). I was able to recover infectious viruses encoding the single glycosylation site 
mutations in GP4 protein. In the MARC-145 cells infected with the mutant viruses, the 
four single mutant GP4 proteins (GP4-N37A, GP4-N84A, GP4-N120A, and GP4-
N130A) migrated with a mobility that correlated with the loss of one glycosylation site 
(Fig. 5.8A,  lanes 2-5) and faster than GP4 protein (Fig. 5.8A, lane 6) . The intracellular 
protein expression profile for all these mutant viruses resembled that of transient protein 
expression assay results indicating the stability of the mutant viruses under in vitro 
growth and passage conditions (Fig. 5.8A). Similarly, in the cells infected with sera 
collected on 21 days post inoculation, the four GP4 single glycosylation mutant proteins 
migrated with mobility faster than that of GP4 protein (Fig. 5.8B). The multi- step growth 
curve analysis results indicated that all the mutant viruses had higher titer than the wild 
type virus (Fig. 5.9). I also observed a larger difference in viral titer in case of FL-GP4-
120A and FL-GP4-130A virus in comparison to FL12 virus. While the FL12 virus had 
highest titer at 72 h post infection, the GP4 single mutant viruses achieved highest titer at 
48 h post infection. FL-GP4-120A and FL-GP4-130A viruses seemed to have almost 10-
50 fold higher titers than wild type FL12 virus at 48 h post infection. At 
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Figure 5.8 Protein expression profiles of recovered GP4 single mutant viruses. (A) 
MARC-145 cells were either left uninfected (Mock, lane 1) or infected with four single 
N-glycosylation defective mutant virus (lanes 2-5) of 10th passage and FL12 virus (lane 
6). Cells were radiolabeled for 4 h at 48 h post-infection, and the radiolabeled proteins 
were analyzed by immunoprecipitation with anti-GP4 antibody, resolved in SDS-
12%PAGE and detected by fluorography. Relative mobilities of molecular mass markers 
in kDa are shown on the left. (B) The experiment was performed similarly as described in 
panel A except sera collected from sham infected animals (lane 1), the single N-
glycosylation defective mutant virus infected animals (lanes 2-5), and FL12 virus 
infected animals were used for infection of naïve MARC-145 cells. Relative mobilities of 
molecular mass markers in kDa are shown on the left. 
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Figure 5.9 Multistep growth kinetics for recovered GP4-wild type and GP4 single N-
deglycosylated mutant viruses. MARC-145 cells were infected with FL12 and GP4 
single N-deglycosylated mutant viruses with 0.1 MOI and supernatant was collected in 
every 12 h interval up to 120 h. Plaque assay was performed as described in materials and 
methods. The viral titer was measured and expressed in log10 scale. The data points 
represent mean values from two independent experiments, and the error bars denote 
standard deviation. 
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most of the time points examined, the mutant viruses exhibited higher titers than the wild 
type FL12 virus. The reasons for better growth of the glycosylation mutant viruses are 
unknown at this time. 
5.1.3 Simultaneous mutation of two N-glycosylation sites of GP4 is lethal for 
infectious virus production 
To study the effect of double mutation of N-glycosylation sites of GP4 on 
infectious virus production, I generated six clones by simultaneously mutating two N 
residues of GP4 (N37/84A, N37/120A, N37/130A, N84/120A, N84/130A, and 
N120/130A) (Fig. 5.10). By losing two glycosylation sites, the transiently expressed 
proteins lost 5 kDa of molecular mass and migrated with a molecular weight of 24 kDa in 
transfected cells (Fig. 5.11, lanes 4-9). The GP4-N37/84A protein found to migrate 
slightly faster than the expected size. The same trend also observed for GP4-N120/130A 
mutation, in which case the protein migrated slower than its expected size. As observed 
for GP4 single N-glycosylation mutants, double mutations of GP4 protein probably 
affected the overall protein folding and hence the difference in protein migration. I 
further introduced these mutations in FL12 genome (FL-GP4-N37/84A, FL-GP4-
N37/120A, FL-GP4-N37/130A, FL-GP4-N84/120A, FL-GP4-N84/130A, and FL-GP4-
N120/130A and the mutation was confirmed by sequencing analysis (data not shown). 
Upon electroporation of in vitro transcribed RNA in MARC-145 cells, the N protein 
expression was observed in case of all the six mutant clones at 48 h post electroporation 
(Fig. 5.12). But, I was not able to successfully recover any of the six GP4 double mutant 
viruses. These results indicated that mutation of more than one glycosylation sites in GP4 
was lethal for infectious virus particle formation. 
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Figure 5.10 Schematic of GP4 double N-glycosylation defective mutants constructed. 
The name of each of the mutant construct is shown on the left. The signal cleavage site 
(SS) and transmembrane (TM) domain is indicated. The predicted N-glycosylation sites 
in amino acid numbers for GP4 are shown. The N to A mutation sites are left blank 
without any attached glycan moiety. 
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Figure 5.11 Protein expressions of GP4–double N-deglycosylated mutant proteins. 
BHK-21 cells were infected with vTF7-3 and transfected with pGEM3 (Empty vector, 
lane 1) or GP4 (lane 2), GP4-N37A (lane 3), and six double N-glycosylation defective 
clones of GP4 (lanes 4-9). Cells were radiolabeled for 4 h at 16 h post-transfection, and 
the radiolabeled proteins were analyzed by immunoprecipitation with anti-GP4 antibody, 
resolved in SDS-12%PAGE and detected by fluorography. The higher band intensities in 
different GP4 transfected constructs (lanes 2-9) in comparison to empty vector 
transfected construct (lane 1) is considered as specific proteins immunoprecipitated by 
anti-GP4 polyclonal antibody. The relative mobilities of the molecular mass markers in 
kDa are shown on the left. 
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Figure 5.12 Expression of N protein in GP4 double N-glycosylation defective mutant 
viruses. MARC-145 cells were electroporated with in vitro transcripts derived from 
pFL12-Pol- (mock), pFL12, pFL-GP4-N37/84A, pFL-GP4-N37/120A, pFL-GP4-
N37/130A, pFL-GP4-N84/120A, pFL-GP4-N84/130A, and pFL-GP4-N120/130A. At 
48h after electroporation, cells were permeabilized and expression of N protein was 
examined using the monoclonal antibody SDOW17 and Alexa-488 conjugated anti-
mouse IgG as secondary antibody. 
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5.2 Role of N-glycosylation of minor envelope glycoproteins on neutralizing 
antibody production in infected piglets 
Twenty one days old weaned piglets were infected with FL12 as well as mutant 
viruses generated for the GP2a and GP4 proteins. For GP2a and GP4, only recovered 
single mutant viruses were used in these experiments. Groups of four 21 days old piglets 
were injected with the mutant viruses. All the different groups of piglets were housed 
separately. Sham infected piglets were included as negative control. The neutralizing 
antibody titer was measured by TCID50 assay (Table 5.1).  Since neutralizing antibody 
response is usually not detected before 21 days post infection, I normalized the titer of 
neutralizing antibody at day 7 as 1 for the wild type and mutant virus-infected sera from 
the animals. The FL12 infected piglet sera was tested against FL12 infected cells 
(homologous titer) and compared with sera collected from mutant virus infected piglets 
(heterologous titer). I did not observe any significant difference between neutralizing 
antibody response produced in case of FL12 virus or other mutant virus. These results 
indicated that hypoglycosylation of GP2a and GP4 did not influence neutralizing 
antibody response in infected piglets (Table 5.1). Overall, the results show that unlike 
GP5 (Ansari et al., 2006), hypoglycosylation of GP2a and GP4 did not induce higher 
neutralizing antibody response in infected pigs and the mutant viruses were not more 
sensitive to neutralization.   
5.3 Role of N-glycosylation of GP2a and GP4 for their interaction with the receptor 
CD163 
 My previous study established that porcine CD163 interacts specifically with 
GP2a and GP4 proteins of PRRSV (Fig. 4.12). I further examined the role of N-   
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Table 5.1 Serum neutralization titer of animals infected with wild type or GP2a and 
GP4 glycosylation mutant PRRSVs. 
 
Groups 
Days post infection 
7 days 46 days 
FL12 1 32 
GP2a FL-N178A 1 9.5 
GP4 FL-N37A 1 13.5 
GP4 FL-N84A 1 22.6 
GP4 FL-N120A 1 26.9 
GP4 FL-N130A 1 38.1 
 
The serum neutralization value of both wild type and mutant viruses are made 1 for 7th 
day for comparison. The results are shown as of average of four animals per each group. 
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glycosylation of GP2a and GP4 in their interaction with CD163 molecule by co-IP assay 
as described in the previous chapter. The receptor CD163 was individually co-expressed 
with GP2a-FLAG, GP2a-FLAG-N178A, GP2a-FLAG-N184A, or GP2a-FLAG-
N178/184A mutant proteins and the protein complexes were co-immunoprecipitated with 
anti-FLAG polyclonal antibody (Fig. 5.13) or anti-CD163 monoclonal antibody (Fig. 
5.14) and resolved in SDS-10% PAGE gel. By using anti-FLAG antibody, CD163 could 
be readily recovered by immunoprecipitation of cell lysate co-expressing GP2a-FLAG,  
GP2a-FLAG-N178A or GP2a-FLAG-N184A proteins (Fig. 5.13, lanes 9-11). But, 
CD163 molecule could not be co-immunoprecipitated when it was expressed with 
completely unglycosylated form of GP2a (GP2a-FLAG-N178/184A) protein (Fig. 5.13, 
lane 12). In a complementary experiment, I examined the interactions using anti-CD163 
monoclonal antibody. The results (Fig. 5.14) showed that CD163 antibody could 
immunoprecipitate wild type GP2a and single glycosylation mutant GP2a proteins. 
However, little or no unglycosylated GP2a was detected by the antibody. These results 
suggest that glycosylation of at least one site in GP2a protein was necessary for efficient 
interaction with the receptor CD163.   
A similar study was performed to determine the role of N-glycosylation of GP4 
protein in its interaction with CD163 (Fig. 5.15). In these studies, I chose to use only one 
double mutant and the quadruple mutant (completely unglycosylated form) GP4 proteins 
for their interaction with CD163. I co-expressed GP4-wild type, GP4-partially double 
glycosylated protein (GP4-N37/84A), and fully unglycosylated GP4 protein (GP4-
N37/84/120/130A) along with CD163 molecule and immunoprecipitated the protein  
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Figure 5.13 Examination of interaction of CD163 with GP2a N-glycosylation 
defective proteins using FLAG antibody. BHK-21 cells were infected with vTF7-3 
virus and mock-transfected (lanes 1 and 3), transfected with both GP2a-FLAG or N-
glycosylation defective GP2a-FLAG plasmids and CD163 plasmid as shown in the 
bottom of the panel. – and + indicate without or with the plasmid shown on the left. The 
cells were radiolabeled and immunoprecipitated with specific antibodies as shown below 
the lanes. The CD163 and GP2a (wild type and mutant) proteins were co-
immunoprecipitated by anti FLAG antibody (lanes 9-12). Immunoprecipitated proteins 
were resolved in SDS-10% PAGE and detected by fluorography. CD163 and different 
glycosylated forms of GP2a proteins are identified on the right. The relative mobilities of 
the molecular mass markers in kDa are shown on the left. 
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Figure 5.14 Examination of interaction of CD163 with GP2a N-glycosylation 
defective proteins using CD163 antibody. BHK-21 cells were infected with vTF7-3 
virus and mock-transfected (lanes 1 and 2), transfected with both GP2a-FLAG or N-
glycosylation defective GP2a-FLAG plasmids and CD163 plasmid as shown in the 
bottom of the panel. – and + indicate without or with the plasmid shown on the left. The 
cells were radiolabeled and immunoprecipitated with specific antibodies as shown below 
the lanes. The CD163 and GP2a (wild type and mutant) proteins were co-
immunoprecipitated by anti CD163 antibody (lanes 8-11). Immunoprecipitated proteins 
were resolved in SDS-10% PAGE and detected by fluorography. CD163 and different 
glycosylated forms of GP2a proteins are identified on the right. The relative mobilities of 
the molecular mass markers in kDa are shown on the left. 
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Figure 5.15 Examination of interaction of CD163 with double and completely 
unglycosylated GP4 proteins using GP4 antibody. BHK-21 cells were infected with 
vTF7-3 virus and mock-transfected (lanes 1 and 2), transfected with the plasmid 
encoding CD163 along with the plasmid encoding wild type GP4, double glycosylation 
mutant GP4 (N37/84A) or quadruple glycosylation mutant GP4 (unglycosylated) as 
shown in the bottom of the panel.  – and + indicate without or with the plasmid shown on 
the left. The cells were radiolabeled and immunoprecipitated with specific antibodies as 
shown below the lanes. The CD163-GP4 (wild type and mutant) proteins were co-
immunoprecipitated by anti GP4 antibody (lanes 7-9). Immunoprecipitated proteins were 
resolved in SDS-10% PAGE and detected by fluorography. CD163 and different GP4 
proteins are identified on the right. The relative mobilities of the molecular mass markers 
in kDa are shown on the left.  
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complex by anti-GP4 polyclonal antibody. The results showed that the interaction 
between CD163 and GP4 was dependent on the extent of glycosylation of GP4. The wild 
type GP4 with glycans at all four sites interacted well with CD163 (Fig. 5.15, lane 7) 
whereas the GP4 mutant with only two glycan moieties interacted less well with CD163 
(Fig. 5.15, lane 8). Further, interaction of unglycosylated GP4 with CD163 was very 
inefficient as only a very small amount of CD163 could be immunoprecipitated with GP4 
antibody (Fig. 5.15, lane 9). Similar results were also observed with other glycosylation 
mutant GP4 proteins (data not shown). Upon repeated experiments, my results showed 
that an 8-to 10-fold reduction in the amount of CD163 was observed when 
unglycosylated GP4 was used whereas 2- to 3-fold reduction in CD163 was seen with 
double glycosylation mutant GP4 proteins. Overall, these studies suggest that 
glycosylation of GP2a and GP4 proteins was necessary for an optimal interaction with 
the receptor CD163.  
5.4 Discussion 
Viruses use host cell machinery for glycosylation of the viral envelope proteins 
(Vigerust & Shepherd, 2007). PRRSV has four envelope glycoproteins GP2a, GP3, GP4, 
and GP5. Our previous study on GP5 protein has shown the importance of N-
glycosylation on viral immune evasion and infectivity (Ansari et al., 2006). My current 
study focused on the role of N-glycosylation of GP2a and GP4 proteins on virus 
infectivity, immune evasion and receptor interaction with CD163. My report concluded 
that (i) glycan addition at N184 of GP2a was individually required for infectious virus 
production. Glycan addition at a minimum two sites in GP4 was required for recovery of 
infectious PRRSV; (ii) N-glycosylation of GP2a and GP4 proteins do not play any 
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discernible role in viral immune evasion against host neutralizing antibody response or 
enhance host neutralizing antibody response; and (iii) Optimal interaction of GP2a and 
GP4 with CD163 molecule was dependent on glycosylation of GP2a and GP4 proteins.  
Lelystad virus (European strain) and FL12 virus (North American strain) of 
PRRSV share approximately 60% nucleotide sequence homology. A previous study with 
GP2a protein of Lelystad virus had shown that both the N-glycosylation sites of GP2a at 
positions 173 and 179 are dispensable for infectious virus production (Wissink et al., 
2004). But, my study with FL12 virus demonstrated that the N-glycosylation site at 
position 184 was required for infectious virus production. This result indicated that there 
were differences in the requirement of glycosylation of the viral glycoproteins for 
infectious virus production in these two viruses. It is also possible that these two 
genotypes of PRRSVs may have differences in their life cycle and/or pathogenic 
characteristics.  
My study has shown that glycan addition at N184 of GP2a may be required for 
proper folding of the protein that is needed for infectious virus production. Defects in 
protein folding, virion assembly or egress have also observed for Dengue virus and 
Japanese encephalitis virus when their envelope glycoproteins were mutated at the 
glycosylation sites (Kim et al., 2008; Mondotte et al., 2007). The four N-glycosylation 
sequons of GP4 were found to be dispensable for infectious virus production. But, no 
virus was recovered upon double deglycosylation of any two of the four sequons. These 
results further corroborate my hypothesis that by mutating multiple glycosylation sites, 
proper folding of the mutant protein is impaired in such a manner that reduces infectious 
virus production or assembly. As observed for Sindbis virus (Knight et al., 2009), single 
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partially glycosylated mutant virus had slightly higher titer observed in comparison to 
parent virus. The FL12 virus achieved highest titer at 72 h post infection, whereas the 
GP4 single mutant viruses achieved highest titer at 48 h post infection. The reason for the 
growth advantage over parental virus was not clear. I speculate that the single 
glycosylation mutant GP4 proteins fold in a manner that was more favourable for 
infectious virus production at higher levels. This could potentially be achieved through 
increased interactions with other viral glycoproteins, incorporation into viral envelope, 
and/or interactions with the host cell receptor. Further studies will be needed to determine 
how the single glycosylation mutant GP4 proteins enhanced virus infectivity or virus 
production. 
The GP5 of PRRSV was previously reported to be immunogenic and is required 
for conferring protection against host neutralizing antibody response (Ansari et al., 2006; 
Pirzadeh & Dea, 1997). On the contrary, I did not observe any effect of N-glycosylation 
of GP2a and GP4 proteins on protection against neutralizing antibody response. It may be 
due to the fact that these two minor envelope glycoproteins are not abundantly expressed 
on the surface of the virion. There may be the existence of a ‘malleable glycan shield’ 
(Wei et al., 2003) in which case the glycan moities on GP5 may protect the minor 
envelope glycoprotein even if they are unglycosylated. Glycan shield generally requires 
co-operative packing of entire envelope protein to prevent antibody access (Wei et al., 
2003). During glycan shielding, steric hindrance of epitope due to glycan addition at a 
nearby prevents its binding to a neutralizing antibody (Wei et al., 2003). It is possible that 
by partial deglycosylation, the potential neutralizing epitopes in these three glycoproteins 
have not been sufficiently exposed to permit binding of neutralizing antibody to each 
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protein. Alternatively, my results could suggest that these three glycoproteins do not 
contain PRRSV neutralizing epitopes or the glycan shielding mechanisms do not operate 
in these GPs. My studies have revealed that two out of the three minor envelope 
glycoproteins (GP2a and GP4) directly interact with CD163 (Fig. 4.12), which is an 
important receptor for PRRSV. Although the amino acid residues of GP2a and GP4 
protein required for their binding with CD163 has not been completely mapped, it is 
plausible that interaction of these proteins with the receptor at the plasma membrane may 
sterically hinder the antibody binding as has been observed for gp120 protein of HIV-1 
(Poon et al., 2007; Wyatt et al., 1998) and a favourable interaction may mask the 
exposure of neutralizing epitope on the surface of the virion. 
 Though I did not observe any significant defect in interaction of GP2a with 
CD163 upon individual mutation of its two glycosylation sites, abrogation of their 
interaction was observed when I mutated both the N residues of the sequons (Fig. 5.13 
and 5.14). As observed for Hantaan virus (Shi & Elliott, 2004), the two sequons of GP2a 
may have different effect on protein folding and intracellular trafficking. It was also 
reported that upon complete deglycosylation of envelope proteins of HIV-1, its 
interaction with CD4 molecule was reduced, but was not completely abolished 
(Fenouillet et al., 1990). Probably for PRRSV, glycan addition of GP2a has 
complementary roles on their functions in receptor interaction and that complete removal 
of the glycans abolishes or drastically reduces their receptor interaction functions. The 
glycan addition in GP4 may also have a similar role in its functions. 
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CHAPTER VI 
 
 
 
 
 
 
ROLE OF N-GLYCOSYLATION OF GP3 OF PRRSV IN INFECTIOUS VIRUS 
PRODUCTION AND NEUTRALIZING ANTIBODY RESPONSE 
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Previous studies from our laboratory had shown that N-glycosylation of GP5 
protein of PRRSV was required for protection against host neutralizing antibody response 
by glycan shielding mechanism (Ansari et al., 2006). Based on the presence on the 
envelope, the GP3 along with GP2a and GP4 are regarded as minor envelope 
glycoproteins. My other studies had also shown the importance of glycan moieties of 
GP2a and GP4 proteins on virus infectivity and interaction with receptor CD163 (chapter 
V). I further studied the role of glycan moieties of GP3 on virus infectivity and viral 
immune evasion. 
6.1 N195 of GP3 is actually not glycosylated 
The GP3 protein was predicted to have seven glycosylation sites (Fig. 6.1).  I 
substituted A in place of N in all the seven predicted sites and cloned the wild type and 
mutant GP3 proteins in pGEM3 vector. The presence of each mutation was confirmed by 
sequencing all the clones (data not shown). The wild type as well as mutant proteins were 
transiently expressed in BHK-21 cells (Fig. 6.2). While the wild type protein migrated 
with a molecular weight of 42 kDa (Fig. 6.2, lane 2), the all single amino acid mutant 
clones  (N29A, N42A, N50A, N131A, N152A, N160A) (Fig. 6.2, lanes 3-8) except 
N195A clone (Fig. 6.2, lane 9) migrated with a molecular weight of 39.5 kDa due to loss 
of one glycosylation site in each case. The substitution of N to A at position 195 of GP3 
seemed to have no effect on protein glycosylation (Fig. 6.2, lane 9). This indicates that 
the N at position 195 was not used for glycan addition in GP3 protein.  
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Figure 6.1 Schematic of GP3 and its single N-glycosylation defective mutant 
proteins. The predicted N-glycosylation sites in amino acid numbers for GP3 are shown. 
The size of the protein in amino acids, signal cleavage sites (SS) and transmembrane 
(TM) domains are indicated. The name of each of the mutant construct is shown on the 
left. The N to A mutation sites are left blank without any attached glycan moiety. 
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Figure 6.2 Protein expressions of GP3 and its single N-glycosylation defective 
mutants. BHK-21 cells were infected with vTF7-3 and transfected with pGEM3 (Empty 
vector, lane 1) or GP3 (lane 2) and its N-glycosylation defective clones (lanes 3-9). Cells 
were radiolabeled for 4 h at 16 h post-transfection, and the radiolabeled proteins were 
analyzed by immunoprecipitation with anti-GP3 antibody, resolved in SDS-12%PAGE 
and detected by fluorography. The extent of glycosylated forms of GP3 are shown on the 
right side. The relative mobilities of the molecular mass markers in kDa are shown on the 
left. 
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6.2 Glycosylation at N42, N50, and N131 of GP3 are crucial for infectious virus 
production 
I subsequently introduced the glycosylation site mutations of GP3 into the FL12 
infectious clone to generate various mutant viruses (pFL-GP3-N29A, pFL-GP3-N42A, 
pFL-GP3-N50A, pFL-GP3-N131A, pFL-GP3-N152A, and pFL-GP3-N160A). The 
presence of the above mutation was confirmed by sequencing the mutant FL12 genome 
(data not shown). The in vitro transcribed RNA of FL12 and single mutant GP3 proteins 
were electroporated in MARC-145 cells. The expression of N protein was confirmed by 
in immunofluorescence assay 48 h post-electroporation (Fig. 6.3). The CPE was observed 
in case of FL-GP3-N29A, FL-GP3-N152A and FL-GP3-N160A after five days of 
electroporation indicating successful recovery of respective viruses. However, even after 
multiple repeat experiments, viruses encoding mutations at the positions 42, 50 or 131 
could not be recovered, indicating that glycan addition at these sites was essential for 
particle formation or infectivity. In MARC-145 cells infected with the GP3 single 
glycosylation defective mutant viruses after 10th passage, the three GP3 single mutant 
proteins (GP3-N29A, GP3-N152A, and GP3-N160A) migrated with a mobility that 
correlated with loss of one glycosylation site (Fig. 6.4, lanes 3-5) and faster than GP3 
wild type protein (Fig. 6.4, lane 2). This indicates that the recovered mutant viruses 
harboured the specific mutation after repeated passage in cell culture and the intracellular 
mutant viral proteins were stable. Two out of the three recovered GP3 single N-
glycosylation defective viruses (FL-GP3-N29A and FL-GP3-N152A) were found to have 
similar or slightly higher growth characteristics in comparison to FL12 virus as observed 
by comparing their multi step growth kinetics (Fig. 6.7A). Whereas, FL-GP3- 
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Figure 6.3 Expression of N protein in GP3 single N-glycosylation defective mutant 
viruses. MARC-145 cells were electroporated with in vitro transcripts derived from 
pFL12-Pol- (mock), pFL12, pFL-GP3-N29A, pFL-GP3-N42A, pFL-GP3-N50A, pFL-
GP3-N131A, pFL-GP3-N152A, and pFL-GP3-N160A. At 48h after electorporation, cells 
were permeabilized and expression of N protein was examined using the monoclonal 
antibody SDOW17 and Alexa-488 conjugated anti-mouse IgG as secondary antibody. 
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Figure 6.4 Protein expression of GP3 recovered single N-glycosylation defective 
mutant viruses. MARC-145 cells were either left uninfected (lane 1) or infected with 
FL12 virus (lane 2), FL-GP3-N29A virus (lane 3), FL-GP3-N152A virus (lane 4), and 
FL-GP3-N160A virus (lane 5) of passage-10. Cells were radiolabeled for 4 h at 48 h post-
infection, and the radiolabeled proteins were analyzed by immunoprecipitation with anti-
GP2a antibody, resolved in SDS-12%PAGE and detected by fluorography. The extent of 
glycosylated forms of GP3 are shown on the right. Relative mobilities of molecular mass 
markers in kDa are shown on the left. 
  
 148 
N160A mutant virus yield after 120 h post-infection was about 8 fold less, indicating that 
this virus may be less stable or grows less efficiently compared to the wild type or other 
mutant viruses.  These results show that glycosylation at amino acid positions 42, 50 and 
131 of GP3 were important for infectious virus production or virus infectivity. 
6.3 Triple mutations of N-glycosylation sites at N29, N152, and N160 positions of 
GP3 reduced the growth titer of mutant virus 
To study the effect of mutation of two or more glycosylation sites at position 29, 
152 and 160, I simultaneously mutated N to A in various combinations (N29/152A, 
N29/160A, and N152/160A, and N29/152/160A) of GP3 (Fig. 6.5). All four mutant 
proteins expressed similar levels of protein as observed in BHK-21 cells (Fig. 6.6A). The 
double mutant GP3 proteins (GP3-N29/152A, GP3-N29/160A, and GP3-N152/160A) 
lost approximately 5 kDa of molecular mass and had molecular weight of 37 kDa (Fig. 
6.6A, lanes 4-6). Similarly, mutation of three glycosylation sites, the GP3-N29/152/160A 
mutant yielded a protein with molecular mass of 34.5 kDa (Fig. 6.6A, lane 7). I further 
introduced these specific double and triple mutations as mentioned for GP3 proteins in 
the FL12 genome of PRRSV (pFL-GP3-N29/152A, pFL-GP3-N29/160A, pFL-GP3-
N152/160A, and pFL-GP3-N29/152/160A). The in vitro transcribed RNA was 
electroporated in MARC-145 cells. I was able to recover infectious viruses from each of 
these mutant RNA transfected cells. The recovered viruses were viable and found to 
retain the correct mutation even after 10th passage in cell culture (data not shown). In 
MARC-145 cells infected with the mutant virus, the GP3-N29/152A, GP3-N29/160A, 
and GP3-N152/160A proteins migrated with a mobility that correlated with the loss of  
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Figure 6.5 Schematics of GP3 double and triple N-glycosylation defective mutants 
constructed. The name of each of the mutant construct is shown on the left. The 
predicted N-glycosylation sites in amino acid numbers for GP3 are shown. The signal 
cleavage sites (SS) and transmembrane (TM) domains are indicated. The N to A mutation 
sites are left blank without any attached glycan moiety. 
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Figure 6.6 Protein expression of GP3 double and triple N-glycosylation defective 
mutants. (A) BHK-21 cells were infected with vTF7-3 and transfected with pGEM3 
(Empty vector, lane 1) or GP3 (lane 2), GP3-N29A (lane 3), three double N-glycosylation 
defective clones of GP3 (lanes 4-6), and triple N-glycosylation defective clone (lane 7). 
Cells were radiolabeled for 4 h at 16 h post-transfection, and the radiolabeled proteins 
were analyzed by immunoprecipitation with anti-GP3 antibody, resolved in SDS-
12%PAGE and detected by fluorography. The relative mobilities of the molecular mass 
markers in kDa are shown on the left. (B) MARC-145 cells were either left uninfected 
(Mock, lane 1) or infected with FL12 virus (lane 2), FL-GP3-N29A virus (lane 3), three 
double N-glycosylation defective mutant viruses of GP3 (lanes 4-6), and triple N-
glycosylation defective mutant virus of GP3 (lane 7) after 10th passage in cell culture. 
Cells were radiolabeled for 4 h at 48 h post-infection, and the radiolabeled proteins were 
analyzed by immunoprecipitation with anti-GP3 antibody, resolved in SDS-12%PAGE 
and detected by fluorography. Relative mobilities of molecular mass markers in kDa are 
shown on the left. 
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two glycosylation sites (Fig. 6.6B, lanes 4-6). Similarly, GP3-N29/152/160A protein 
migrated with a mobility that correlated with loss of three glycosylation sites (Fig. 6.6B, 
lane 7). The GP3 proteins synthesized in these mutant virus infected cells migrated faster 
than the GP3 protein synthesized in FL12 virus-infected cells (Fig. 6.6B, lane 2) and FL-
GP3-N29A infected cells (Fig. 6.6B, lane 3), demonstrating the stability of the mutant 
virus under in vitro growth and passage conditions.  The recovered double and triple 
mutant viruses were found to have different growth characteristics in comparison to wild 
type and single mutant GP3 proteins (Fig. 6.7B). They grew to a lower titer and in the 
case of the triple N-glycosylation defective mutant virus (FL-GP3-N29/152/160A), I 
observed a hundred fold decrease in virus titer in comparison to the FL12 virus (Fig. 
6.7B). Also, in the case of FL-GP3-N29/152/160A virus infected MARC-145 cells, the 
time required for observable CPE was prolonged. These results suggested that 
simultaneous mutation of N to A at amino acid positions 29, 152 and 160 affected 
optimal virus growth and infectious virus production. Further, in cells infected with the 
mutant virus, the duration of appearance of CPE was prolonged.  
6.4 Role of N-glycosylation of GP3 on neutralizing antibody production in infected 
piglets 
Twenty one days old weaned piglets were infected with FL12 as well as mutant 
viruses generated for GP3 protein. For GP3 sites, I had generated seven mutant viruses 
out of which three have mutations in single amino acid position (FL-GP3-N29A, FL-
GP3-N152A, and FL-GP3-N160A), three have mutation in two amino acid positions in 
different combinations (FL-GP3-N29/152A, FL-GP3-N29/160A,  and FL-GP3-
N152/160A) and one possessed mutations in three amino acid 
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Figure 6.7 Multistep growth kinetics of recovered single, double, and triple N-
glycosylation defective mutant viruses. (A) Multi step growth kinetics of recovered 
GP3 single N-glycosylation mutant viruses. MARC-145 cells were infected with wild 
type and mutant viruses (FL-GP3-N29A, FL-GP3-N152A, and FL-GP3-N160A) with 
0.001 MOI and supernatant was collected in every 12 h interval up to 120 h. Plaque assay 
was performed as described in materials and methods. The viral titer was measured and 
expressed in log10 scale. The data points represent mean values from two independent 
experiments, and the error bars denote standard deviation. (B) Multi step growth kinetics 
of recovered GP3 double (FL-GP3-N29/152A, FL-GP3-N29/160A, and FL-GP3-
N152/160A) and triple deglycosylation (FL-GP3-N29/152/160A) mutant viruses. The 
experiment was performed similarly as described for panel A. 
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positions (FL-GP3-N29/152/160A). Based on the previous report (Wei et al., 2003) on 
cumulative effect of N-glycosylation sites of a protein on glycan shielding, I used one of 
recovered double deglycosylated mutant virus (FL-GP3-N29/152A) and triple 
deglycosylated mutant virus (FL-GP3-29/152/160A) for inoculation in piglets. Groups of 
four 21 days old piglets were injected with the mutant viruses. All the different groups of 
piglets were housed separately. Sham infected piglets were included as negative control. 
The neutralizing antibody titer was measured by TCID50 assay (Table 6.1).  Since 
neutralizing antibody response is usually not detected before 21 days post infection, I 
normalized the titer of neutralizing antibody at day 7 as 1 for the wild type and GP3 
mutant virus-infected sera from the animals. The FL12 infected piglet sera was tested 
against FL12 infected cells (homologous titer) and compared with sera collected from 
mutant virus infected piglets (heterologous titer). I did not observe any significant 
difference between neutralizing antibody response produced in case of FL12 virus or 
other GP3 mutant virus. These results indicated that hypoglycosylation of GP3 did not 
influence neutralizing antibody response in infected piglets (Table 6.1). Overall, the 
results show that unlike GP5 (Ansari et al., 2006), hypoglycosylation of GP3 did not 
induce higher neutralizing antibody response in infected pigs and the mutant viruses were 
not more sensitive to neutralization by neutralizing antibodies in the infected animals.  
6.5 Discussion 
PRRSV has four envelope glycoproteins GP2a, GP3, GP4, and GP5. Our previous 
study on GP5 protein has shown the importance of N-glycosylation on viral immune 
evasion and infectivity (Ansari et al., 2006). The N-glycosylation of GP2a and GP4 
protein was also shown to be required for infectious virus production and interaction with  
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Table 6.1 Serum neutralization titer of animals infected with wild type or GP3 
glycosylation defective mutant PRRSVs. 
 
Groups 
Days post infection 
7 days 46 days 
FL12 1 32 
GP3 FL-N29/152A 1 13.5 
GP3 FL-N29/152/160A 1 16 
 
The serum neutralization value of both wild type and mutant viruses are made 1 for 7th 
day for comparison. The results are shown as of average of four animals per each group. 
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receptor CD163 (chapter V). My current study focused on the role of N-glycosylation of 
GP3 on virus infectivity and immune evasion. My report concluded that (i) glycan 
addition at N42, N50, and N131 of GP3 were individually required for infectious virus 
production and (ii) N-glycosylation of GP3 did not play any discernible role in viral 
immune evasion against host neutralizing antibody response or enhancement of host 
neutralizing antibody response. 
My study had shown that N195 of GP3 proteins is not glycosylated. The 
bioinformatics analysis of the protein showed that residue has intracytoplasmic 
orientation, perhaps making it unavailable for glycosylation by host enzymes. Studies 
with the prototype foamy virus revealed that 14 out of 15 predicted glycosylation sites of 
its envelope protein were actually glycosylated in the virion and the glycan addition site 
present on the signal peptide is not glycosylated (Luftenegger et al., 2005). The N42, 
N50, and N131 of GP3 protein of PRRSV are individually required for infectious virus 
production. It is possible that without glycan addition at these positions, the synthesized 
GP3 adopted a protein conformation that was not favorable for generation of infectious 
particle formation. Although I recovered a PRRSV encoding GP3 with mutations at 
glycan addition sites N29, N152, and N160, this mutant virus was found to have lower 
titers than wild type, single, or double mutant viruses. These results imply that by 
mutating multiple glycosylation sites, proper folding of the mutant protein was impaired 
in such a manner that reduced infectious virus production or assembly.  
The GP5 of PRRSV was previously reported to be immunogenic and was required 
for conferring protection against host neutralizing antibody response (Pirzadeh & Dea, 
1997). As reported for GP2a and GP4 (chapter V), I did not observe any effect of N-
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glycosylation of GP3 on protection against neutralizing antibody response. It may be due 
to the fact that these three minor envelope glycoproteins (GP2a, GP3, and GP4) are not 
abundantly expressed on the surface of the virion. There may be the existence of a 
‘malleable glycan shield’ (Wei et al., 2003) in which case the glycan moities on GP5 may 
protect the minor envelope glycoprotein even if they are unglycosylated. Glycan shield 
generally requires co-operative packing of entire envelope protein to prevent antibody 
access (Wei et al., 2003). During glycan shielding, steric hindrance of epitope due to 
glycan addition at a nearby position prevents its binding to a neutralizing antibody (Wei 
et al., 2003). It is possible that by partial deglycosylation, the potential neutralizing 
epitopes in these three glycoproteins have not been sufficiently exposed to permit binding 
of neutralizing antibody to each protein. Alternatively, my results could suggest that these 
three glycoproteins do not contain PRRSV neutralizing epitopes or the glycan shielding 
mechanisms do not operate in these GPs. It should be noted that GP3 of North American 
strain seems to possess neutralizing epitopes (Yang et al., 2000). So the later possibility 
appears to be more likely.  
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CONCLUSION 
PRRSV encodes one major envelope glycoprotein (GP5) and three minor 
envelope glycoproteins (GP2a, GP3, and GP4). The studies reported in this dissertation 
focused on examining interactions of these minor glycoproteins amongst themselves and 
also with the PRRSV receptor CD163. Further, the role of glycan addition at various sites 
in these glycoproteins in GP-receptor interactions, neutralizing antibody response, and 
generation of infectious virus production were examined. The following conclusions 
were derived from these studies: 
1. Individually expressed envelope glycoproteins are localized in the ER 
 By the use of monospecific antibodies to the individual GPs or tagged antibodies, 
I was able to demonstrate expression of both mature as well as partially glycosylated 
form of the proteins in BHK-21, HeLa, and MARC-145 cells (Fig. 3.1, 3.2, and 3.3). By 
immunofluorescence microscopy and endo H digestion studies, I have also shown that 
upon ectopic expression, the individual glycoproteins remained in the ER and were not 
transported to the plasma membrane (Fig. 3.4 and 3.5).  
2. GP2a, GP3, and GP4 are co-translationally glycosylated, whereas GP5 is post-
translationally glycosylated 
 Previously, it was reported that STT3A ad STT3B subunits of OST enzyme 
complex were required for co-translational and post-translational glycosylation of 
glycoproteins in the cell. Though most the glycoproteins are co-translationally 
glycosylated, post-translational glycosylation of some proteins including coagulation 
factor VII and L protein of hepatitis B virus were reported. In my attempt to decipher 
whether viral GPs are co-translationally or post-translationally glycosylated, I employed 
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short pulse labelling of the proteins and subsequent examination of the proteins during 
various lengths of chase periods. My results show that GP2a, GP3, and GP4 proteins are 
co-translationally glycosylated whereas; GP5 protein is post-translationally glycosylated 
(Fig. 3.7, 3.8, 3.9, and 3.10). The significance of post-translational glycosylation of GP5 
in the viral life cycle is not clear. 
3. GP4 interacts with GP5 and mediates formation of multiprotein complex 
Co-expression of multiple proteins and co-IP studies revealed that GP2a interacts 
strongly with GP3 and GP4 proteins, but not with GP5 (Fig. 4.1). The GP3 interacts 
strongly with GP2a and GP4 proteins, but not with GP5 (Fig. 4.2). The GP4 interacts 
with GP2a, GP3, and GP5 proteins (Fig. 4.3). The GP5 interacts primarily with GP4 and 
this interaction was required for multiprotein complex formation of the glycoproteins 
(Fig. 4.4 and 4.5). Previously it was reported that GP5 and M proteins interact with each 
other and form a heterodimer. Based on these results (Table 4.1), I speculate that GP4 
acts as a bridge between the three minor envelope glycoproteins and GP5 and this is 
important for virus assembly.   
4. Both GP2a and GP4 interact with PRRSV receptor CD163  
 The porcine CD163 receptor was the major receptor for PRRSV in PAM cells. I 
had also independently cloned and characterized porcine CD163 molecule (Fig. 4.9, 4.10, 
and 4.11). Expression of this receptor in non-susceptible BHK-21 cells conferred 
permissivity to PRRSV infection. I also obtained a truncated form of the receptor protein 
(CD163∆TM) which lacked the 9th SRCR domain and transmembrane domain of CD163. 
Expression of this mutant protein in BHK-21 cells did not confer permissivity to PRRSV 
infection because this protein was not expressed on the plasma membrane due to the 
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absence of the transmembrane domain (Fig. 4.11). The CD163 molecule was found to 
interact specifically with GP2a and GP4 proteins of PRRSV (Fig. 4.12). The CD163∆TM 
protein was also found to interact with both GP2a and GP4 (Fig. 4.14) indicating that the 
9th SRCR domain was not required for this interaction. I have concluded that porcine 
CD163 interacts with GP2a and GP4 proteins of PRRSV. 
5. Specific regions of GP2a and GP4 that interact with CD163 
 By generating  a series of deletion mutants of GP2a as well as GP4 and examining 
their interactions with CD163, it was observed that GP2a region spanning amino acids 
residues 76-112 are critical for its interaction with CD163 (Fig. 4.16). Similarly, amino 
acid regions 141-177 of GP4 are required for its efficient interaction with CD163 (Fig. 
4.17).  
6. N-glycosylation of GP2a and GP4 protein of PRRSV is required for their 
interaction with receptor CD163 
 To study the effect of N-glycosylation of GP2a and GP4 with their interaction 
with receptor CD163, I co-expressed the mutant proteins with the receptor and performed 
co-IP assays. Although single site N-glycosylation mutations of GP2a had no negative 
effect on interactions with CD163, completely unglycosylated GP2a was defective in 
interaction with CD163 molecule (Fig. 5.13 and 5.14). A similar co-IP study for CD163-
GP4 interaction showed that mutation of individual N-glycosylation sites of GP4 had no 
effect for this interaction. But, upon deglycosylation of two or more sites, significant 
reduction in the interaction with CD163 was observed (Fig. 5.15). Based on these 
observations, I conclude that the N-glycosylation sites of GP2a and GP4 proteins of 
PRRSV are required for their optimal interaction with receptor CD163.  
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7. N-glycosylation of minor envelope glycoproteins of PRRSV is required for 
infectious virus production 
 The N-glycan moieties of GP5 for both European and North American strains of 
PRRSV are required for virus infectivity. But, the glycan moieties of GP2a of European 
strain (Lelystad virus) are dispensable for virus production. To study the role of N-
glycosylation of GP2a, GP3, and GP4 proteins on virus infectivity, I mutated N residue 
of predicted glycan moities of the proteins to A residue in infectious clone FL12 of 
PRRSV. Of the two glycan addition sites (N178 and N184) of GP2a, N184 is required for 
virus production. GP3 has seven potential glycosylation sites at positions N29, N42, N50, 
N131, N152, N160, and N195. My studies have revealed that N195 site is not 
glycosylated (Fig. 6.2). Furthermore, glycan addition at sites N42, N50, and N131 is 
required for infectious virus production. GP4 has four N-glycosylation sites at positions 
N37, N84, N120, and N130. Although individual glycosylation site mutations at any of 
these sites did not affect infectious virus production, introduction of double site mutations 
of various combinations was lethal for infectious virus recovery. Taken together, my data 
suggest that addition of glycan moities at several sites in the three minor envelope 
glycoproteins of PRRSV is required for virus infectivity.  
8. N-glycosylation of minor envelope glycoproteins of PRRSV is not required for 
glycan shielding against host neutralizing antibody response 
 The N-glycosylation of GP5 was important for protection against host 
neutralizing antibody response by glycan shielding mechanism. To further address the 
role of glycan moities of GP2a, GP3, and GP4 proteins in glycan shielding mechanism, I 
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performed animal studies using various recovered glycosylation mutant viruses. 
Neutralizing antibody titers in piglets infected with various mutant viruses revealed no 
significant increase in neutralizing antibody production (Tables 5.1 and 6.1). These 
results indicate that N-glycosylation sites of GP2a, GP3, and GP4 protein of PRRSV are 
not required for protection of the virus against host neutralizing antibody response and 
that hypoglycosylation of the minor glycoproteins do not induce higher neutralizing 
antibody titers. Considering the fact that GP2a, GP3, and GP4 are minor envelope 
proteins it is possible that the virus does not use glycan moities of these proteins for 
protection against host neutralizing antibody response. This is in contrast to GP5 in which 
hypoglycosylation of the protein induces higher neutralizing antibody response and the 
virus containing hypoglycosylated forms of GP5 are readily neutralized by neutralizing 
antibodies. Also, GP2a and GP4 protein apparently interact with receptor CD163 (Fig. 
4.12).  Based on these observations, I hypothesize that PRRSV mobilizes the different 
envelope proteins for different functions for successful viral infection and immune 
evasion. 
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OVERVIEW 
My dissertation research involves study of interactions among the four 
glycoproteins of PRRSV, the interaction of the glycoproteins with one of the PRRSV 
receptor CD163, and the role of N-glycosylation of three minor glycoproteins (GP2a, 
GP3, and GP4) in receptor interactions, infectious virus production, and protection 
against host neutralizing antibody response. Specific interaction patterns between 
different glycoproteins have been demonstrated by my study. I hypothesize that the GP4 
and GP5 interaction probably helps in viral particle formation. Similarly, I also observed 
that GP2a and GP4 proteins of PRRSV interact with the receptor CD163. This specific 
interaction is probably required for virus entry and uncoating inside the infected cells.  
Studies from our laboratory and other laboratories have indicated that certain N-
glycosylation sites of PRRSV envelope proteins are required for infectious virus 
production. While the glycan moieties of GP5 are required for protection against host 
neutralizing antibody response, N-glycosylation of GP2a, GP3, and GP4 is not required 
for protection against host neutralizing antibody response. Out of four glycoproteins, 
GP2a, GP3, and GP4 are co-translationally glycosylated whereas, GP5 is post-
translationally glycosylated. The significance of the different mechanism for 
glycosylation in the biology and/or pathogenesis of PRRSV are unknown at this time and 
further investigation in these lines will be required. 
Overall, my dissertation research has provided an understanding of the role and 
requirement of glycosylation of envelope proteins of PRRSV and their interactions in 
particle formation, host-cell interactions, and immune response. 
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